<units>
<unit type="BATCH">
<unit-content>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_7</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>NF-κB</author-keyword>
<author-keyword>PDAC</author-keyword>
<author-keyword>Muscle atrophy</author-keyword>
<author-keyword>Muscle regeneration</author-keyword>
<author-keyword>Cachexia</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">NF-kB Signaling in the Macroenvironment of Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>B.R.</ce:initials>
<ce:surname>Pryce</ce:surname>
<ce:given-name>Benjamin R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>Denis C.</ce:given-name>
<ce:e-address>guttridg@musc.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Pediatrics</organization>
<organization>the Hollings Cancer Center</organization>
<organization>Medical University of South Carolina</organization>
<city>Charleston</city>
<state>SC</state>
<country iso-code="USA"/>
<ce:source-text>Department of Pediatrics, and the Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>Denis C.</ce:given-name>
</person>
<affiliation>
<organization>Department of Pediatrics</organization>
<organization>the Hollings Cancer Center</organization>
<organization>Medical University of South Carolina</organization>
<city>Charleston</city>
<state>SC</state>
<country iso-code="USA"/>
<ce:source-text>Department of Pediatrics, and the Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA</ce:source-text>
</affiliation>
<ce:e-address>guttridg@musc.edu</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para> The Nuclear Factor Kappa B (NF-κB) tran scription factor is ubiquitously expressed and  has been shown to control various cellular  processes such as survival, proliferation, dif ferentiation, and inflammation. While critical  for cellular survival, dysregulation of NF-κB  signaling has been linked to the progression of  cancer. Although NF-κB has been shown to  play a role in various cancers, this chapter will  focus on pancreatic cancer and how canonical  NF-κB  signaling  macroenvironment  perturbs  of  the  tumor–tissue  interactions. This will include exploring how  NF-κB can mediate various stages of disease  development, beginning with tumor initiation  and progression through interactions with the  immune systems as well as promoting  epithelial–mesenchymal transition (EMT),  metastasis, and chemoresistance. All these  aspects underscore NF-κB as being involved  in various stages of pancreatic cancer develop ment. We will also describe the role of NF-κB  in normal skeletal muscle and how this is  changed drastically in pancreatic cancer  patients, leading to a muscle wasting disease  known as cancer cachexia. These effects can  be observed by NF-κB activity in both the  myofiber and muscle stem cells, ultimately  leading to muscle decline. Overall, this chapter  will illustrate the central role that NF-κB sig naling plays in the macroenvironment between  pancreatic tumor cells and peripheral skeletal  muscle.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>135</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="132">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by  a posttranslational mechanism.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Baltimore</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>mechanism. Cell.</ref-sourcetitle>
<ref-publicationyear first="1986"/>
<volisspag>
<volume-issue-number>
<vol-first>47</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>921</first-page>
<last-page>928</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Sen, R., Baltimore, D.: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by  a posttranslational mechanism. Cell. 47(6), 921–928  (1986)</ref-fulltext>
<ce:source-text> Sen, R., Baltimore, D.: Inducibility of kappa immu noglobulin enhancer-binding protein Nf-kappa B by  a posttranslational mechanism. Cell. 47(6), 921–928  (1986)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB signaling: a  tale of two pathways in skeletal myogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bakkar</ce:surname>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol.  Rev</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>495</first-page>
<last-page>511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bakkar, N., Guttridge, D.C.: NF-kappaB signaling: a  tale of two pathways in skeletal myogenesis. Physiol.  Rev. 90(2), 495–511 (2010)</ref-fulltext>
<ce:source-text>Bakkar, N., Guttridge, D.C.: NF-kappaB signaling: a  tale of two pathways in skeletal myogenesis. Physiol.  Rev. 90(2), 495–511 (2010)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear factor-kappaB and IkappaB  kinase are constitutively active in human pancreatic  cells, and their down-regulation by curcumin  (diferuloylmethane) is associated with the suppres sion of proliferation and the induction of apoptosis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer.</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>101</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2351</first-page>
<last-page>2362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Li, L., et al.: Nuclear factor-kappaB and IkappaB  kinase are constitutively active in human pancreatic  cells, and their down-regulation by curcumin  (diferuloylmethane) is associated with the suppres sion of proliferation and the induction of apoptosis.  Cancer. 101(10), 2351–2362 (2004)</ref-fulltext>
<ce:source-text> Li, L., et al.: Nuclear factor-kappaB and IkappaB  kinase are constitutively active in human pancreatic  cells, and their down-regulation by curcumin  (diferuloylmethane) is associated with the suppres sion of proliferation and the induction of apoptosis.  Cancer. 101(10), 2351–2362 (2004)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle></ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>An epidemiological  survey of cachexia in advanced cancer patients and  analysis on its diagnostic and treatment status.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname> Sun</ce:surname>
</author>
<author seq="2">
<ce:initials>X.Q.</ce:initials>
<ce:surname>Quan</ce:surname>
<ce:given-name>X.Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>67</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1062</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Sun, L., Quan, X.Q., Yu, S.: An epidemiological  survey of cachexia in advanced cancer patients and  analysis on its diagnostic and treatment status. Nutr.  Cancer. 67(7), 1056–1062 (2015)</ref-fulltext>
<ce:source-text> Sun, L., Quan, X.Q., Yu, S.: An epidemiological  survey of cachexia in advanced cancer patients and  analysis on its diagnostic and treatment status. Nutr.  Cancer. 67(7), 1056–1062 (2015)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english></ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Karin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>441</vol-first>
<iss-first>7092</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>436</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Karin, M.: Nuclear factor-kappaB in cancer develop ment and progression. Nature. 441(7092), 431–436  (2006)</ref-fulltext>
<ce:source-text> Karin, M.: Nuclear factor-kappaB in cancer develop ment and progression. Nature. 441(7092), 431–436  (2006)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB functions in tumor  initiation by suppressing the surveillance of both  innate and adaptive immune cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname> Wang</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>103</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, D.J., et al.: NF-kappaB functions in tumor  initiation by suppressing the surveillance of both  innate and adaptive immune cells. Cell Rep. 9(1),  90–103 (2014)</ref-fulltext>
<ce:source-text>. Wang, D.J., et al.: NF-kappaB functions in tumor  initiation by suppressing the surveillance of both  innate and adaptive immune cells. Cell Rep. 9(1),  90–103 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The nuclear factor-kappa B RelA  transcription factor is constitutively activated in  humanpancreatic adenocarcinoma cells. Clin.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer  Res</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, W., et al.: The nuclear factor-kappa B RelA  transcription factor is constitutively activated in  humanpancreatic adenocarcinoma cells. Clin. Cancer  Res. 5(1), 119–127 (1999)</ref-fulltext>
 <ce:source-text>Wang, W., et al.: The nuclear factor-kappa B RelA  transcription factor is constitutively activated in  humanpancreatic adenocarcinoma cells. Clin. Cancer  Res. 5(1), 119–127 (1999)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Signaling to NF-kappaB.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.S.</ce:initials>
<ce:surname>Hayden</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2195</first-page>
<last-page>224</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hayden, M.S., Ghosh, S.: Signaling to NF-kappaB.  Genes Dev. 18(18), 2195–2224 (2004)</ref-fulltext>
<ce:source-text>Hayden, M.S., Ghosh, S.: Signaling to NF-kappaB.  Genes Dev. 18(18), 2195–2224 (2004)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The NF-kappa B and I kappa B  proteins: new discoveries and insights.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>BaldwinJr</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev.  Immunol.</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>649</first-page>
<last-page>683</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baldwin Jr., A.S.: The NF-kappa B and I kappa B  proteins: new discoveries and insights. Annu. Rev.  Immunol. 14, 649–683 (1996)</ref-fulltext>
<ce:source-text>Baldwin Jr., A.S.: The NF-kappa B and I kappa B  proteins: new discoveries and insights. Annu. Rev.  Immunol. 14, 649–683 (1996)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Shared principles in NF-kappaB signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.S.</ce:initials>
<ce:surname>Hayden</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>344</first-page>
<last-page>362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hayden, M.S., Ghosh, S.: Shared principles in NF-kappaB signaling. Cell. 132(3), 344–362 (2008)</ref-fulltext>
<ce:source-text>Hayden, M.S., Ghosh, S.: Shared principles in NF-kappaB signaling. Cell. 132(3), 344–362 (2008)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>May</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.B.</ce:initials>
<ce:surname>Kopp</ce:surname>
<ce:given-name>E.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>225</first-page>
<last-page>260</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ghosh, S., May, M.J., Kopp, E.B.: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225–260 (1998)</ref-fulltext>
<ce:source-text>Ghosh, S., May, M.J., Kopp, E.B.: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225–260 (1998)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>30 Years of NF-kappaB: A blossoming of relevance to human pathobiology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Lenardo</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Baltimore</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>37</first-page>
<last-page>57</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, Q., Lenardo, M.J., Baltimore, D.: 30 Years of NF-kappaB: A blossoming of relevance to human pathobiology. Cell. 168(1–2), 37–57 (2017)</ref-fulltext>
<ce:source-text>Zhang, Q., Lenardo, M.J., Baltimore, D.: 30 Years of NF-kappaB: A blossoming of relevance to human pathobiology. Cell. 168(1–2), 37–57 (2017)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>292</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>372</first-page>
<last-page>382</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Judge, A.R., et al.: Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 292(1), C372–C382 (2007)</ref-fulltext>
<ce:source-text>Judge, A.R., et al.: Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 292(1), C372–C382 (2007)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.T.</ce:initials>
<ce:surname>Smale</ce:surname>
<ce:given-name>S.T</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunol. Rev</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>246</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>204</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Smale, S.T.: Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol. Rev. 246(1), 193–204 (2012)</ref-fulltext>
<ce:source-text>Smale, S.T.: Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol. Rev. 246(1), 193–204 (2012)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Genetic approaches to study Rel/NF-kappa B/I kappa B function in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>Attar</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cancer Biol</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>93</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Attar, R.M., et al.: Genetic approaches to study Rel/NF-kappa B/I kappa B function in mice. Semin. Cancer Biol. 8(2), 93–101 (1997)</ref-fulltext>
<ce:source-text>Attar, R.M., et al.: Genetic approaches to study Rel/NF-kappa B/I kappa B function in mice. Semin. Cancer Biol. 8(2), 93–101 (1997)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Xiao</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Fong</ce:surname>
</author>
<author seq="3">
<ce:initials>S.C.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>279</vol-first>
<iss-first>29</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30099</first-page>
<last-page>30105</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, G., Fong, A., Sun, S.C.: Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J. Biol. Chem. 279(29), 30099–30105 (2004)</ref-fulltext>
<ce:source-text>Xiao, G., Fong, A., Sun, S.C.: Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J. Biol. Chem. 279(29), 30099–30105 (2004)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: A mechanism for NF-kappa B activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.A.</ce:initials>
<ce:surname>Beg</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="1993"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3301</first-page>
<last-page>3310</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Beg, A.A., et al.: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: A mechanism for NF-kappa B activation. Mol. Cell. Biol. 13(6), 3301–3310 (1993)</ref-fulltext>
<ce:source-text>Beg, A.A., et al.: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: A mechanism for NF-kappa B activation. Mol. Cell. Biol. 13(6), 3301–3310 (1993)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 induces NF-kappa B activation in the intestinal epithelia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>171</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3194</first-page>
<last-page>3201</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, L., et al.: IL-6 induces NF-kappa B activation in the intestinal epithelia. J. Immunol. 171(6), 3194–3201 (2003)</ref-fulltext>
<ce:source-text>Wang, L., et al.: IL-6 induces NF-kappa B activation in the intestinal epithelia. J. Immunol. 171(6), 3194–3201 (2003)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Schreck</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Rieber</ce:surname>
</author>
<author seq="3">
<ce:initials>P.A.</ce:initials>
<ce:surname>Baeuerle</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2247</first-page>
<last-page>2258</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schreck, R., Rieber, P., Baeuerle, P.A.: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10(8), 2247–2258 (1991)</ref-fulltext>
<ce:source-text>Schreck, R., Rieber, P., Baeuerle, P.A.: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10(8), 2247–2258 (1991)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Claudio</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Immunol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>958</first-page>
<last-page>965</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Claudio, E., et al.: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3(10), 958–965 (2002)</ref-fulltext>
<ce:source-text>Claudio, E., et al.: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3(10), 958–965 (2002)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.V.</ce:initials>
<ce:surname>Novack</ce:surname>
<ce:given-name>D.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Novack, D.V., et al.: The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198(5), 771–781 (2003)</ref-fulltext>
<ce:source-text>Novack, D.V., et al.: The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198(5), 771–781 (2003)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5785</first-page>
<last-page>5799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guttridge, D.C., et al.: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19(8), 5785–5799 (1999)</ref-fulltext>
<ce:source-text>Guttridge, D.C., et al.: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19(8), 5785–5799 (1999)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Straughn</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>53</first-page>
<last-page>66</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Straughn, A.R., et al.: Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis. J. Mol. Cell Biol. 11(1), 53–66 (2019)</ref-fulltext>
<ce:source-text>Straughn, A.R., et al.: Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis. J. Mol. Cell Biol. 11(1), 53–66 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.K.</ce:initials>
<ce:surname>Enwere</ce:surname>
<ce:given-name>E.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Signal</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>246</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Enwere, E.K., et al., TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci. Signal., 2012. 5(246): P. ra75</ref-fulltext>
<ce:source-text>Enwere, E.K., et al., TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci. Signal., 2012. 5(246): P. ra75</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>IKK/NF-kappaB regulates skeletal  myogenesis via a signaling switch to inhibit differen tiation and promote mitochondrial biogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bakkar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell  Biol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>787</first-page>
<last-page>802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bakkar, N., et al.: IKK/NF-kappaB regulates skeletal  myogenesis via a signaling switch to inhibit differen tiation and promote mitochondrial biogenesis. J. Cell  Biol. 180(4),787–802 (2008)</ref-fulltext>
<ce:source-text>. Bakkar, N., et al.: IKK/NF-kappaB regulates skeletal  myogenesis via a signaling switch to inhibit differen tiation and promote mitochondrial biogenesis. J. Cell  Biol. 180(4),787–802 (2008)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english> IKKalpha and alternative  NF-kappaB regulate PGC-1beta to promote oxidative  muscle metabolism.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bakkar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>196</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>497</first-page>
<last-page>511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Bakkar, N., et al.: IKKalpha and alternative  NF-kappaB regulate PGC-1beta to promote oxidative  muscle metabolism. J. Cell Biol. 196(4),497–511(2012)</ref-fulltext>
<ce:source-text> Bakkar, N., et al.: IKKalpha and alternative NF-kappaB regulate PGC-1beta to promote oxidative  muscle metabolism. J. Cell Biol. 196(4),497–511(2012)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Shintaku</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>514</first-page>
<last-page>526</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shintaku, J., et al.: MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-kappaB. Cell Rep. 17(2), 514–526 (2016)</ref-fulltext>
<ce:source-text>Shintaku, J., et al.: MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-kappaB. Cell Rep. 17(2), 514–526 (2016)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Epidemiology of pancreatic cancer: Global trends, etiology and risk factors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Rawla</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Sunkara</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Gaduputi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>World J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
<last-page>27</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rawla, P., Sunkara, T., Gaduputi, V.: Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10(1), 10–27 (2019)</ref-fulltext>
<ce:source-text>Rawla, P., Sunkara, T., Gaduputi, V.: Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10(1), 10–27 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Advancement of NF-kappaB signaling pathway: A novel target in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Pramanik</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Pramanik, K.C., et al.: Advancement of NF-kappaB signaling pathway: A novel target in pancreatic cancer. Int. J. Mol. Sci. 19(12) (2018)</ref-fulltext>
<ce:source-text>Pramanik, K.C., et al.: Advancement of NF-kappaB signaling pathway: A novel target in pancreatic cancer. Int. J. Mol. Sci. 19(12) (2018)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting apoptosis pathways in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Arlt</ce:surname>
</author>
<author seq="2">
<ce:initials>S.S.</ce:initials>
<ce:surname>Muerkoster</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Schafer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>332</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>346</first-page>
<last-page>358</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arlt, A., Muerkoster, S.S., Schafer, H.: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 332(2), 346–358 (2013)</ref-fulltext>
<ce:source-text>Arlt, A., Muerkoster, S.S., Schafer, H.: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 332(2), 346–358 (2013)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ling</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>105</first-page>
<last-page>120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ling, J., et al.: KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 21(1), 105–120 (2012)</ref-fulltext>
<ce:source-text>Ling, J., et al.: KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 21(1), 105–120 (2012)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhuang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1432</first-page>
<last-page>1444</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhuang, Z., et al.: IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation. Clin. Cancer Res. 22(6), 1432–1444 (2016)</ref-fulltext>
<ce:source-text>Zhuang, Z., et al.: IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation. Clin. Cancer Res. 22(6), 1432–1444 (2016)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor suppressive functions of p53</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Zilfou</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.W.</ce:initials>
<ce:surname>Lowe</ce:surname>
<ce:given-name>S.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cold Spring Harb. Perspect. Biol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zilfou, J.T., Lowe, S.W.: Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 1(5), a001883 (2009)</ref-fulltext>
<ce:source-text>Zilfou, J.T., Lowe, S.W.: Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 1(5), a001883 (2009)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Xia</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>106</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2629</first-page>
<last-page>2634</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xia, Y., et al.: Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc. Natl. Acad. Sci. USA. 106(8), 2629–2634 (2009)</ref-fulltext>
<ce:source-text>Xia, Y., et al.: Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc. Natl. Acad. Sci. USA. 106(8), 2629–2634 (2009)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Transcriptional cross talk between NF-kappaB and p53</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.A.</ce:initials>
<ce:surname>Webster</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.D.</ce:initials>
<ce:surname>Perkins</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3485</first-page>
<last-page>3495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webster, G.A., Perkins, N.D.: Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19(5), 3485–3495 (1999)</ref-fulltext>
<ce:source-text>Webster, G.A., Perkins, N.D.: Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19(5), 3485–3495 (1999)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of PTEN expression by NF-kappa B prevents apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Vasudevan</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Gurumurthy</ce:surname>
</author>
<author seq="3">
<ce:initials>V.M.</ce:initials>
<ce:surname>Rangnekar</ce:surname>
<ce:given-name>V.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1007</first-page>
<last-page>1021</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vasudevan, K.M., Gurumurthy, S., Rangnekar, V.M.: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 24(3), 1007–1021 (2004)</ref-fulltext>
<ce:source-text>Vasudevan, K.M., Gurumurthy, S., Rangnekar, V.M.: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 24(3), 1007–1021 (2004)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammation and development of pancreatic ductal adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Xue</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Chin. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shi, J., Xue, J.: Inflammation and development of pancreatic ductal adenocarcinoma. Chin. Clin. Oncol. 8(2), 19 (2019)</ref-fulltext>
<ce:source-text>Shi, J., Xue, J.: Inflammation and development of pancreatic ductal adenocarcinoma. Chin. Clin. Oncol. 8(2), 19 (2019)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Hinz</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2690</first-page>
<last-page>2698</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hinz, M., et al.: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19(4), 2690–2698 (1999)</ref-fulltext>
<ce:source-text>Hinz, M., et al.: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19(4), 2690–2698 (1999)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.M.</ce:initials>
<ce:surname>Ratnam</ce:surname>
<ce:given-name>N.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>127</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3796</first-page>
<last-page>3809</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ratnam, N.M., et al.: NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127(10), 3796–3809 (2017)</ref-fulltext>
<ce:source-text>Ratnam, N.M., et al.: NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127(10), 3796–3809 (2017)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of survival pathways MAPK and NF-kB triggers apoptosis in pancreatic ductal adenocarcinoma cells via suppression of autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Papademetrio</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Target. Oncol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>195</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Papademetrio, D.L., et al.: Inhibition of survival pathways MAPK and NF-kB triggers apoptosis in pancreatic ductal adenocarcinoma cells via suppression of autophagy. Target. Oncol. 11(2), 183–195 (2016)</ref-fulltext>
<ce:source-text>Papademetrio, D.L., et al.: Inhibition of survival pathways MAPK and NF-kB triggers apoptosis in pancreatic ductal adenocarcinoma cells via suppression of autophagy. Target. Oncol. 11(2), 183–195 (2016)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB, an active player in human cancers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Xia</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="3">
<ce:initials>I.M.</ce:initials>
<ce:surname>Verma</ce:surname>
<ce:given-name>I.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Immunol. Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>823</first-page>
<last-page>830</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xia, Y., Shen, S., Verma, I.M.: NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2(9), 823–830 (2014)</ref-fulltext>
<ce:source-text>Xia, Y., Shen, S., Verma, I.M.: NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2(9), 823–830 (2014)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta-induced epithelial to mesenchymal transition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Lamouille</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>156</first-page>
<last-page>172</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, J., Lamouille, S., Derynck, R.: TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19(2), 156–172 (2009)</ref-fulltext>
<ce:source-text>Xu, J., Lamouille, S., Derynck, R.: TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19(2), 156–172 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.J.</ce:initials>
<ce:surname>Maier</ce:surname>
<ce:given-name>H.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>295</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>228</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maier, H.J., et al.: NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 295(2), 214–228 (2010)</ref-fulltext>
<ce:source-text>Maier, H.J., et al.: NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 295(2), 214–228 (2010)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Matsuo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Dig. Dis. Sci</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1167</first-page>
<last-page>1176</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matsuo, Y., et al.: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig. Dis. Sci. 55(4), 1167–1176 (2010)</ref-fulltext>
<ce:source-text>Matsuo, Y., et al.: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig. Dis. Sci. 55(4), 1167–1176 (2010)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Elliott</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Hum. Reprod</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>787</first-page>
<last-page>790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elliott, C.L., et al.: Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol. Hum. Reprod. 7(8), 787–790 (2001)</ref-fulltext>
<ce:source-text>Elliott, C.L., et al.: Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol. Hum. Reprod. 7(8), 787–790 (2001)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.X.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>T.X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>725</first-page>
<last-page>732</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xie, T.X., et al.: Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol. Rep. 23(3), 725–732 (2010)</ref-fulltext>
<ce:source-text>Xie, T.X., et al.: Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol. Rep. 23(3), 725–732 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.W.</ce:initials>
<ce:surname>Rhee</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biochem. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>88</first-page>
<last-page>94</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhee, J.W., et al.: NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J. Biochem. Mol. Biol. 40(1), 88–94 (2007)</ref-fulltext>
<ce:source-text>Rhee, J.W., et al.: NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J. Biochem. Mol. Biol. 40(1), 88–94 (2007)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Role of angiogenesis in tumor growth and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Folkman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>6</iss-first>
<suppl>Supplement 16</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
<last-page>18</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Folkman, J.: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl 16), 15–18 (2002)</ref-fulltext>
<ce:source-text>Folkman, J.: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl 16), 15–18 (2002)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1454</first-page>
<last-page>1466</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., et al.: Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells. 31(8), 1454–1466 (2013)</ref-fulltext>
<ce:source-text>Sun, L., et al.: Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells. 31(8), 1454–1466 (2013)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2455</first-page>
<last-page>2464</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, X., et al.: Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. 74(9), 2455–2464 (2014)</ref-fulltext>
<ce:source-text>Zhao, X., et al.: Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. 74(9), 2455–2464 (2014)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Samuel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>599</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Samuel, T., et al.: Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer. 14, 599 (2014)</ref-fulltext>
<ce:source-text>Samuel, T., et al.: Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer. 14, 599 (2014)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>An undesired effect of chemother apy: gemcitabine promotes pancreatic cancer cell  invasiveness through reactive oxygen species dependent, nuclear factor kappaB- and hypoxia inducible factor 1alpha-mediated up-regulation of  CXCR4.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Arora</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>288</vol-first>
<iss-first>29</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21197</first-page>
<last-page>21207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Arora, S., et al.: An undesired effect of chemother apy: gemcitabine promotes pancreatic cancer cell  invasiveness through reactive oxygen species dependent, nuclear factor kappaB- and hypoxia inducible factor 1alpha-mediated up-regulation of  CXCR4. J. Biol. Chem. 288(29), 21197–21207  (2013)</ref-fulltext>
<ce:source-text> Arora, S., et al.: An undesired effect of chemother apy: gemcitabine promotes pancreatic cancer cell  invasiveness through reactive oxygen species dependent, nuclear factor kappaB- and hypoxia inducible factor 1alpha-mediated up-regulation of  CXCR4. J. Biol. Chem. 288(29), 21197–21207  (2013)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.H.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Z.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science.</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>311</vol-first>
<iss-first>5764</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1141</first-page>
<last-page>1146</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, Z.H., et al.: Molecular linkage between the kinase ATM and NF-kappaB signaling in response  to genotoxic stimuli. Science. 311(5764),1141–1146 (2006)</ref-fulltext>
<ce:source-text>Wu, Z.H., et al.: Molecular linkage between the  kinase ATM and NF-kappaB signaling in response  to genotoxic stimuli. Science. 311(5764), 1141–1146  (2006)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Activation of NF-kappaB by  antineoplastic agents. Role of protein kinase C. J. Biol.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Das</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.W.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Chem.</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
<iss-first>23</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14914</first-page>
<last-page>14920</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, K.C., White, C.W.: Activation of NF-kappaB by  antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272(23), 14914–14920 (1997)</ref-fulltext>
<ce:source-text>Das, K.C., White, C.W.: Activation of NF-kappaB by  antineoplastic agents. Role of protein kinase C. J.  Biol. Chem. 272(23), 14914–14920 (1997)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Role of NF-kappaB and Akt/PI3K in  the resistance of pancreatic carcinoma cell lines  against gemcitabine-induced cell death.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Arlt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3243</first-page>
<last-page>3251</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arlt, A., et al.: Role of NF-kappaB and Akt/PI3K in  the resistance of pancreatic carcinoma cell lines  against gemcitabine-induced cell death. Oncogene.  22(21), 3243–3251 (2003)</ref-fulltext>
<ce:source-text>Arlt, A., et al.: Role of NF-kappaB and Akt/PI3K in  the resistance of pancreatic carcinoma cell lines  against gemcitabine-induced cell death. Oncogene.  22(21), 3243–3251 (2003)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Evodiamine inactivates NF-kappaB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. Onco. Targets</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>257</first-page>
<last-page>267</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, Q., et al.: Evodiamine inactivates NF-kappaB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. Onco. Targets. Ther. 12, 257–267 (2019)</ref-fulltext>
<ce:source-text>Guo, Q., et al.: Evodiamine inactivates NF-kappaB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. Onco. Targets. Ther. 12, 257–267 (2019)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Waters</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>158</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>881</first-page>
<last-page>888</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waters, J.A., et al.: Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery. 158(4), 881–8 (2015); discussion 888–9</ref-fulltext>
<ce:source-text>Waters, J.A., et al.: Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery. 158(4), 881–8 (2015); discussion 888–9</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Uwagawa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3173</first-page>
<last-page>3178</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Uwagawa, T., et al.: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 29(8), 3173–3178 (2009)</ref-fulltext>
<ce:source-text>Uwagawa, T., et al.: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 29(8), 3173–3178 (2009)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4349</first-page>
<last-page>4357</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mackey, J.R., et al.: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58(19), 4349–4357 (1998)</ref-fulltext>
<ce:source-text>Mackey, J.R., et al.: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58(19), 4349–4357 (1998)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer chemoresistance to gemcitabine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Amrutkar</ce:surname>
</author>
<author seq="2">
<ce:initials>I.P.</ce:initials>
<ce:surname>Gladhaug</ce:surname>
<ce:given-name>I.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Amrutkar, M., Gladhaug, I.P.: Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel).9, 11 (2017)</ref-fulltext>
<ce:source-text>Amrutkar, M., Gladhaug, I.P.: Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel). 9, 11 (2017)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Spratlin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6956</first-page>
<last-page>6961</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Spratlin, J., et al.: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20), 6956–6961 (2004)</ref-fulltext>
<ce:source-text>Spratlin, J., et al.: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20), 6956–6961 (2004)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.D.</ce:initials>
<ce:surname>Bhutia</ce:surname>
<ce:given-name>Y.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1825</first-page>
<last-page>1835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhutia, Y.D., et al.: CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 71(5), 1825–1835 (2011)</ref-fulltext>
<ce:source-text>Bhutia, Y.D., et al.: CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 71(5), 1825–1835 (2011)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Skrypek</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1714</first-page>
<last-page>1723</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skrypek, N., et al.: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 32(13), 1714–1723 (2013)</ref-fulltext>
<ce:source-text>Skrypek, N., et al.: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 32(13), 1714–1723 (2013)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of nuclear factor-kappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Momeny</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>9</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Momeny, M., et al.: Blockade of nuclear factor-kappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. Int. J. Biochem. Cell Biol. 99, 1–9 (2018)</ref-fulltext>
<ce:source-text>Momeny, M., et al.: Blockade of nuclear factor-kappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. Int. J. Biochem. Cell Biol. 99, 1–9 (2018)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: Overcoming transport defects using a nanoparticle approach</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.W.</ce:initials>
<ce:surname>Hung</ce:surname>
<ce:given-name>S.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>359</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>240</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hung, S.W., et al.: Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett. 359(2), 233–240 (2015)</ref-fulltext>
<ce:source-text>Hung, S.W., et al.: Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett. 359(2), 233–240 (2015)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-kappaB/STAT3 signaling cascade</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>382</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>53</first-page>
<last-page>63</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, Z., et al.: Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-kappaB/STAT3 signaling cascade. Cancer Lett. 382(1), 53–63 (2016)</ref-fulltext>
<ce:source-text>Zhang, Z., et al.: Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-kappaB/STAT3 signaling cascade. Cancer Lett. 382(1), 53–63 (2016)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Curcumin and gemcitabine in patients with advanced pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Epelbaum</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1137</first-page>
<last-page>1141</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Epelbaum, R., et al.: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer. 62(8), 1137–1141 (2010)</ref-fulltext>
<ce:source-text>Epelbaum, R., et al.: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer. 62(8), 1137–1141 (2010)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Cao</ce:surname>
</author>
<author seq="3">
<ce:initials>A.Z.</ce:initials>
<ce:surname>Dudek</ce:surname>
<ce:given-name>A.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1027</first-page>
<last-page>1031</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Cao, Q., Dudek, A.Z.: Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 32(3), 1027–1031 (2012)</ref-fulltext>
<ce:source-text>Wang, H., Cao, Q., Dudek, A.Z.: Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 32(3), 1027–1031 (2012)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wackerhage</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2019.</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>43</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wackerhage, H., et al.: Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise. J. Appl. Physiol. 2019. 126(1), 30–43 (1985)</ref-fulltext>
<ce:source-text>Wackerhage, H., et al.: Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise. J. Appl. Physiol. 2019. 126(1), 30–43 (1985)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear factor-kappa B signaling in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Malhotra</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Med. (Berl).</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1113</first-page>
<last-page>1126</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, H., Malhotra, S., Kumar, A.: Nuclear factor-kappa B signaling in skeletal muscle atrophy. J. Mol. Med. (Berl). 86(10), 1113–1126 (2008)</ref-fulltext>
<ce:source-text>Li, H., Malhotra, S., Kumar, A.: Nuclear factor-kappa B signaling in skeletal muscle atrophy. J. Mol. Med. (Berl). 86(10), 1113–1126 (2008)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy induced by mechanical unloading: Mechanisms and potential countermeasures</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>235</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, Y., et al.: Muscle atrophy induced by mechanical unloading: mechanisms and potential countermeasures. Front. Physiol. 9, 235 (2018)</ref-fulltext>
<ce:source-text>Gao, Y., et al.: Muscle atrophy induced by mechanical unloading: mechanisms and potential countermeasures. Front. Physiol. 9, 235 (2018)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Signaling pathways perturbing muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>225</first-page>
<last-page>229</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Glass, D.J.: Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care. 13(3), 225–229 (2010)</ref-fulltext>
<ce:source-text>Glass, D.J.: Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care. 13(3), 225–229 (2010)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Structural insights into the catalysis and regulation of E3 ubiquitin ligases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Buetow</ce:surname>
</author>
<author seq="2">
<ce:initials>D.T.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>D.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Mol. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>626</first-page>
<last-page>642</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buetow, L., Huang, D.T.: Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 17(10), 626–642 (2016)</ref-fulltext>
<ce:source-text>Buetow, L., Huang, D.T.: Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 17(10), 626–642 (2016)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of ubiquitin ligases required for skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Bodine</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>5547</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1704</first-page>
<last-page>1708</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bodine, S.C., et al.: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294(5547), 1704–1708 (2001)</ref-fulltext>
<ce:source-text>Bodine, S.C., et al.: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294(5547), 1704–1708 (2001)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Gomes</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>25</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14440</first-page>
<last-page>14445</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gomes, M.D., et al.: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA. 98(25), 14440–14445 (2001)</ref-fulltext>
<ce:source-text>Gomes, M.D., et al.: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA. 98(25), 14440–14445 (2001)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin-protein ligases in muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.R.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.J.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>H.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lecker</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2088</first-page>
<last-page>2097</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cao, P.R., Kim, H.J., Lecker, S.H.: Ubiquitin-protein ligases in muscle wasting. Int. J. Biochem. Cell Biol. 37(10), 2088–2097 (2005)</ref-fulltext>
<ce:source-text>Cao, P.R., Kim, H.J., Lecker, S.H.: Ubiquitin-protein ligases in muscle wasting. Int. J. Biochem. Cell Biol. 37(10), 2088–2097 (2005)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>835</first-page>
<last-page>847</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shi, J., et al.: The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell. 21(5), 835–847 (2011)</ref-fulltext>
<ce:source-text>Shi, J., et al.: The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell. 21(5), 835–847 (2011)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ye</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Gene</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>404</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>53</first-page>
<last-page>60</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, J., et al.: FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy. Gene. 404(1–2), 53–60 (2007)</ref-fulltext>
<ce:source-text>Ye, J., et al.: FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy. Gene. 404(1–2), 53–60 (2007)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Rhoads</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>191</first-page>
<last-page>197</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhoads, M.G., et al.: Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. 46(1), 191–197 (2010)</ref-fulltext>
<ce:source-text>Rhoads, M.G., et al.: Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. 46(1), 191–197 (2010)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>IKKbeta/NF-kappaB activation causes severe muscle wasting in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>119</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>298</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cai, D., et al.: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119(2), 285–298 (2004)</ref-fulltext>
<ce:source-text>Cai, D., et al.: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119(2), 285–298 (2004)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Mourkioti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>116</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2945</first-page>
<last-page>2954</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mourkioti, F., et al.: Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 116(11), 2945–2954 (2006)</ref-fulltext>
<ce:source-text>Mourkioti, F., et al.: Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 116(11), 2945–2954 (2006)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>306</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>C762</first-page>
<last-page>C767</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, C.L., et al.: NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy. Am. J. Physiol. Cell Physiol. 306(8), C762–C767 (2014)</ref-fulltext>
<ce:source-text>Wu, C.L., et al.: NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy. Am. J. Physiol. Cell Physiol. 306(8), C762–C767 (2014)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the protein acetylase, GCN5</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>290</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30269</first-page>
<last-page>30279</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, D., Goldberg, A.L.: Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the protein acetylase, GCN5. J. Biol. Chem. 290(51), 30269–30279 (2015)</ref-fulltext>
<ce:source-text>Lee, D., Goldberg, A.L.: Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the protein acetylase, GCN5. J. Biol. Chem. 290(51), 30269–30279 (2015)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia is regulated by selective targeting of skeletal muscle gene products</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>370</first-page>
<last-page>378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Acharyya, S., et al.: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114(3), 370–378 (2004)</ref-fulltext>
<ce:source-text>Acharyya, S., et al.: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114(3), 370–378 (2004)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2261</first-page>
<last-page>2268</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yuan, L., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. 33(5), 2261–2268 (2015)</ref-fulltext>
<ce:source-text>Yuan, L., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. 33(5), 2261–2268 (2015)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>D'orlando</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>528</first-page>
<last-page>533</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>D'Orlando, C., et al.: Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle. Muscle Nerve. 49(4), 528–533 (2014)</ref-fulltext>
<ce:source-text>D'Orlando, C., et al.: Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle. Muscle Nerve. 49(4), 528–533 (2014)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Williams</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>744</first-page>
<last-page>749</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Williams, A., et al.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 126(4): P. 744–9 (1999); discussion 749–50</ref-fulltext>
<ce:source-text>Williams, A., et al.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 126(4): P. 744–9 (1999); discussion 749–50</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2196</first-page>
<last-page>2206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Khal, J., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37(10), 2196–2206 (2005)</ref-fulltext>
<ce:source-text>Khal, J., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37(10), 2196–2206 (2005)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genome Med</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., et al.: Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2(1), 1 (2010)</ref-fulltext>
<ce:source-text>Stephens, N.A., et al.: Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2(1), 1 (2010)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Modeling human cancer-induced cachexia</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e4</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Talbert</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1612</first-page>
<last-page>1622</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Talbert, E.E., et al.: Modeling human cancer-induced cachexia. Cell Rep. 28(6), 1612–1622 e4 (2019)</ref-fulltext>
<ce:source-text>Talbert, E.E., et al.: Modeling human cancer-induced cachexia. Cell Rep. 28(6), 1612–1622 e4 (2019)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.W.</ce:initials>
<ce:surname>Cornwell</ce:surname>
<ce:given-name>E.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Cornwell, E.W., et al.: C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent. PLoS One. 9(1), e87776 (2014)</ref-fulltext>
<ce:source-text>Cornwell, E.W., et al.: C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent. PLoS One. 9(1), e87776 (2014)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Toxicol. Appl. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>278</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>199</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>472</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7590</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy: Cellular and molecular mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Glick</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Barth</ce:surname>
</author>
<author seq="3">
<ce:initials>K.F.</ce:initials>
<ce:surname>Macleod</ce:surname>
<ce:given-name>K.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>221</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Glick, D., Barth, S., Macleod, K.F.: Autophagy: Cellular and molecular mechanisms. J. Pathol. 221(1), 3–12 (2010)</ref-fulltext>
<ce:source-text>Glick, D., Barth, S., Macleod, K.F.: Autophagy: Cellular and molecular mechanisms. J. Pathol. 221(1), 3–12 (2010)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>The IKK complex contributes to the induction of autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Criollo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>619</first-page>
<last-page>631</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Criollo, A., et al.: The IKK complex contributes to the induction of autophagy. EMBO J. 29(3), 619–631 (2010)</ref-fulltext>
<ce:source-text>Criollo, A., et al.: The IKK complex contributes to the induction of autophagy. EMBO J. 29(3), 619–631 (2010)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>IKK-dependent, NF-kappaB-independent control of autophagic gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.C.</ce:initials>
<ce:surname>Comb</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>14</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1727</first-page>
<last-page>1732</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Comb, W.C., et al.: IKK-dependent, NF-kappaB-independent control of autophagic gene expression. Oncogene. 30(14), 1727–1732 (2011)</ref-fulltext>
<ce:source-text>Comb, W.C., et al.: IKK-dependent, NF-kappaB-independent control of autophagic gene expression. Oncogene. 30(14), 1727–1732 (2011)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagic degradation contributes to muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>182</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1367</first-page>
<last-page>1378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. 182(4), 1367–1378 (2013)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. 182(4), 1367–1378 (2013)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Denervation-induced oxidative stress and autophagy signaling in muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>O'leary</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Hood</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>230</first-page>
<last-page>231</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>O'Leary, M.F., Hood, D.A.: Denervation-induced oxidative stress and autophagy signaling in muscle. Autophagy. 5(2), 230–231 (2009)</ref-fulltext>
<ce:source-text>O'Leary, M.F., Hood, D.A.: Denervation-induced oxidative stress and autophagy signaling in muscle. Autophagy. 5(2), 230–231 (2009)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy is required to maintain muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Masiero</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>507</first-page>
<last-page>515</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Masiero, E., et al.: Autophagy is required to maintain muscle mass. Cell Metab. 10(6), 507–515 (2009)</ref-fulltext>
<ce:source-text>Masiero, E., et al.: Autophagy is required to maintain muscle mass. Cell Metab. 10(6), 507–515 (2009)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>431</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2674</first-page>
<last-page>2686</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. 431(15), 2674–2686 (2019)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. 431(15), 2674–2686 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Pax7 is required for the specification of myogenic satellite cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Seale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>777</first-page>
<last-page>786</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Seale, P., et al.: Pax7 is required for the specification of myogenic satellite cells. Cell. 102(6), 777–786 (2000)</ref-fulltext>
<ce:source-text>Seale, P., et al.: Pax7 is required for the specification of myogenic satellite cells. Cell. 102(6), 777–786 (2000)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>The molecular regulation of myogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Sabourin</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Rudnicki</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin.</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16</first-page>
<last-page>25</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sabourin, L.A., Rudnicki, M.A.: The molecular regulation of myogenesis. Clin. Genet. 57(1), 16–25  (2000)</ref-fulltext>
<ce:source-text>Sabourin, L.A., Rudnicki, M.A.: The molecular regulation of myogenesis. Clin. Genet. 57(1), 16–25 (2000)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Satellite cells and  the muscle stem cell niche.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Yin</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Price</ce:surname>
</author>
<author seq="3">
<ce:initials>M.A.</ce:initials>
<ce:surname>Rudnicki</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>23</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, H., Price, F., Rudnicki, M.A.: Satellite cells and  the muscle stem cell niche. Physiol. Rev. 93(1),  23–67 (2013)</ref-fulltext> <ce:source-text>Yin, H., Price, F., Rudnicki, M.A.: Satellite cells and  the muscle stem cell niche. Physiol. Rev. 93(1),  23–67 (2013)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Lukjanenko</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Stem Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>446</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lukjanenko, L., et al.: Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell. 24(3), 433–446 e7 (2019)</ref-fulltext>
<ce:source-text>Lukjanenko, L., et al.: Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell. 24(3), 433–446 e7 (2019)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Joe</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>163</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Joe, A.W., et al.: Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12(2), 153–163 (2010)</ref-fulltext>
<ce:source-text>Joe, A.W., et al.: Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12(2), 153–163 (2010)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Dellavalle</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>267</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dellavalle, A., et al.: Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9(3), 255–267 (2007)</ref-fulltext>
<ce:source-text>Dellavalle, A., et al.: Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9(3), 255–267 (2007)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>beta-Catenin activation in muscle progenitor cells regulates tissue repair</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Rudolf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1277</first-page>
<last-page>1290</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rudolf, A., et al.: beta-Catenin activation in muscle progenitor cells regulates tissue repair. Cell Rep. 15(6), 1277–1290 (2016)</ref-fulltext>
<ce:source-text>Rudolf, A., et al.: beta-Catenin activation in muscle progenitor cells regulates tissue repair. Cell Rep. 15(6), 1277–1290 (2016)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ikeya</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Takada</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Development</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4969</first-page>
<last-page>4976</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ikeya, M., Takada, S.: Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. Development. 125(24), 4969–4976 (1998)</ref-fulltext>
<ce:source-text>Ikeya, M., Takada, S.: Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. Development. 125(24), 4969–4976 (1998)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Black</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2950</first-page>
<last-page>2966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ref-fulltext>
<ce:source-text>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.M.</ce:initials>
<ce:surname>Conboy</ce:surname>
<ce:given-name>I.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>397</first-page>
<last-page>409</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Conboy, I.M., Rando, T.A.: The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell. 3(3), 397–409 (2002)</ref-fulltext>
<ce:source-text>Conboy, I.M., Rando, T.A.: The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell. 3(3), 397–409 (2002)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.A.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Clin.Invest</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4821</first-page>
<last-page>4835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W.A., et al.: NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123(11), 4821–4835 (2013)</ref-fulltext>
<ce:source-text>He, W.A., et al.: NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123(11), 4821–4835 (2013)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>289</vol-first>
<iss-first>5488</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2363</first-page>
<last-page>2366</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guttridge, D.C., et al.: NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science. 289(5488), 2363–2366 (2000)</ref-fulltext>
<ce:source-text>Guttridge, D.C., et al.: NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science. 289(5488), 2363–2366 (2000)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Inaba</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Inaba, S., et al.: Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential. PLoS One. 13(10), e0205467 (2018)</ref-fulltext>
<ce:source-text>Inaba, S., et al.: Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential. PLoS One. 13(10), e0205467 (2018)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Satellite cells senescence in limb muscle of severe patients with COPD</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Theriault</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
 
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Theriault, M.E., et al.: Satellite cells senescence in limb muscle of severe patients with COPD. PLoS One. 7(6), e39124 (2012)</ref-fulltext>
<ce:source-text>Theriault, M.E., et al.: Satellite cells senescence in limb muscle of severe patients with COPD. PLoS One. 7(6), e39124 (2012)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
 
</ref-authors>
<ref-sourcetitle>J. Am. Soc. Nephrol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>419</first-page>
<last-page>427</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., et al.: Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 21(3), 419–427 (2010)</ref-fulltext>
<ce:source-text>Zhang, L., et al.: Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 21(3), 419–427 (2010)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Spontaneous physical activity downregulates Pax7 in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Coletti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells Int</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>2016</vol-first>
</volume-issue-number>
</volisspag>
<ref-text>6729268</ref-text>
</ref-info>
<ref-fulltext>Coletti, D., et al.: Spontaneous physical activity downregulates Pax7 in cancer cachexia. Stem Cells Int. 2016, 6729268 (2016)</ref-fulltext>
<ce:source-text>Coletti, D., et al.: Spontaneous physical activity downregulates Pax7 in cancer cachexia. Stem Cells Int. 2016, 6729268 (2016)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4374</first-page>
<last-page>4387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., et al.: NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27(12), 4374–4387 (2007)</ref-fulltext>
<ce:source-text>Wang, H., et al.: NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27(12), 4374–4387 (2007)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>369</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., et al.: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 14(5), 369–381 (2008)</ref-fulltext>
<ce:source-text>Wang, H., et al.: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 14(5), 369–381 (2008)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Parajuli</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>712</first-page>
<last-page>725</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Parajuli, P., et al.: Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev. Cell. 45(6), 712–725 e6 (2018)</ref-fulltext>
<ce:source-text>Parajuli, P., et al.: Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev. Cell. 45(6), 712–725 e6 (2018)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.W.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1290</first-page>
<last-page>1300</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, C.W., et al.: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72(5), 1290–1300 (2012)</ref-fulltext>
<ce:source-text>Li, C.W., et al.: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72(5), 1290–1300 (2012)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>The Colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Vis. Exp</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<page-information>
<pages>
<first-page>117</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: The Colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: The Colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2273</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7(1), 2273 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7(1), 2273 (2017)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Nosacka</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Nosacka, R.L., et al.: Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. J. Cachexia. Sarcopenia Muscle. (2020)</ref-fulltext>
<ce:source-text>Nosacka, R.L., et al.: Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. J. Cachexia. Sarcopenia Muscle. (2020)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1861</first-page>
<last-page>1874</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Judge, S.M., et al.: MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer. Cancer Res. 80(9), 1861–1874 (2020)</ref-fulltext>
<ce:source-text>Judge, S.M., et al.: MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer. Cancer Res. 80(9), 1861–1874 (2020)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating myeloid cells invade the nervous system to mediate cachexia during pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.G.</ce:initials>
<ce:surname>Burfeind</ce:surname>
<ce:given-name>K.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Elife</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Burfeind, K.G., et al.: Circulating myeloid cells invade the nervous system to mediate cachexia during pancreatic cancer. elife. 9 (2020)</ref-fulltext>
<ce:source-text>Burfeind, K.G., et al.: Circulating myeloid cells invade the nervous system to mediate cachexia during pancreatic cancer. elife. 9 (2020)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Promising models for cancer-induced cachexia drug discovery</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Suzuki</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Springer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Expert Opin. Drug Discovery</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>627</first-page>
<last-page>637</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Suzuki, T., Von Haehling, S., Springer, J.: Promising models for cancer-induced cachexia drug discovery. Expert Opin. Drug Discovery. 15(5), 627–637 (2020)</ref-fulltext>
<ce:source-text>Suzuki, T., Von Haehling, S., Springer, J.: Promising models for cancer-induced cachexia drug discovery. Expert Opin. Drug Discovery. 15(5), 627–637 (2020)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Adipose triglyceride lipase contributes to cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Das</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>333</vol-first>
<iss-first>6039</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, S.K., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ref-fulltext>
<ce:source-text>Das, S.K., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging treatment options for cancer-associated cachexia: A literature review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ther. Clin. Risk Manag</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1266</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T.: Emerging treatment options for cancer-associated cachexia: A literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ref-fulltext>
<ce:source-text>Naito, T.: Emerging treatment options for cancer-associated cachexia: A literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>778</first-page>
<last-page>788</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Solheim, T.S., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 8(5), 778–788 (2017)</ref-fulltext>
<ce:source-text>Solheim, T.S., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 8(5), 778–788 (2017)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting IKKbeta in cancer: Challenges and opportunities for the therapeutic utilisation of IKKbeta inhibitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Prescott</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Cook</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Prescott, J.A., Cook, S.J.: Targeting IKKbeta in cancer: Challenges and opportunities for the therapeutic utilisation of IKKbeta inhibitors. Cell. 7(9) (2018)</ref-fulltext>
<ce:source-text>Prescott, J.A., Cook, S.J.: Targeting IKKbeta in cancer: Challenges and opportunities for the therapeutic utilisation of IKKbeta inhibitors. Cell. 7(9) (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_8</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Chemotherapy</author-keyword>
<author-keyword>Skeletal muscle</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Muscle weakness</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Therapy-Induced Toxicities Associated with the Onset of Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>Joshua R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>Fabrizio</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>Joshua R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>Fabrizio</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Anatomy, Cell Biology and Physiology</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="3">
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Otolaryngology – Head and Neck Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Otolaryngology – Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="4">
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Simon Comprehensive Cancer Center</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="5">
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Indiana Center for Musculoskeletal Health</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="6">
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Pathology</organization>
<organization>University of Colorado Anschutz Medical Campus</organization>
<city>Aurora</city>
<state>CO</state>
<country iso-code="USA"/>
<ce:source-text>Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
</person>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA"/>
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Cancer is the second-leading cause of death worldwide. Notably, 40% of all patients suffer from cachexia, a debilitating muscle wasting syndrome that represents one of the primary causes of death in advanced cancer patients. Despite their known side effects, such as vomiting, anorexia, mucositis, neuropathy, musculoskeletal and metabolic alterations, chemotherapy treatments are the most effective and extensively used strategies against cancer. Moreover, chemotherapeutic agents may participate in and even exacerbate the pathophysiological alterations driving cachexia. Indeed, skeletal muscle atrophy and cardiac abnormalities occurring as a consequence of chemotherapy administration can worsen the response to anticancer therapies, reduce physical activity and severely impede the quality of life in cancer patients. Hence, chemotherapy-induced cachexia has recently emerged as a critical clinical problem impacting outcomes and overall survival in cancer patients. Here, we review some of the mechanism(s) through which chemotherapeutics induce musculoskeletal deficits related to cachexia. Lastly, we discuss different strategies currently under consideration to protect muscle tissue from chemotherapy-related toxicities, including nutritional interventions, mitochondria-targeted molecules, ghrelin, bisphosphonates, ACVR2B antagonists, and physical exercise.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>139</first-page>
<last-page>153</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="157">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics2018</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ref-fulltext>
<ce:source-text>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Arem</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Loftfield</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Lifestyle Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>200</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arem, H., Loftfield, E.: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ref-fulltext>
<ce:source-text>Arem, H., Loftfield, E.: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Evolution of cancer pharmacological treatments at the turn of the third millennium</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Falzone</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Salomone</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Libra</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1300</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018)</ref-fulltext>
<ce:source-text>Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment – objectives and quality of life issues</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Khan</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.S.</ce:initials>
<ce:surname>Akhtar</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Sheikh</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Malays. J. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>5</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ref-fulltext>
<ce:source-text>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of the evolution of cancer treatment therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Arruebo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3279</first-page>
<last-page>3330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011)</ref-fulltext>
<ce:source-text>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Improving radiotherapy in cancer treatment: Promises and challenges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.H.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>H.H.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Kuo</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>37</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>62742</first-page>
<last-page>62758</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ref-fulltext>
<ce:source-text>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Radiation oncology in the era of precision medicine. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Baumann</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>234</first-page>
<last-page>249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016)</ref-fulltext>
<ce:source-text>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Hormonal therapy for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Jacinta Abraham</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Medicine</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ref-fulltext>
<ce:source-text>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Current status and future directions of cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1773</first-page>
<last-page>1781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Delivery strategies of cancer immunotherapy: Recent advances and future perspectives</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>126</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ref-fulltext>
<ce:source-text>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Alkylating Agents</ref-titletext-english>
</ref-title>
<ref-sourcetitle>Livertox: Clinical and Research Information on Drug-Induced Liver Injury</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-text>Bethesda (MD)</ref-text>
</ref-info>
<ref-fulltext>Alkylating Agents, in LiverTox: Clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ref-fulltext>
<ce:source-text>Alkylating Agents, in LiverTox: Clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lansiaux</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Antimetabolites. Bull. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1263</first-page>
<last-page>1274</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ref-fulltext>
<ce:source-text>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Topoisomerase I inhibitors: Camptothecins and beyond</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pommier</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, Y.: Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ref-fulltext>
<ce:source-text>Pommier, Y.: Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Vinca alkaloids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Moudi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Prev. Med.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1231</first-page>
<last-page>1235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ref-fulltext>
<ce:source-text>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Taxane pathway. Pharmacogenet</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Oshiro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genomics</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>979</first-page>
<last-page>983</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ref-fulltext>
<ce:source-text>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nurgali</ce:surname>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Abalo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>245</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ref-fulltext>
<ce:source-text>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Boltong</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Keast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Aranda</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2765</first-page>
<last-page>2774</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ref-fulltext>
<ce:source-text>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Drug-induced myelosuppression: Diagnosis and management</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.J.</ce:initials>
<ce:surname>Carey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Drug Saf</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>691</first-page>
<last-page>706</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ref-fulltext>
<ce:source-text>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.L.</ce:initials>
<ce:surname>Rapoport</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ref-fulltext>
<ce:source-text>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>The role of vagal neurocircuits in the regulation of nausea and vomiting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Babic</ce:surname>
</author>
<author seq="2">
<ce:initials>K.N.</ce:initials>
<ce:surname>Browning</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>722</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>38</first-page>
<last-page>47</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ref-fulltext>
<ce:source-text>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 Induces Anorexia through Nausea and Emesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ref-fulltext>
<ce:source-text>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.W.W.</ce:initials>
<ce:surname>Tsai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018)</ref-fulltext>
<ce:source-text>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Cinausero</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>354</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017)</ref-fulltext>
<ce:source-text>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of oral mucositis due to chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Chaveli-Lopez</ce:surname>
</author>
<author seq="2">
<ce:initials>J.V.</ce:initials>
<ce:surname>Bagan-Sebastian</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Exp Dent</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e201</first-page>
<last-page>e209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ref-fulltext>
<ce:source-text>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of chemotherapy-induced peripheral neuropathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Zajaczkowska</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ref-fulltext>
<ce:source-text>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Kolb</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JAMA Neurol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>860</first-page>
<last-page>866</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, N.A., et al.: The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ref-fulltext>
<ce:source-text>Kolb, N.A., et al.: The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy, cognitive impairment and hippocampal toxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Dietrich</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Prust</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Kaiser</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neuroscience</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>224</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ref-fulltext>
<ce:source-text>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Caeyenberghs</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neurosci. Biobehav. Rev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>92</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>304</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ref-fulltext>
<ce:source-text>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and chemotherapy-induced musculoskeletal degradation</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e10187</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JBMR Plus</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sturgeon, K.M., et al.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ref-fulltext>
<ce:source-text>Sturgeon, K.M., et al.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Baylink</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1983"/>
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>306</first-page>
<last-page>308</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ref-fulltext>
<ce:source-text>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Quach</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>886</first-page>
<last-page>897</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015)</ref-fulltext>
<ce:source-text>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Saarto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1341</first-page>
<last-page>1347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ref-fulltext>
<ce:source-text>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14470</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Essex</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>809</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ref-fulltext>
<ce:source-text>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>472</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue and quality of life outcomes of exercise during cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Mock</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Pract</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001)</ref-fulltext>
<ce:source-text>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7590</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>420</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ref-fulltext>
<ce:source-text>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Le Bricon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Metabolism</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1340</first-page>
<last-page>1348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ref-fulltext>
<ce:source-text>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Crawford</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>68</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ref-fulltext>
<ce:source-text>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2012</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Naishadham</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ref-fulltext>
<ce:source-text>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>72</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ref-fulltext>
<ce:source-text>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43442</first-page>
<last-page>43460</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ref-fulltext>
<ce:source-text>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>154</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ref-fulltext>
<ce:source-text>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic value of the six-minute walk in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Kasymjanova</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Thorac. Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>602</first-page>
<last-page>607</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ref-fulltext>
<ce:source-text>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Kurk</ce:surname>
<ce:given-name>S.A.</ce:given-name>

</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>909</first-page>
<last-page>919</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ref-fulltext>
<ce:source-text>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Freedman</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2248</first-page>
<last-page>2253</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ref-fulltext>
<ce:source-text>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Awad</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>74</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ref-fulltext>
<ce:source-text>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Poterucha</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Burnette</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1005</first-page>
<last-page>1009</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ref-fulltext>
<ce:source-text>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Toxicol. Appl. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>278</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>199</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Stacchiotti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
</volisspag>
<ref-text>840951</ref-text>
</ref-info>
<ref-fulltext>Stacchiotti, A., et al.: Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ref-fulltext>
<ce:source-text>Stacchiotti, A., et al.: Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Feather</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>650</first-page>
<last-page>658</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ref-fulltext>
<ce:source-text>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Sorensen</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>137</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ref-fulltext>
<ce:source-text>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.A.</ce:initials>
<ce:surname>de Lima</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>233</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9652</first-page>
<last-page>9662</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ref-fulltext>
<ce:source-text>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Hulmi</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>417</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hulmi, J.J., et al.: Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ref-fulltext>
<ce:source-text>Hulmi, J.J., et al.: Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32695</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Powers</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>471</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ref-fulltext>
<ce:source-text>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nishiyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3723</first-page>
<last-page>3738</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ref-fulltext>
<ce:source-text>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
<ce:given-name>W.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Grothey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>381</vol-first>
<iss-first>9863</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>303</first-page>
<last-page>312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ref-fulltext>
<ce:source-text>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shingina</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Can. J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>396</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ref-fulltext>
<ce:source-text>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sirago</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13017</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ref-fulltext>
<ce:source-text>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Tarpey</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19709</first-page>
<last-page>19722</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ref-fulltext>
<ce:source-text>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle weakness and neuromuscular junctions in aging and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Shigemoto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Geriatr Gerontol Int</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<suppl>Supplement 1</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S137</first-page>
<last-page>S147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010)</ref-fulltext>
<ce:source-text>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.</ce:initials>
<ce:surname>de Vos</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genet</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2720</first-page>
<last-page>2728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ref-fulltext>
<ce:source-text>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magrane</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>229</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ref-fulltext>
<ce:source-text>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular disease: Mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Malkki</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Neurol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>556</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ref-fulltext>
<ce:source-text>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ahn</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>428</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ref-fulltext>
<ce:source-text>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Rudolf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Age (Dordr.).</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ref-fulltext>
<ce:source-text>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.T.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Integr. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ref-fulltext>
<ce:source-text>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>McQuade</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3502</first-page>
<last-page>3521</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ref-fulltext>
<ce:source-text>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Webster</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>146</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1027</first-page>
<last-page>1039</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ref-fulltext>
<ce:source-text>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Modification of neuromuscular junction protein expression by exercise and doxorubicin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Huertas</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Huertas, A.M., et al.: Modification of neuromuscular junction protein expression by exercise and doxorubicin. Med. Sci. Sports Exerc. (2020)</ref-fulltext>
<ce:source-text>Huertas, A.M., et al.: Modification of neuromuscular junction protein expression by exercise and doxorubicin. Med. Sci. Sports Exerc. (2020)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english></ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>ERK inhibition</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ref-fulltext>
<ce:source-text>. Penna, F., et al.: Muscle wasting and impaired  myogenesis in tumor bearing mice are prevented by  ERK inhibition. PLoS One. 5(10), e13604 (2010)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english> p38beta MAPK mediates ULK1 dependent induction of autophagy in skeletal muscle  of tumor-bearing mice.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Stress.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>311</first-page>
<last-page>324</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Liu, Z., et al.: p38beta MAPK mediates ULK1 dependent induction of autophagy in skeletal muscle  of tumor-bearing mice. Cell Stress. 2(11), 311–324  (2018)</ref-fulltext>
<ce:source-text> Liu, Z., et al.: p38beta MAPK mediates ULK1 dependent induction of autophagy in skeletal muscle  of tumor-bearing mice. Cell Stress. 2(11), 311–324  (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Quan-Jun</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer Ther.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>334</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ref-fulltext>
<ce:source-text> Quan-Jun, Y., et al.: Selumetinib attenuates skeletal  muscle wasting in murine cachexia model through  ERK inhibition and AKT activation. Mol. Cancer  Ther. 16(2), 334–343 (2017)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Ghrelin prevents tumour- and  cisplatin-induced muscle wasting: characterization  of multiple mechanisms involved.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>132</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.A., et al.: Ghrelin prevents tumour- and  cisplatin-induced muscle wasting: characterization  of multiple mechanisms involved. J. Cachexia.  Sarcopenia Muscle. 6(2), 132–143 (2015)</ref-fulltext>
<ce:source-text>Chen, J.A., et al.: Ghrelin prevents tumour- and  cisplatin-induced muscle wasting: characterization  of multiple mechanisms involved. J. Cachexia.  Sarcopenia Muscle. 6(2), 132–143 (2015)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Dexamethasone exacerbates cisplatin-induced muscle atrophy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol. Physiol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp.Pharmacol. Physiol. 46(1), 19–28 (2019)</ref-fulltext>
<ce:source-text> Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp.Pharmacol. Physiol. 46(1), 19–28 (2019)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B  ligands protects myocardium from acute ischemia reperfusion injury.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magga</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>600</first-page>
<last-page>610</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magga, J., et al.: Systemic blockade of ACVR2B  ligands protects myocardium from acute ischemia reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ref-fulltext>
<ce:source-text>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated cardiomyocyte senes cence contributes to late-onset doxorubicin-induced  cardiotoxicity.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Mitry</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle></ref-sourcetitle>
<ref-publicationyear first="2020"/>
<ref-text>Am. J. Physiol.</ref-text>
</ref-info>
<ref-fulltext>Mitry, M.A., et al.: Accelerated cardiomyocyte senes cence contributes to late-onset doxorubicin-induced  cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ref-fulltext>
<ce:source-text>Mitry, M.A., et al.: Accelerated cardiomyocyte senes cence contributes to late-onset doxorubicin-induced  cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Dexrazoxane ameliorates doxorubicin induced cardiotoxicity by inhibiting both apoptosis  and necroptosis in cardiomyocytes. Biochem.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochem.Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin induced cardiotoxicity by inhibiting both apoptosis  and necroptosis in cardiomyocytes. Biochem.  Biophys. Res. Commun. (2019)</ref-fulltext>
<ce:source-text>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin induced cardiotoxicity by inhibiting both apoptosis  and necroptosis in cardiomyocytes. Biochem.  Biophys. Res. Commun. (2019)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>C.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Apoptosis</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>894</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ref-fulltext>
<ce:source-text>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of rutin on cisplatin-induced oxidative cardiac damage in rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Topal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Anatol. J. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>142</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ref-fulltext>
<ce:source-text>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Constantinou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
<last-page>24</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ref-fulltext>
<ce:source-text>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>On the origin of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1956"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>3191</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ref-fulltext>
<ce:source-text>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
<ce:given-name>L.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
<ce:given-name>C.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
<iss-first>5930</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Energy metabolism in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rohm</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>EMBO Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ref-fulltext>
<ce:source-text>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>279</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>163</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>643</first-page>
<last-page>655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ref-fulltext>
<ce:source-text>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Lipid metabolism in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.D.</ce:initials>
<ce:surname>Mulligan</ce:surname>
<ce:given-name>H.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Beck</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>57</first-page>
<last-page>61</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ref-fulltext>
<ce:source-text>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance and body composition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Dev</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Dalal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<suppl>Supplement _2</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>ii18</first-page>
<last-page>ii26</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ref-fulltext>
<ce:source-text>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Hyperglycemia and insulin resistance: Possible mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Tomas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. N. Y. Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>967</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ref-fulltext>
<ce:source-text>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Acute hyperglycemia associated with anti-cancer medication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hwangbo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.K.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>E.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinol. Metab. (Seoul).</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>23</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ref-fulltext>
<ce:source-text>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Pathophysiology of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Younes</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Noguchi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Hosp. Clin. Fac. Med. Sao Paulo</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>181</first-page>
<last-page>193</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ref-fulltext>
<ce:source-text>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Cho</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Pediatr. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>226</first-page>
<last-page>228</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ref-fulltext>
<ce:source-text>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of the activity of the pyruvate dehydrogenase complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Harris</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>Adv. Enzym. Regul</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>249</first-page>
<last-page>259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ref-fulltext>
<ce:source-text>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7778</first-page>
<last-page>7790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>41</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43202</first-page>
<last-page>43215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Shum</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
 
</ref-authors>
<ref-sourcetitle>Aging (Albany NY)</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>133</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shum, A.M., et al.: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY). 4(2), 133–143 (2012)</ref-fulltext>
<ce:source-text>Shum, A.M., et al.: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY). 4(2), 133–143 (2012)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived oxidant stress</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Guigni</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
 
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>315</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>C744</first-page>
<last-page>C756</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ref-fulltext>
<ce:source-text>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms for fiber-type specificity of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Pessin</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>250</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ref-fulltext>
<ce:source-text>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress as key regulator of muscle wasting during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Abrigo</ce:surname>
</author>
 
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ref-fulltext>
<ce:source-text>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Eley</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>282</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7087</first-page>
<last-page>7097</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ref-fulltext>
<ce:source-text>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.I.</ce:initials>
<ce:surname>Block</ce:surname>
<ce:given-name>K.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1227</first-page>
<last-page>1239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ref-fulltext>
<ce:source-text>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cannavino</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>592</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4575</first-page>
<last-page>4589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ref-fulltext>
<ce:source-text>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>44</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16260</first-page>
<last-page>16265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ref-fulltext>
<ce:source-text>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ref-fulltext>
<ce:source-text>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.L.</ce:initials>
<ce:surname>Xi</ce:surname>
<ce:given-name>Q.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Lett</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4013</first-page>
<last-page>4020</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ref-fulltext>
<ce:source-text>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Molinari</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>954</first-page>
<last-page>973</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ref-fulltext>
<ce:source-text>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.</ce:initials>
<ce:surname>Padilha</ce:surname>
<ce:given-name>C.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>923</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ref-fulltext>
<ce:source-text>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Combined exercise training positively affects muscle wasting in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ranjbar</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
<last-page>1395</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ref-fulltext>
<ce:source-text>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5482</first-page>
<last-page>5494</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>469</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1495</first-page>
<last-page>1505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cave</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3337</first-page>
<last-page>3351</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ref-fulltext>
<ce:source-text>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Mijwel</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>169</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>93</first-page>
<last-page>103</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ref-fulltext>
<ce:source-text>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of muscle growth by multiple ligands signaling through activin type II receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18117</first-page>
<last-page>18122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ref-fulltext>
<ce:source-text>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Activin signaling as an emerging target for therapeutic interventions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tsuchida</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Cell Commun. Signal</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ref-fulltext>
<ce:source-text>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>26</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ref-fulltext>
<ce:source-text>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>514</first-page>
<last-page>529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>The systemic activin response to pancreatic cancer: Implications for effective cancer cachexia therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhong</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1083</first-page>
<last-page>1101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ref-fulltext>
<ce:source-text>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ref-fulltext>
<ce:source-text>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Bone and muscle: Interactions beyond mechanical</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brotto</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Bonewald</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109</first-page>
<last-page>114</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brotto, M., Bonewald, L.: Bone and muscle: Interactions beyond mechanical. Bone. 80, 109–114 (2015)</ref-fulltext>
<ce:source-text>Brotto, M., Bonewald, L.: Bone and muscle: Interactions beyond mechanical. Bone. 80, 109–114 (2015)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Differential bone loss in mouse models of colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>679</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>700</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Pamidronate attenuates muscle loss after pediatric burn injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Borsheim</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1369</first-page>
<last-page>1372</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ref-fulltext>
<ce:source-text>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bonnet</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>129</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3214</first-page>
<last-page>3223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ref-fulltext>
<ce:source-text>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Nutrition interventions to treat low muscle mass in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Purcell</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Laviano</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ref-fulltext>
<ce:source-text>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations of protein turnover underlying disuse atrophy in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Phillips</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.I.</ce:initials>
<ce:surname>Glover</ce:surname>
<ce:given-name>E.I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Rennie</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2009.</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>645</first-page>
<last-page>654</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ref-fulltext>
<ce:source-text>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.S.</ce:initials>
<ce:surname>Van der Meij</ce:surname>
<ce:given-name>B.S.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2399</first-page>
<last-page>2407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ref-fulltext>
<ce:source-text>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN guidelines on nutrition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
<last-page>48</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ref-fulltext>
<ce:source-text>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cereda</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>16</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6923</first-page>
<last-page>6932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ref-fulltext>
<ce:source-text>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bumrungpert</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>J. Med. Food</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>612</first-page>
<last-page>616</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ref-fulltext>
<ce:source-text>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Tozer</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>Antioxid. Redox Signal</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>402</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ref-fulltext>
<ce:source-text>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Cruz</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Oliveira</ce:surname>
</author>
<author seq="3">
<ce:initials>M.C.C.</ce:initials>
<ce:surname>Gomes-Marcondes</ce:surname>
<ce:given-name>M.C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>96</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>253</first-page>
<last-page>260</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ref-fulltext>
<ce:source-text>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Toneto</ce:surname>
<ce:given-name>A.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>577</first-page>
<last-page>586</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ref-fulltext>
<ce:source-text>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Int. J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>713</first-page>
<last-page>720</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ref-fulltext>
<ce:source-text>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>May</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>479</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ref-fulltext>
<ce:source-text>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Gramignano</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutrition</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>145</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ref-fulltext>
<ce:source-text>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1775</first-page>
<last-page>1782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ref-fulltext>
<ce:source-text>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>311</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>R89</first-page>
<last-page>R96</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ref-fulltext>
<ce:source-text>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e23</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Fujitsuka</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Psychiatry</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ref-fulltext>
<ce:source-text>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.O.</ce:initials>
<ce:surname>Villars</ce:surname>
<ce:given-name>F.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ref-fulltext>
<ce:source-text>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Yoshimura</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>811</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>37</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ref-fulltext>
<ce:source-text>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiomi</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>818</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ref-fulltext>
<ce:source-text>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hiura</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4785</first-page>
<last-page>4794</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ref-fulltext>
<ce:source-text>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_9</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Bone metastasis</author-keyword>
<author-keyword>Bone-muscle crosstalk</author-keyword>
<author-keyword>Muscle function</author-keyword>
<author-keyword>Bone resorption</author-keyword>
<author-keyword>Chemotherapy</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Bone-Muscle Crosstalk in Advanced Cancer and Chemotherapy</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>David L.</ce:given-name>
<ce:e-address>dwaning@psu.edu</ce:e-address>
</author>
<affiliation>
<organization>Penn State College of Medicine</organization>
<city>Hershey</city>
<state>PA</state>
<country iso-code="USA"/>
<ce:source-text>Penn State College of Medicine, Hershey, PA, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>David L.</ce:given-name>
<ce:e-address>dwaning@psu.edu</ce:e-address>
</author>
<affiliation>
<organization>Penn State Cancer Institute</organization>
<city>Hershey</city>
<state>PA</state>
<country iso-code="USA"/>
<ce:source-text>Penn State Cancer Institute, Hershey, PA, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>David L.</ce:given-name>
</person>
<affiliation>
<organization>Penn State College of Medicine</organization>
<city>Hershey</city>
<state>PA</state>
<country iso-code="USA"/>
<ce:source-text>Penn State College of Medicine, Hershey, PA, USA</ce:source-text>
</affiliation>
<ce:e-address>dwaning@psu.edu</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Advanced cancers metastasize to distant sites and bone is a common site for metastases from breast, lung, and prostate cancers. Breast and lung cancer bone metastases typically lead to osteolytic lesions. Osteolytic bone metastases lead to bone pain, nerve compression, hypercalcemia, increased risk of fractures from falls, and muscle weakness. Bone metastases are incurable, and therapies for osteolytic lesions are aimed at reducing tumor burden and limiting bone loss. In addition to growth of tumor cells in bone, systemic effects to the musculoskeletal system are important in the overall reduction in mobility and increased morbidity. The focus of this chapter will be on the process of breast cancer cell colonization of bone, and bone-muscle crosstalk in breast cancer bone metastases and chemotherapy-induced bone loss. Much progress has been made recently in our understanding of the interplay between bone and muscle in cancer and chemotherapy, and future therapeutic strategies will likely include considerations for both of these tissues in the context of reducing overall tumor burden in bone.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>155</first-page>
<last-page>167</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="129">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2018</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocr. Rev</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18</first-page>
<last-page>54</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guise, T.A., Mundy, G.R.: Cancer and bone. Endocr. Rev. 19(1), 18–54 (1998)</ref-fulltext>
<ce:source-text>Guise, T.A., Mundy, G.R.: Cancer and bone. Endocr. Rev. 19(1), 18–54 (1998)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: A fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>The bone extracellular matrix as an ideal milieu for cancer cell metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, A.D., Bussard, K.M.: The bone extracellular matrix as an ideal milieu for cancer cell metastases. Cancers (Basel). 11(7) (2019)</ref-fulltext>
<ce:source-text>Kolb, A.D., Bussard, K.M.: The bone extracellular matrix as an ideal milieu for cancer cell metastases. Cancers (Basel). 11(7) (2019)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Kinetics of metastatic breast cancer cell trafficking in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.A.</ce:initials>
<ce:surname>Phadke</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.R.</ce:initials>
<ce:surname>Mercer</ce:surname>
<ce:given-name>R.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.F.</ce:initials>
<ce:surname>Harms</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Jia</ce:surname>
</author>
<author seq="5">
<ce:initials>A.R.</ce:initials>
<ce:surname>Frost</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.L.</ce:initials>
<ce:surname>Jewell</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1431</first-page>
<last-page>1440</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Phadke, P.A., Mercer, R.R., Harms, J.F., Jia, Y., Frost, A.R., Jewell, J.L., et al.: Kinetics of metastatic breast cancer cell trafficking in bone. Clin. Cancer Res. 12(5), 1431–1440 (2006)</ref-fulltext>
<ce:source-text>Phadke, P.A., Mercer, R.R., Harms, J.F., Jia, Y., Frost, A.R., Jewell, J.L., et al.: Kinetics of metastatic breast cancer cell trafficking in bone. Clin. Cancer Res. 12(5), 1431–1440 (2006)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphology and organization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.B.</ce:initials>
<ce:surname>Burr</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Akkus</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Basic and Applied Bone Biology</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-text>Burr, D.B., Allen, M.R. (eds.), 2nd edn. Elsevier</ref-text>
</ref-info>
<ref-fulltext>Burr, D.B., Akkus, O.: Bone morphology and organization. In: Burr, D.B., Allen, M.R. (eds.) Basic and applied bone biology, 2nd edn. Elsevier (2014)</ref-fulltext>
<ce:source-text>Burr, D.B., Akkus, O.: Bone morphology and organization. In: Burr, D.B., Allen, M.R. (eds.) Basic and applied bone biology, 2nd edn. Elsevier (2014)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Novel techniques to study the bone-tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Shupp</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Exp. Med. Biol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>1225</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>18</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shupp, A.B., Kolb, A.D., Bussard, K.M.: Novel techniques to study the bone-tumor microenvironment. Adv. Exp. Med. Biol. 1225, 1–18 (2020)</ref-fulltext>
<ce:source-text>Shupp, A.B., Kolb, A.D., Bussard, K.M.: Novel techniques to study the bone-tumor microenvironment. Adv. Exp. Med. Biol. 1225, 1–18 (2020)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer metastases to bone: Concepts, mechanisms, and interactions with bone osteoblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Shupp</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Mukhopadhyay</ce:surname>
</author>
<author seq="4">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Shupp, A.B., Kolb, A.D., Mukhopadhyay, D., Bussard, K.M.: Cancer metastases to bone: Concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel). 10(6) (2018)</ref-fulltext>
<ce:source-text>Shupp, A.B., Kolb, A.D., Mukhopadhyay, D., Bussard, K.M.: Cancer metastases to bone: Concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel). 10(6) (2018)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Location matters: Osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Holen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Metastasis</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>927</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, H.K., Ottewell, P.D., Evans, C.A., Holen, I.: Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin. Exp. Metastasis. 29(8), 927–938 (2012)</ref-fulltext>
<ce:source-text>Brown, H.K., Ottewell, P.D., Evans, C.A., Holen, I.: Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin. Exp. Metastasis. 29(8), 927–938 (2012)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Welte</ce:surname>
</author>
<author seq="5">
<ce:initials>A.M.</ce:initials>
<ce:surname>Muscarella</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27(2), 193–210 (2015)</ref-fulltext>
<ce:source-text>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27(2), 193–210 (2015)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e7</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Goldstein</ce:surname>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Bado</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>823</first-page>
<last-page>839</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., et al.: The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell. 34(5), 823–39 e7 (2018)</ref-fulltext>
<ce:source-text>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., et al.: The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell. 34(5), 823–39 e7 (2018)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Connexins, connexons, and intercellular communication. Annu</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Goodenough</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Goliger</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.L.</ce:initials>
<ce:surname>Paul</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Biochem</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>475</first-page>
<last-page>502</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goodenough, D.A., Goliger, J.A., Paul, D.L.: Connexins, connexons, and intercellular communication. Annu. Rev. Biochem. 65, 475–502 (1996)</ref-fulltext>
<ce:source-text>Goodenough, D.A., Goliger, J.A., Paul, D.L.: Connexins, connexons, and intercellular communication. Annu. Rev. Biochem. 65, 475–502 (1996)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.K.</ce:initials>
<ce:surname>Lim</ce:surname>
<ce:given-name>P.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Bliss</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Taborga</ce:surname>
</author>
<author seq="5">
<ce:initials>M.A.</ce:initials>
<ce:surname>Dave</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gregory</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author> 
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1550</first-page>
<last-page>1560</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lim, P.K., Bliss, S.A., Patel, S.A., Taborga, M., Dave, M.A., Gregory, L.A., et al.: Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71(5), 1550–1560 (2011)</ref-fulltext>
<ce:source-text>Lim, P.K., Bliss, S.A., Patel, S.A., Taborga, M., Dave, M.A., Gregory, L.A., et al.: Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71(5), 1550–1560 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: The next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>144</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>646</first-page>
<last-page>674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144(5), 646–674 (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144(5), 646–674 (2011)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.P.</ce:initials>
<ce:surname>Rong</ce:surname>
<ce:given-name>Y.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Aromolaran</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Bultynck</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Zhong</ce:surname>
</author>
<author seq="5">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>McColl</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Mol. Cell</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rong, Y.P., Aromolaran, A.S., Bultynck, G., Zhong, F., Li, X., McColl, K., et al.: Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals. Mol. Cell. 31(2), 255–265 (2008)</ref-fulltext>
<ce:source-text>Rong, Y.P., Aromolaran, A.S., Bultynck, G., Zhong, F., Li, X., McColl, K., et al.: Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals. Mol. Cell. 31(2), 255–265 (2008)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Crosstalk between calcium and reactive oxygen species signaling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Hempel</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Trebak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Calcium</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>63</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>70</first-page>
<last-page>96</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hempel, N., Trebak, M.: Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium. 63, 70–96 (2017)</ref-fulltext>
<ce:source-text>Hempel, N., Trebak, M.: Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium. 63, 70–96 (2017)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Dai</ce:surname>
</author>
<author seq="3">
<ce:initials>C.G.</ce:initials>
<ce:surname>Winter</ce:surname>
<ce:given-name>C.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Bae</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kasimir-Bauer</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>731</first-page>
<last-page>747</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., et al.: Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. 32(6), 731–47 e6 (2017)</ref-fulltext>
<ce:source-text>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., et al.: Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. 32(6), 731–47 e6 (2017)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Mu</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20(6), 701–714 (2011)</ref-fulltext>
<ce:source-text>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20(6), 701–714 (2011)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Lou</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="5">
<ce:initials>R.S.</ce:initials>
<ce:surname>Taichman</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.K.</ce:initials>
<ce:surname>Lau</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4302</first-page>
<last-page>4308</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liang, Z., Wu, T., Lou, H., Yu, X., Taichman, R.S., Lau, S.K., et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64(12), 4302–4308 (2004)</ref-fulltext>
<ce:source-text>Liang, Z., Wu, T., Lou, H., Yu, X., Taichman, R.S., Lau, S.K., et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64(12), 4302–4308 (2004)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>The role of chemokine receptor CXCR4 in breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Mukherjee</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>46</first-page>
<last-page>57</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mukherjee, D., Zhao, J.: The role of chemokine receptor CXCR4 in breast cancer metastasis. Am. J. Cancer Res. 3(1), 46–57 (2013)</ref-fulltext>
<ce:source-text>Mukherjee, D., Zhao, J.: The role of chemokine receptor CXCR4 in breast cancer metastasis. Am. J. Cancer Res. 3(1), 46–57 (2013)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.S.</ce:initials>
<ce:surname>Bendre</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>Montague</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Peery</ce:surname>
</author>
<author seq="4">
<ce:initials>N.S.</ce:initials>
<ce:surname>Akel</ce:surname>
<ce:given-name>N.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Gaddy</ce:surname>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Suva</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28</first-page>
<last-page>37</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bendre, M.S., Montague, D.C., Peery, T., Akel, N.S., Gaddy, D., Suva, L.J.: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 33(1), 28–37 (2003)</ref-fulltext>
<ce:source-text>Bendre, M.S., Montague, D.C., Peery, T., Akel, N.S., Gaddy, D., Suva, L.J.: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 33(1), 28–37 (2003)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Venzon</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Mastro</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1138</first-page>
<last-page>1148</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bussard, K.M., Venzon, D.J., Mastro, A.M.: Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J. Cell. Biochem. 111(5), 1138–1148 (2010)</ref-fulltext>
<ce:source-text>Bussard, K.M., Venzon, D.J., Mastro, A.M.: Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J. Cell. Biochem. 111(5), 1138–1148 (2010)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.B.</ce:initials>
<ce:surname>Shupp</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Mukhopadhyay</ce:surname>
</author>
<author seq="4">
<ce:initials>F.C.</ce:initials>
<ce:surname>Marini</ce:surname>
<ce:given-name>F.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>31</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, A.D., Shupp, A.B., Mukhopadhyay, D., Marini, F.C., Bussard, K.M.: Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 21(1), 31 (2019)</ref-fulltext>
<ce:source-text>Kolb, A.D., Shupp, A.B., Mukhopadhyay, D., Marini, F.C., Bussard, K.M.: Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 21(1), 31 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cao</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Palomares</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Yan</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Breast Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>127</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, X., Cao, M., Palomares, M., Wu, X., Li, A., Yan, W., et al.: Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 20(1), 127 (2018)</ref-fulltext>
<ce:source-text>Liu, X., Cao, M., Palomares, M., Wu, X., Li, A., Yan, W., et al.: Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 20(1), 127 (2018)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Dang</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10872</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., et al.: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016)</ref-fulltext>
<ce:source-text>Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., et al.: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Nie</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Peng</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Discov</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16015</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, W., Zhao, C., Li, Y., Wang, L., Nie, G., Peng, J., et al.: Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2, 16015 (2016)</ref-fulltext>
<ce:source-text>Sun, W., Zhao, C., Li, Y., Wang, L., Nie, G., Peng, J., et al.: Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2, 16015 (2016)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Xie</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Ge</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1033</first-page>
<last-page>1041</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xie, Y., Chen, Y., Zhang, L., Ge, W., Tang, P.: The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J. Cell. Mol. Med. 21(5), 1033–1041 (2017)</ref-fulltext>
<ce:source-text>Xie, Y., Chen, Y., Zhang, L., Ge, W., Tang, P.: The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J. Cell. Mol. Med. 21(5), 1033–1041 (2017)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Cappariello</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Loftus</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Muraca</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Maurizi</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Rucci</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Teti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>517</first-page>
<last-page>533</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cappariello, A., Loftus, A., Muraca, M., Maurizi, A., Rucci, N., Teti, A.: Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone. J. Bone Miner. Res. 33(3), 517–533 (2018)</ref-fulltext>
<ce:source-text>Cappariello, A., Loftus, A., Muraca, M., Maurizi, A., Rucci, N., Teti, A.: Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone. J. Bone Miner. Res. 33(3), 517–533 (2018)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Bone-derived extracellular vesicles: Novel players of interorgan crosstalk</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Yin</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Lv</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Deng</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>846</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y., Yin, P., Guo, Z., Lv, H., Deng, Y., Chen, M., et al.: Bone-derived extracellular vesicles: novel players of interorgan crosstalk. Front. Endocrinol. (Lausanne). 10, 846 (2019)</ref-fulltext>
<ce:source-text>Li, Y., Yin, P., Guo, Z., Lv, H., Deng, Y., Chen, M., et al.: Bone-derived extracellular vesicles: novel players of interorgan crosstalk. Front. Endocrinol. (Lausanne). 10, 846 (2019)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Bliss</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Sinha</ce:surname>
</author>
<author seq="3">
<ce:initials>O.A.</ce:initials>
<ce:surname>Sandiford</ce:surname>
<ce:given-name>O.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.M.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.J.</ce:initials>
<ce:surname>Engelberth</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Guiro</ce:surname>
</author> 
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>76</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5832</first-page>
<last-page>5844</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bliss, S.A., Sinha, G., Sandiford, O.A., Williams, L.M., Engelberth, D.J., Guiro, K., et al.: Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 76(19), 5832–5844 (2016)</ref-fulltext>
<ce:source-text>Bliss, S.A., Sinha, G., Sandiford, O.A., Williams, L.M., Engelberth, D.J., Guiro, K., et al.: Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 76(19), 5832–5844 (2016)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Vallabhaneni</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Penfornis</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Hassler</ce:surname>
</author>
<author seq="5">
<ce:initials>K.V.</ce:initials>
<ce:surname>Adams</ce:surname>
<ce:given-name>K.V.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.Y.</ce:initials>
<ce:surname>Mo</ce:surname>
<ce:given-name>Y.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>66</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109861</first-page>
<last-page>109876</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vallabhaneni, K.C., Penfornis, P., Xing, F., Hassler, Y., Adams, K.V., Mo, Y.Y., et al.: Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 8(66), 109861–109876 (2017)</ref-fulltext>
<ce:source-text>Vallabhaneni, K.C., Penfornis, P., Xing, F., Hassler, Y., Adams, K.V., Mo, Y.Y., et al.: Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 8(66), 109861–109876 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes and extracellular RNA in muscle and bone aging and crosstalk</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Qin</ce:surname>
</author>
<author seq="2">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>548</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Qin, W., Dallas, S.L.: Exosomes and extracellular RNA in muscle and bone aging and crosstalk. Curr. Osteoporos. Rep. 17(6), 548–559 (2019)</ref-fulltext>
<ce:source-text>Qin, W., Dallas, S.L.: Exosomes and extracellular RNA in muscle and bone aging and crosstalk. Curr. Osteoporos. Rep. 17(6), 548–559 (2019)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Q.</ce:initials>
<ce:surname>Hassan</ce:surname>
<ce:given-name>M.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Maeda</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Jafferji</ce:surname>
</author>
<author seq="6">
<ce:initials>J.A.</ce:initials>
<ce:surname>Gordon</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>42084</first-page>
<last-page>42092</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A., et al.: miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 287(50), 42084–42092 (2012)</ref-fulltext>
<ce:source-text>Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A., et al.: miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 287(50), 42084–42092 (2012)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Cheng</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>H.B.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>H.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="5">
<ce:initials>H.D.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>H.D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Xie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1180</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, P., Chen, C., He, H.B., Hu, R., Zhou, H.D., Xie, H., et al.: miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J. Bone Miner. Res. 28(5), 1180–1190 (2013)</ref-fulltext>
<ce:source-text>Cheng, P., Chen, C., He, H.B., Hu, R., Zhou, H.D., Xie, H., et al.: miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J. Bone Miner. Res. 28(5), 1180–1190 (2013)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNA functions in osteogenesis and dysfunctions in osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>van Wijnen</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Van de Peppel</ce:surname>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>van Leeuwen</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.B.</ce:initials>
<ce:surname>Lian</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.S.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.J.</ce:initials>
<ce:surname>Westendorf</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>82</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Wijnen, A.J., van de Peppel, J., van Leeuwen, J.P., Lian, J.B., Stein, G.S., Westendorf, J.J., et al.: MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11(2), 72–82 (2013)</ref-fulltext>
<ce:source-text>van Wijnen, A.J., van de Peppel, J., van Leeuwen, J.P., Lian, J.B., Stein, G.S., Westendorf, J.J., et al.: MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11(2), 72–82 (2013)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs in bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Hesse</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>122</first-page>
<last-page>128</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hesse, E., Taipaleenmaki, H.: MicroRNAs in bone metastasis. Curr. Osteoporos. Rep. 17(3), 122–128 (2019)</ref-fulltext>
<ce:source-text>Hesse, E., Taipaleenmaki, H.: MicroRNAs in bone metastasis. Curr. Osteoporos. Rep. 17(3), 122–128 (2019)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Browne</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Akech</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Zustin</ce:surname>
</author>
<author seq="5">
<ce:initials>A.J.</ce:initials>
<ce:surname>van Wijnen</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.L.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>75</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1433</first-page>
<last-page>1444</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Taipaleenmaki, H., Browne, G., Akech, J., Zustin, J., van Wijnen, A.J., Stein, J.L., et al.: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75(7), 1433–1444 (2015)</ref-fulltext>
<ce:source-text>Taipaleenmaki, H., Browne, G., Akech, J., Zustin, J., van Wijnen, A.J., Stein, J.L., et al.: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75(7), 1433–1444 (2015)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Krzeszinski</ce:surname>
<ce:given-name>J.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Huynh</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Jin</ce:surname>
</author>
<author seq="5">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="6">
<ce:initials>T.C.</ce:initials>
<ce:surname>Chang</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>512</vol-first>
<iss-first>7515</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>435</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Krzeszinski, J.Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.C., et al.: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 512(7515), 431–435 (2014)</ref-fulltext>
<ce:source-text>Krzeszinski, J.Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.C., et al.: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 512(7515), 431–435 (2014)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Croset</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pantano</ce:surname>
</author>
<author seq="3">
<ce:initials>C.W.S.</ce:initials>
<ce:surname>Kan</ce:surname>
<ce:given-name>C.W.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Bonnelye</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:surname>Descotes</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5259</first-page>
<last-page>5273</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Croset, M., Pantano, F., Kan, C.W.S., Bonnelye, E., Descotes, F., Alix-Panabieres, C., et al.: miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78(18), 5259–5273 (2018)</ref-fulltext>
<ce:source-text>Croset, M., Pantano, F., Kan, C.W.S., Bonnelye, E., Descotes, F., Alix-Panabieres, C., et al.: miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78(18), 5259–5273 (2018)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
</author>
<author seq="2">
<ce:initials>N.H.</ce:initials>
<ce:surname>Farina</ce:surname>
<ce:given-name>N.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>van Wijnen</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.L.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Hesse</ce:surname>
</author>
<author seq="6">
<ce:initials>G.S.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>48</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>79032</first-page>
<last-page>79046</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Taipaleenmaki, H., Farina, N.H., van Wijnen, A.J., Stein, J.L., Hesse, E., Stein, G.S., et al.: Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 7(48), 79032–79046 (2016)</ref-fulltext>
<ce:source-text>Taipaleenmaki, H., Farina, N.H., van Wijnen, A.J., Stein, J.L., Hesse, E., Stein, G.S., et al.: Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 7(48), 79032–79046 (2016)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Bren-Mattison</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hausburg</ce:surname>
</author>
<author seq="3">
<ce:initials>B.B.</ce:initials>
<ce:surname>Olwin</ce:surname>
<ce:given-name>B.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>356</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>486</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bren-Mattison, Y., Hausburg, M., Olwin, B.B.: Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev. Biol. 356(2), 486–495 (2011)</ref-fulltext>
<ce:source-text>Bren-Mattison, Y., Hausburg, M., Olwin, B.B.: Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev. Biol. 356(2), 486–495 (2011)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>The ‘muscle-bone unit’ during the pubertal growth spurt</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Rauch</ce:surname>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Bailey</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Baxter-Jones</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Mirwald</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Faulkner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
<last-page>775</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rauch, F., Bailey, D.A., Baxter-Jones, A., Mirwald, R., Faulkner, R.: The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 34(5), 771–775 (2004)</ref-fulltext>
<ce:source-text>Rauch, F., Bailey, D.A., Baxter-Jones, A., Mirwald, R., Faulkner, R.: The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 34(5), 771–775 (2004)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenia-consequences, mechanisms, and potential therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Greenlund</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Nair</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mech. Ageing Dev</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>287</first-page>
<last-page>299</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Greenlund, L.J., Nair, K.S.: Sarcopenia-consequences, mechanisms, and potential therapies. Mech. Ageing Dev. 124(3), 287–299 (2003)</ref-fulltext>
<ce:source-text>Greenlund, L.J., Nair, K.S.: Sarcopenia-consequences, mechanisms, and potential therapies. Mech. Ageing Dev. 124(3), 287–299 (2003)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Steensberg</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>van Hall</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Osada</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sacchetti</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Saltin</ce:surname>
</author>
<author seq="6">
<ce:initials>P.B.</ce:initials>
<ce:surname>Klarlund</ce:surname>
<ce:given-name>P.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
<part>Part 1</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>237</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., Klarlund, P.B.: Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 529(Pt 1), 237–242 (2000)</ref-fulltext>
<ce:source-text>Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., Klarlund, P.B.: Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 529(Pt 1), 237–242 (2000)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Serrano</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Baeza-Raja</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Perdiguero</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Jardi</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Munoz-Canoves</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>33</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., Munoz-Canoves, P.: Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 7(1), 33–44 (2008)</ref-fulltext>
<ce:source-text>Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., Munoz-Canoves, P.: Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 7(1), 33–44 (2008)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-sourcetitle>The Role of Exercise-Induced Myokines in Muscle Homeostasis and the Defense against Chronic Diseases</ref-sourcetitle>
<ref-publicationyear first="2010"/>
</ref-info>
<ref-fulltext>The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases, (2010)</ref-fulltext>
<ce:source-text>The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases, (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bostrom</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>M.P.</ce:initials>
<ce:surname>Jedrychowski</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Korde</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Ye</ce:surname>
</author>
<author seq="6">
<ce:initials>J.C.</ce:initials>
<ce:surname>Lo</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>481</vol-first>
<iss-first>7382</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>463</first-page>
<last-page>468</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bostrom, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al.: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 481(7382), 463–468 (2012)</ref-fulltext>
<ce:source-text>Bostrom, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al.: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 481(7382), 463–468 (2012)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kleiner</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>513</vol-first>
<iss-first>7516</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ref-fulltext>
<ce:source-text>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Schweiger</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Schreiber</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Campos-Olivas</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Tsoli</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Allen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ref-fulltext>
<ce:source-text>Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lipids Health Dis</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Han, J., Meng, Q., Shen, L., Wu, G.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ref-fulltext>
<ce:source-text>Han, J., Meng, Q., Shen, L., Wu, G.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>McPherron</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Lawler</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>387</vol-first>
<iss-first>6628</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>83</first-page>
<last-page>90</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387(6628), 83–90 (1997)</ref-fulltext>
<ce:source-text>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387(6628), 83–90 (1997)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McFarlane</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Plummer</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Hennebry</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Ashby</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Ling</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>209</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>514</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. 209(2), 501–514 (2006)</ref-fulltext>
<ce:source-text>McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. 209(2), 501–514 (2006)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Bone and skeletal muscle: Neighbors with close ties</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Digirolamo</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.P.</ce:initials>
<ce:surname>Kiel</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.A.</ce:initials>
<ce:surname>Esser</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1509</first-page>
<last-page>1518</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DiGirolamo, D.J., Kiel, D.P., Esser, K.A.: Bone and skeletal muscle: neighbors with close ties. J. Bone Miner. Res. 28(7), 1509–1518 (2013)</ref-fulltext>
<ce:source-text>DiGirolamo, D.J., Kiel, D.P., Esser, K.A.: Bone and skeletal muscle: neighbors with close ties. J. Bone Miner. Res. 28(7), 1509–1518 (2013)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Vallejo</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Gutheil</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Vemula</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Jahn</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Yi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1531</first-page>
<last-page>1544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kitase, Y., Vallejo, J.A., Gutheil, W., Vemula, H., Jahn, K., Yi, J., et al.: beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 22(6), 1531–1544 (2018)</ref-fulltext>
<ce:source-text>Kitase, Y., Vallejo, J.A., Gutheil, W., Vemula, H., Jahn, K., Yi, J., et al.: beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 22(6), 1531–1544 (2018)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Pun</ce:surname>
</author>
<author seq="3">
<ce:initials>T.J.</ce:initials>
<ce:surname>Wronski</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>140</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5780</first-page>
<last-page>5788</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liang, H., Pun, S., Wronski, T.J.: Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology. 140(12), 5780–5788 (1999)</ref-fulltext>
<ce:source-text>Liang, H., Pun, S., Wronski, T.J.: Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology. 140(12), 5780–5788 (1999)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating levels of IGF-1 directly regulate bone growth and density</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yakar</ce:surname>
</author>
<author seq="2">
<ce:initials>C.J.</ce:initials>
<ce:surname>Rosen</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.G.</ce:initials>
<ce:surname>Beamer</ce:surname>
<ce:given-name>W.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Ackert-Bicknell</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="6">
<ce:initials>J.L.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>110</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yakar, S., Rosen, C.J., Beamer, W.G., Ackert-Bicknell, C.L., Wu, Y., Liu, J.L., et al.: Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110(6), 771–781 (2002)</ref-fulltext>
<ce:source-text>Yakar, S., Rosen, C.J., Beamer, W.G., Ackert-Bicknell, C.L., Wu, Y., Liu, J.L., et al.: Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110(6), 771–781 (2002)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Y.Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.L.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Li, X., Zhou, Z.Y., Zhang, Y.Y., Yang, H.L.: IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse. PLoS One. 11(4), e0154677 (2016)</ref-fulltext>
<ce:source-text>Li, X., Zhou, Z.Y., Zhang, Y.Y., Yang, H.L.: IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse. PLoS One. 11(4), e0154677 (2016)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Kellum</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Starr</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Arounleut</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Immel</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Fulzele</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Wenger</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17</first-page>
<last-page>23</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kellum, E., Starr, H., Arounleut, P., Immel, D., Fulzele, S., Wenger, K., et al.: Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 44(1), 17–23 (2009)</ref-fulltext>
<ce:source-text>Kellum, E., Starr, H., Arounleut, P., Immel, D., Fulzele, S., Wenger, K., et al.: Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 44(1), 17–23 (2009)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Wallner</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Jaurich</ce:surname>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Becerikli</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Harati</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Dadras</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9878</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallner, C., Jaurich, H., Wagner, J.M., Becerikli, M., Harati, K., Dadras, M., et al.: Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Sci. Rep. 7(1), 9878 (2017)</ref-fulltext>
<ce:source-text>Wallner, C., Jaurich, H., Wagner, J.M., Becerikli, M., Harati, K., Dadras, M., et al.: Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Sci. Rep. 7(1), 9878 (2017)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of myokines on bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Kaji</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bonekey Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>826</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaji, H.: Effects of myokines on bone. Bonekey Rep. 5, 826 (2016)</ref-fulltext>
<ce:source-text>Kaji, H.: Effects of myokines on bone. Bonekey Rep. 5, 826 (2016)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.W.</ce:initials>
<ce:surname>Hamrick</ce:surname>
<ce:given-name>M.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Samaddar</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Pennington</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>McCormick</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>477</first-page>
<last-page>483</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hamrick, M.W., Samaddar, T., Pennington, C., McCormick, J.: Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J. Bone Miner. Res. 21(3), 477–483 (2006)</ref-fulltext>
<ce:source-text>Hamrick, M.W., Samaddar, T., Pennington, C., McCormick, J.: Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J. Bone Miner. Res. 21(3), 477–483 (2006)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenic role of Fgf23 in Hyp mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Rowe</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.D.</ce:initials>
<ce:surname>Quarles</ce:surname>
<ce:given-name>L.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>291</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D.W., Quarles, L.D.: Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291(1), E38–E49 (2006)</ref-fulltext>
<ce:source-text>Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D.W., Quarles, L.D.: Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291(1), E38–E49 (2006)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Aono</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Hasegawa</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yamazaki</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Shimada</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Fujita</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Yamashita</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>803</first-page>
<last-page>810</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aono, Y., Hasegawa, H., Yamazaki, Y., Shimada, T., Fujita, T., Yamashita, T., et al.: Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J. Bone Miner. Res. 26(4), 803–810 (2011)</ref-fulltext>
<ce:source-text>Aono, Y., Hasegawa, H., Yamazaki, Y., Shimada, T., Fujita, T., Yamashita, T., et al.: Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J. Bone Miner. Res. 26(4), 803–810 (2011)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>FGF23 induces left ventricular hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Faul</ce:surname>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Amaral</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Oskouei</ce:surname>
</author>
<author seq="4">
<ce:initials>M.C.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Sloan</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Isakova</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4393</first-page>
<last-page>4408</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., et al.: FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121(11), 4393–4408 (2011)</ref-fulltext>
<ce:source-text>Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., et al.: FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121(11), 4393–4408 (2011)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Mera</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Laue</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ferron</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Confavreux</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Galan-Diez</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1078</first-page>
<last-page>1092</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mera, P., Laue, K., Ferron, M., Confavreux, C., Wei, J., Galan-Diez, M., et al.: Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 23(6), 1078–1092 (2016)</ref-fulltext>
<ce:source-text>Mera, P., Laue, K., Ferron, M., Confavreux, C., Wei, J., Galan-Diez, M., et al.: Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 23(6), 1078–1092 (2016)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Osteocalcin is necessary and sufficient to maintain muscle mass in older mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Mera</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Laue</ce:surname>
</author>
<author seq="3">
<ce:initials>J.W.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Berger</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Karsenty</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Metab</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1042</first-page>
<last-page>1047</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mera, P., Laue, K., Wei, J.W., Berger, J.M., Karsenty, G.: Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol. Metab. 5(10), 1042–1047 (2016)</ref-fulltext>
<ce:source-text>Mera, P., Laue, K., Wei, J.W., Berger, J.M., Karsenty, G.: Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol. Metab. 5(10), 1042–1047 (2016)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of activin in the regulation of bone metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Eto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>188</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, R., Eto, Y.: Involvement of activin in the regulation of bone metabolism. Mol. Cell. Endocrinol. 180(1–2), 183–188 (2001)</ref-fulltext>
<ce:source-text>Sakai, R., Eto, Y.: Involvement of activin in the regulation of bone metabolism. Mol. Cell. Endocrinol. 180(1–2), 183–188 (2001)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Quantification of various growth factors in different demineralized bone matrix preparations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Wildemann</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Kadow-Romacker</ce:surname>
</author>
<author seq="3">
<ce:initials>N.P.</ce:initials>
<ce:surname>Haas</ce:surname>
<ce:given-name>N.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Schmidmaier</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biomed. Mater. Res. A</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>81</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>437</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wildemann, B., Kadow-Romacker, A., Haas, N.P., Schmidmaier, G.: Quantification of various growth factors in different demineralized bone matrix preparations. J. Biomed. Mater. Res. A. 81(2), 437–442 (2007)</ref-fulltext>
<ce:source-text>Wildemann, B., Kadow-Romacker, A., Haas, N.P., Schmidmaier, G.: Quantification of various growth factors in different demineralized bone matrix preparations. J. Biomed. Mater. Res. A. 81(2), 437–442 (2007)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Role of transforming growth factor-beta in bone remodeling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.F.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Orthop. Relat. Res</ref-sourcetitle>
<ref-publicationyear first="1990"/>
<volisspag>
<volume-issue-number>
<vol-first>250</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>261</first-page>
<last-page>276</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonewald, L.F., Mundy, G.R.: Role of transforming growth factor-beta in bone remodeling. Clin. Orthop. Relat. Res. 250, 261–276 (1990)</ref-fulltext>
<ce:source-text>Bonewald, L.F., Mundy, G.R.: Role of transforming growth factor-beta in bone remodeling. Clin. Orthop. Relat. Res. 250, 261–276 (1990)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Rosser</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>277</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21352</first-page>
<last-page>21360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dallas, S.L., Rosser, J.L., Mundy, G.R., Bonewald, L.F.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ref-fulltext>
<ce:source-text>Dallas, S.L., Rosser, J.L., Mundy, G.R., Bonewald, L.F.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Tulley</ce:surname>
</author>
<author seq="4">
<ce:initials>G.P.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>G.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Serganova</ce:surname>
</author>
<author seq="6">
<ce:initials>C.R.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13909</first-page>
<last-page>13914</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ref-fulltext>
<ce:source-text>Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Shu</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Drobnjak</ce:surname>
</author>
<author seq="5">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Cordon-Cardo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Korpal</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="5">
<ce:initials>D.A.</ce:initials>
<ce:surname>Lerit</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>960</first-page>
<last-page>966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D.A., Kang, Y.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ref-fulltext>
<ce:source-text>Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D.A., Kang, Y.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Selander</ce:surname>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Chirgwin</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Dallas</ce:surname>
</author>
<author seq="5">
<ce:initials>B.G.</ce:initials>
<ce:surname>Grubbs</ce:surname>
<ce:given-name>B.G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Wieser</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>197</first-page>
<last-page>206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ref-fulltext>
<ce:source-text>Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Xie</ce:surname>
</author>
<author seq="5">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>John</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., Mohammad, K.S., Reiken, S., Xie, W., Andersson, D.C., John, S., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., Mohammad, K.S., Reiken, S., Xie, W., Andersson, D.C., John, S., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Regan</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mikesell</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="5">
<ce:initials>A.R.</ce:initials>
<ce:surname>Marks</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Regan, J.N., Mikesell, C., Reiken, S., Xu, H., Marks, A.R., Mohammad, K.S., et al.: Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model. Front. Endocrinol. (Lausanne). 8, 358 (2017)</ref-fulltext>
<ce:source-text>Regan, J.N., Mikesell, C., Reiken, S., Xu, H., Marks, A.R., Mohammad, K.S., et al.: Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model. Front. Endocrinol. (Lausanne). 8, 358 (2017)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Physiology and pathophysiology of excitation-contraction coupling: The functional role of ryanodine receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Santulli</ce:surname>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Lewis</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.R.</ce:initials>
<ce:surname>Marks</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Muscle Res. Cell Motil</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>37</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Santulli, G., Lewis, D.R., Marks, A.R.: Physiology and pathophysiology of excitation-contraction coupling: The functional role of ryanodine receptor. J. Muscle Res. Cell Motil. 38(1), 37–45 (2017)</ref-fulltext>
<ce:source-text>Santulli, G., Lewis, D.R., Marks, A.R.: Physiology and pathophysiology of excitation-contraction coupling: The functional role of ryanodine receptor. J. Muscle Res. Cell Motil. 38(1), 37–45 (2017)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Betzenhauser</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
</author>
<author seq="4">
<ce:initials>A.C.</ce:initials>
<ce:surname>Meli</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Umanskaya</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Xie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andersson, D.C., Betzenhauser, M.J., Reiken, S., Meli, A.C., Umanskaya, A., Xie, W., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ref-fulltext>
<ce:source-text>Andersson, D.C., Betzenhauser, M.J., Reiken, S., Meli, A.C., Umanskaya, A., Xie, W., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Bellinger</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Carlson</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Mongillo</ce:surname>
</author>
<author seq="5">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Rothman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>325</first-page>
<last-page>330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bellinger, A.M., Reiken, S., Carlson, C., Mongillo, M., Liu, X., Rothman, L., et al.: Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15(3), 325–330 (2009)</ref-fulltext>
<ce:source-text>Bellinger, A.M., Reiken, S., Carlson, C., Mongillo, M., Liu, X., Rothman, L., et al.: Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15(3), 325–330 (2009)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Ago</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Kitazono</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Ooboshi</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Iyama</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>Y.H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Takada</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>227</first-page>
<last-page>233</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ago, T., Kitazono, T., Ooboshi, H., Iyama, T., Han, Y.H., Takada, J., et al.: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 109(2), 227–233 (2004)</ref-fulltext>
<ce:source-text>Ago, T., Kitazono, T., Ooboshi, H., Iyama, T., Han, Y.H., Takada, J., et al.: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 109(2), 227–233 (2004)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Carmona-Cuenca</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Roncero</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Sancho</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Caja</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Fausto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Fernandez</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Hepatol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>965</first-page>
<last-page>976</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carmona-Cuenca, I., Roncero, C., Sancho, P., Caja, L., Fausto, N., Fernandez, M., et al.: Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49(6), 965–976 (2008)</ref-fulltext>
<ce:source-text>Carmona-Cuenca, I., Roncero, C., Sancho, P., Caja, L., Fausto, N., Fernandez, M., et al.: Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49(6), 965–976 (2008)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Nyman</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.R.</ce:initials>
<ce:surname>Merkel</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Uppuganti</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Nayak</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Rowland</ce:surname>
</author>
<author seq="6">
<ce:initials>A.J.</ce:initials>
<ce:surname>Makowski</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>91</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>81</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nyman, J.S., Merkel, A.R., Uppuganti, S., Nayak, B., Rowland, B., Makowski, A.J., et al.: Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone. 91, 81–91 (2016)</ref-fulltext>
<ce:source-text>Nyman, J.S., Merkel, A.R., Uppuganti, S., Nayak, B., Rowland, B., Makowski, A.J., et al.: Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone. 91, 81–91 (2016)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.K.</ce:initials>
<ce:surname>Dunn</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.G.</ce:initials>
<ce:surname>Fournier</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.R.</ce:initials>
<ce:surname>McKenna</ce:surname>
<ce:given-name>C.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.W.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Niewolna</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Dunn, L.K., Mohammad, K.S., Fournier, P.G., McKenna, C.R., Davis, H.W., Niewolna, M., et al.: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 4(9), e6896 (2009)</ref-fulltext>
<ce:source-text>Dunn, L.K., Mohammad, K.S., Fournier, P.G., McKenna, C.R., Davis, H.W., Niewolna, M., et al.: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 4(9), e6896 (2009)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.O.</ce:initials>
<ce:surname>Marx</ce:surname>
<ce:given-name>S.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Hisamatsu</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Jayaraman</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Burkhoff</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Rosemblit</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>101</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>365</first-page>
<last-page>376</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marx, S.O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., et al.: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 101(4), 365–376 (2000)</ref-fulltext>
<ce:source-text>Marx, S.O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., et al.: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 101(4), 365–376 (2000)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mendias</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Gumucio</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.W.</ce:initials>
<ce:surname>Bromley</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.S.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<author seq="6">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>55</first-page>
<last-page>59</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mendias, C.L., Gumucio, J.P., Davis, M.E., Bromley, C.W., Davis, C.S., Brooks, S.V.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ref-fulltext>
<ce:source-text>Mendias, C.L., Gumucio, J.P., Davis, M.E., Bromley, C.W., Davis, C.S., Brooks, S.V.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.K.</ce:initials>
<ce:surname>Boxhorn</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="1987"/>
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>567</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Allen, R.E., Boxhorn, L.K.: Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J. Cell. Physiol. 133(3), 567–572 (1987)</ref-fulltext>
<ce:source-text>Allen, R.E., Boxhorn, L.K.: Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J. Cell. Physiol. 133(3), 567–572 (1987)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.K.</ce:initials>
<ce:surname>Boxhorn</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<volisspag>
<volume-issue-number>
<vol-first>138</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>311</first-page>
<last-page>315</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Allen, R.E., Boxhorn, L.K.: Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J. Cell. Physiol. 138(2), 311–315 (1989)</ref-fulltext>
<ce:source-text>Allen, R.E., Boxhorn, L.K.: Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J. Cell. Physiol. 138(2), 311–315 (1989)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Nagaraju</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Bakay</ce:surname>
</author>
<author seq="4">
<ce:initials>O.</ce:initials>
<ce:surname>McIntyre</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Rawat</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neurology</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>826</first-page>
<last-page>834</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, Y.W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R., et al.: Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 65(6), 826–834 (2005)</ref-fulltext>
<ce:source-text>Chen, Y.W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R., et al.: Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 65(6), 826–834 (2005)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta and myostatin signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.D.</ce:initials>
<ce:surname>Kollias</ce:surname>
<ce:given-name>H.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.C.</ce:initials>
<ce:surname>McDermott</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2008</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>579</first-page>
<last-page>587</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kollias, H.D., McDermott, J.C.: Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol. 2008, 104(3), 579–587 (1985)</ref-fulltext>
<ce:source-text>Kollias, H.D., McDermott, J.C.: Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol. 2008, 104(3), 579–587 (1985)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of muscle growth by multiple ligands signaling through activin type II receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.A.</ce:initials>
<ce:surname>Reed</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.V.</ce:initials>
<ce:surname>Davies</ce:surname>
<ce:given-name>M.V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Girgenrath</ce:surname>
</author>
<author seq="5">
<ce:initials>M.E.</ce:initials>
<ce:surname>Goad</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.N.</ce:initials>
<ce:surname>Tomkinson</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18117</first-page>
<last-page>18122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, S.J., Reed, L.A., Davies, M.V., Girgenrath, S., Goad, M.E., Tomkinson, K.N., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ref-fulltext>
<ce:source-text>Lee, S.J., Reed, L.A., Davies, M.V., Girgenrath, S., Goad, M.E., Tomkinson, K.N., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Song</ce:surname>
</author>
<author seq="5">
<ce:initials>K.S.</ce:initials>
<ce:surname>Kwak</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Q.</ce:initials>
<ce:surname>Jiao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ref-fulltext>
<ce:source-text>Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bogdanovich</ce:surname>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Goncalves</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.S.</ce:initials>
<ce:surname>Ahima</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Lachey</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Seehra</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1287</first-page>
<last-page>1297</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pistilli, E.E., Bogdanovich, S., Goncalves, M.D., Ahima, R.S., Lachey, J., Seehra, J., et al.: Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178(3), 1287–1297 (2011)</ref-fulltext>
<ce:source-text>Pistilli, E.E., Bogdanovich, S., Goncalves, M.D., Ahima, R.S., Lachey, J., Seehra, J., et al.: Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178(3), 1287–1297 (2011)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>BMP signaling controls muscle mass. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sartori</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Schirwis</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Blaauw</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Bortolanza</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:surname>Enzo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genet</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1309</first-page>
<last-page>1318</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309–1318 (2013)</ref-fulltext>
<ce:source-text>Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309–1318 (2013)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation and dysregulation of fibrosis in skeletal muscle. Exp</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Serrano</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Munoz-Canoves</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>316</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3050</first-page>
<last-page>3058</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Serrano, A.L., Munoz-Canoves, P.: Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 316(18), 3050–3058 (2010)</ref-fulltext>
<ce:source-text>Serrano, A.L., Munoz-Canoves, P.: Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 316(18), 3050–3058 (2010)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: Insights from genetic models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Schiaffino</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mammucari</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schiaffino, S., Mammucari, C.: Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet. Muscle. 1(1), 4 (2011)</ref-fulltext>
<ce:source-text>Schiaffino, S., Mammucari, C.: Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet. Muscle. 1(1), 4 (2011)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>Growth hormone and the insulin-like growth factor system in myogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Florini</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.Z.</ce:initials>
<ce:surname>Ewton</ce:surname>
<ce:given-name>D.Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Coolican</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocr. Rev</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>481</first-page>
<last-page>517</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Florini, J.R., Ewton, D.Z., Coolican, S.A.: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17(5), 481–517 (1996)</ref-fulltext>
<ce:source-text>Florini, J.R., Ewton, D.Z., Coolican, S.A.: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17(5), 481–517 (1996)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Wang-Gillam</ce:surname>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Miles</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.F.</ce:initials>
<ce:surname>Hutchins</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>821</first-page>
<last-page>827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang-Gillam, A., Miles, D.A., Hutchins, L.F.: Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 13(7), 821–827 (2008)</ref-fulltext>
<ce:source-text>Wang-Gillam, A., Miles, D.A., Hutchins, L.F.: Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 13(7), 821–827 (2008)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.H.</ce:initials>
<ce:surname>Burne</ce:surname>
<ce:given-name>T.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.N.</ce:initials>
<ce:surname>Johnston</ce:surname>
<ce:given-name>A.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>McGrath</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Mackay-Sim</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Brain Res. Bull</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>74</first-page>
<last-page>78</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Burne, T.H., Johnston, A.N., McGrath, J.J., Mackay-Sim, A.: Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull. 69(1), 74–78 (2006)</ref-fulltext>
<ce:source-text>Burne, T.H., Johnston, A.N., McGrath, J.J., Mackay-Sim, A.: Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull. 69(1), 74–78 (2006)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Impaired motor performance in mice lacking neurosteroid vitamin D receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.V.</ce:initials>
<ce:surname>Kalueff</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.R.</ce:initials>
<ce:surname>Lou</ce:surname>
<ce:given-name>Y.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Laaksi</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Tuohimaa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Brain Res. Bull</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalueff, A.V., Lou, Y.R., Laaksi, I., Tuohimaa, P.: Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain Res. Bull. 64(1), 25–29 (2004)</ref-fulltext>
<ce:source-text>Kalueff, A.V., Lou, Y.R., Laaksi, I., Tuohimaa, P.: Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain Res. Bull. 64(1), 25–29 (2004)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Osteomalacic myopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="1994"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>580</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Russell, J.A.: Osteomalacic myopathy. Muscle Nerve. 17(6), 578–580 (1994)</ref-fulltext>
<ce:source-text>Russell, J.A.: Osteomalacic myopathy. Muscle Nerve. 17(6), 578–580 (1994)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle weakness in osteomalacia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.D.</ce:initials>
<ce:surname>Schott</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.R.</ce:initials>
<ce:surname>Wills</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1976"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>7960</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>626</first-page>
<last-page>629</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schott, G.D., Wills, M.R.: Muscle weakness in osteomalacia. Lancet. 1(7960), 626–629 (1976)</ref-fulltext>
<ce:source-text>Schott, G.D., Wills, M.R.: Muscle weakness in osteomalacia. Lancet. 1(7960), 626–629 (1976)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Antiresorptive therapy in the management of cancer treatment-induced bone loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Garg</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Leitzel</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Ali</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>73</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Garg, A., Leitzel, K., Ali, S., Lipton, A.: Antiresorptive therapy in the management of cancer treatment-induced bone loss. Curr. Osteoporos. Rep. 13(2), 73–77 (2015)</ref-fulltext>
<ce:source-text>Garg, A., Leitzel, K., Ali, S., Lipton, A.: Antiresorptive therapy in the management of cancer treatment-induced bone loss. Curr. Osteoporos. Rep. 13(2), 73–77 (2015)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Bone loss and fracture risk associated with cancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1121</first-page>
<last-page>1131</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guise, T.A.: Bone loss and fracture risk associated with cancer therapy. Oncologist. 11(10), 1121–1131 (2006)</ref-fulltext>
<ce:source-text>Guise, T.A.: Bone loss and fracture risk associated with cancer therapy. Oncologist. 11(10), 1121–1131 (2006)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment and survivorship statistics, 2016</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.C.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.B.</ce:initials>
<ce:surname>Mariotto</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.L.</ce:initials>
<ce:surname>Kramer</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>271</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al.: Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66(4), 271–289 (2016)</ref-fulltext>
<ce:source-text>Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al.: Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66(4), 271–289 (2016)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.O.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>A.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.B.</ce:initials>
<ce:surname>Jacobsen</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Norgaard</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Yong</ce:surname>
</author>
<author seq="5">
<ce:initials>J.P.</ce:initials>
<ce:surname>Fryzek</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.T.</ce:initials>
<ce:surname>Sorensen</ce:surname>
<ce:given-name>H.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jensen, A.O., Jacobsen, J.B., Norgaard, M., Yong, M., Fryzek, J.P., Sorensen, H.T.: Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer. 11, 29 (2011)</ref-fulltext>
<ce:source-text>Jensen, A.O., Jacobsen, J.B., Norgaard, M., Yong, M., Fryzek, J.P., Sorensen, H.T.: Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer. 11, 29 (2011)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Natural history and treatment of bone complications in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Saad</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Clarke</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Colombel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>429</first-page>
<last-page>440</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saad, F., Clarke, N., Colombel, M.: Natural history and treatment of bone complications in prostate cancer. Eur. Urol. 49(3), 429–440 (2006)</ref-fulltext>
<ce:source-text>Saad, F., Clarke, N., Colombel, M.: Natural history and treatment of bone complications in prostate cancer. Eur. Urol. 49(3), 429–440 (2006)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.L.</ce:initials>
<ce:surname>Nicolson</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Conklin</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Metastasis</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>169</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nicolson, G.L., Conklin, K.A.: Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin. Exp. Metastasis. 25(2), 161–169 (2008)</ref-fulltext>
<ce:source-text>Nicolson, G.L., Conklin, K.A.: Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin. Exp. Metastasis. 25(2), 161–169 (2008)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gilliam</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.K.</ce:initials>
<ce:surname>St Clair</ce:surname>
<ce:given-name>D.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Antioxid. Redox Signal</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2543</first-page>
<last-page>2563</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gilliam, L.A., St Clair, D.K.: Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress. Antioxid. Redox Signal. 15(9), 2543–2563 (2011)</ref-fulltext>
<ce:source-text>Gilliam, L.A., St Clair, D.K.: Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress. Antioxid. Redox Signal. 15(9), 2543–2563 (2011)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>D'oronzo</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Stucci</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Tucci</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Silvestris</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat. Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>41</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>798</first-page>
<last-page>808</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>D'Oronzo, S., Stucci, S., Tucci, M., Silvestris, F.: Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treat. Rev. 41(9), 798–808 (2015)</ref-fulltext>
<ce:source-text>D'Oronzo, S., Stucci, S., Tucci, M., Silvestris, F.: Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treat. Rev. 41(9), 798–808 (2015)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Stadler</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
</author>
<author seq="4">
<ce:initials>A.S.</ce:initials>
<ce:surname>Baldwin</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7590</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., Stadler, M.E., Acharyya, S., Baldwin, A.S., Couch, M.E., Guttridge, D.C.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., Stadler, M.E., Acharyya, S., Baldwin, A.S., Couch, M.E., Guttridge, D.C.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Rana</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Chakrabarti</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Freeman</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Biswas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Rana, T., Chakrabarti, A., Freeman, M., Biswas, S.: Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta. PLoS One. 8(10), e78043 (2013)</ref-fulltext>
<ce:source-text>Rana, T., Chakrabarti, A., Freeman, M., Biswas, S.: Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta. PLoS One. 8(10), e78043 (2013)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Wilcox</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Mutua</ce:surname>
</author>
<author seq="5">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid. Communications</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., Xu, H., Wilcox, J.R., Mutua, D., Waning, D.L.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid. Communications. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., Xu, H., Wilcox, J.R., Mutua, D., Waning, D.L.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid. Communications. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Jude</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="4">
<ce:initials>D.M.</ce:initials>
<ce:surname>Smuin</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.J.</ce:initials>
<ce:surname>Fox</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.C.</ce:initials>
<ce:surname>Elfar</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>368</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., Jude, B., Xu, H., Smuin, D.M., Fox, E.J., Elfar, J.C., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ref-fulltext>
<ce:source-text>Hain, B.A., Jude, B., Xu, H., Smuin, D.M., Fox, E.J., Elfar, J.C., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Matsumoto</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="5">
<ce:initials>K.C.</ce:initials>
<ce:surname>Colston</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14470</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., Kitase, Y., Matsumoto, T., Pin, F., Colston, K.C., Couch, K.E., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ref-fulltext>
<ce:source-text>Barreto, R., Kitase, Y., Matsumoto, T., Pin, F., Colston, K.C., Couch, K.E., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
<author seq="2">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="5">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43442</first-page>
<last-page>43460</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., Waning, D.L., Gao, H., Liu, Y., Zimmers, T.A., Bonetto, A.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., Waning, D.L., Gao, H., Liu, Y., Zimmers, T.A., Bonetto, A.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Essex</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.I.</ce:initials>
<ce:surname>Plotkin</ce:surname>
<ce:given-name>L.I.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>809</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Essex, A.L., Pin, F., Huot, J.R., Bonewald, L.F., Plotkin, L.I., Bonetto, A.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ref-fulltext>
<ce:source-text>Essex, A.L., Pin, F., Huot, J.R., Bonewald, L.F., Plotkin, L.I., Bonetto, A.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gilliam</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.F.</ce:initials>
<ce:surname>Ferreira</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Bruton</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.S.</ce:initials>
<ce:surname>Moylan</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Westerblad</ce:surname>
</author>
<author seq="6">
<ce:initials>D.K.</ce:initials>
<ce:surname>St Clair</ce:surname>
<ce:given-name>D.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2009</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1935</first-page>
<last-page>1942</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J. Appl. Physiol. 2009, 107(6), 1935–1942 (1985)</ref-fulltext>
<ce:source-text>Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J. Appl. Physiol. 2009, 107(6), 1935–1942 (1985)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gilliam</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Moylan</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.A.</ce:initials>
<ce:surname>Callahan</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.P.</ce:initials>
<ce:surname>Sumandea</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.B.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>M.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gilliam, L.A., Moylan, J.S., Callahan, L.A., Sumandea, M.P., Reid, M.B.: Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve. 43(1), 94–102 (2011)</ref-fulltext>
<ce:source-text>Gilliam, L.A., Moylan, J.S., Callahan, L.A., Sumandea, M.P., Reid, M.B.: Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve. 43(1), 94–102 (2011)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>An overview of sarcopenia: Facts and numbers on prevalence and clinical impact</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>129</first-page>
<last-page>133</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Morley, J.E., Anker, S.D.: An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J. Cachexia. Sarcopenia Muscle. 1(2), 129–133 (2010)</ref-fulltext>
<ce:source-text>von Haehling, S., Morley, J.E., Anker, S.D.: An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J. Cachexia. Sarcopenia Muscle. 1(2), 129–133 (2010)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle dysfunction in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.F.</ce:initials>
<ce:surname>Christensen</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.L.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Daugaard</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Rorth</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Hojman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>947</first-page>
<last-page>958</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Christensen, J.F., Jones, L.W., Andersen, J.L., Daugaard, G., Rorth, M., Hojman, P.: Muscle dysfunction in cancer patients. Ann. Oncol. 25(5), 947–958 (2014)</ref-fulltext>
<ce:source-text>Christensen, J.F., Jones, L.W., Andersen, J.L., Daugaard, G., Rorth, M., Hojman, P.: Muscle dysfunction in cancer patients. Ann. Oncol. 25(5), 947–958 (2014)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of primary breast cancer therapy on energetic capacity and body composition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Ballinger</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Reddy</ce:surname>
</author>
<author seq="3">
<ce:initials>S.K.</ce:initials>
<ce:surname>Althouse</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.M.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.S.</ce:initials>
<ce:surname>Sledge</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Ballinger, T.J., Reddy, A., Althouse, S.K., Nelson, E.M., Miller, K.D., Sledge, J.S.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. (2018)</ref-fulltext>
<ce:source-text>Ballinger, T.J., Reddy, A., Althouse, S.K., Nelson, E.M., Miller, K.D., Sledge, J.S.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. (2018)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Hesse</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Schroder</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Brandt</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Pamperin</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Saito</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JCI. Insight</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>5</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hesse, E., Schroder, S., Brandt, D., Pamperin, J., Saito, H., Taipaleenmaki, H.: Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI. Insight. 5 (2019)</ref-fulltext>
<ce:source-text>Hesse, E., Schroder, S., Brandt, D., Pamperin, J., Saito, H., Taipaleenmaki, H.: Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI. Insight. 5 (2019)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonates: Mechanism of action and role in clinical practice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.T.</ce:initials>
<ce:surname>Drake</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khosla</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mayo Clin. Proc</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1032</first-page>
<last-page>1045</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Drake, M.T., Clarke, B.L., Khosla, S.: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83(9), 1032–1045 (2008)</ref-fulltext>
<ce:source-text>Drake, M.T., Clarke, B.L., Khosla, S.: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83(9), 1032–1045 (2008)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Romosozumab for the treatment of osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Bandeira</ce:surname>
</author>
<author seq="2">
<ce:initials>E.M.</ce:initials>
<ce:surname>Lewiecki</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>Bilezikian</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Expert. Opin. Biol. Ther</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>263</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bandeira, L., Lewiecki, E.M., Bilezikian, J.P.: Romosozumab for the treatment of osteoporosis. Expert. Opin. Biol. Ther. 17(2), 255–263 (2017)</ref-fulltext>
<ce:source-text>Bandeira, L., Lewiecki, E.M., Bilezikian, J.P.: Romosozumab for the treatment of osteoporosis. Expert. Opin. Biol. Ther. 17(2), 255–263 (2017)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The science and practice of bone health in oncology: Managing bone loss and metastasis in patients with solid tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Uzzo</ce:surname>
</author>
<author seq="3">
<ce:initials>R.J.</ce:initials>
<ce:surname>Amato</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.K.</ce:initials>
<ce:surname>Ellis</ce:surname>
<ce:given-name>G.K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Hakimian</ce:surname>
</author>
<author seq="6">
<ce:initials>G.D.</ce:initials>
<ce:surname>Roodman</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Compr. Cancer Netw</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<suppl>Supplement 7</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Lipton, A., Uzzo, R., Amato, R.J., Ellis, G.K., Hakimian, B., Roodman, G.D., et al.: The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J. Natl. Compr. Cancer Netw. 7(Suppl 7), S1–29 (2009); quiz S30</ref-fulltext>
<ce:source-text>Lipton, A., Uzzo, R., Amato, R.J., Ellis, G.K., Hakimian, B., Roodman, G.D., et al.: The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J. Natl. Compr. Cancer Netw. 7(Suppl 7), S1–29 (2009); quiz S30</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.K.</ce:initials>
<ce:surname>Swenson</ce:surname>
<ce:given-name>K.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Henly</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.C.</ce:initials>
<ce:surname>Shapiro</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.M.</ce:initials>
<ce:surname>Schroeder</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. J. Oncol. Nurs</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>177</first-page>
<last-page>184</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Swenson, K.K., Henly, S.J., Shapiro, A.C., Schroeder, L.M.: Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin. J. Oncol. Nurs. 9(2), 177–184 (2005)</ref-fulltext>
<ce:source-text>Swenson, K.K., Henly, S.J., Shapiro, A.C., Schroeder, L.M.: Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin. J. Oncol. Nurs. 9(2), 177–184 (2005)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>American College of Sports M: American College of Sports Medicine Position Stand: Physical activity and bone health. Med. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.M.</ce:initials>
<ce:surname>Kohrt</ce:surname>
<ce:given-name>W.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Bloomfield</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.D.</ce:initials>
<ce:surname>Little</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.E.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>V.R.</ce:initials>
<ce:surname>Yingling</ce:surname>
<ce:given-name>V.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1985</first-page>
<last-page>1996</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kohrt, W.M., Bloomfield, S.A., Little, K.D., Nelson, M.E., Yingling, V.R., American College of Sports M: American College of Sports Medicine Position Stand: Physical activity and bone health. Med. Sci. Sports Exerc. 36(11), 1985–1996 (2004)</ref-fulltext>
<ce:source-text>Kohrt, W.M., Bloomfield, S.A., Little, K.D., Nelson, M.E., Yingling, V.R., American College of Sports M: American College of Sports Medicine Position Stand: Physical activity and bone health. Med. Sci. Sports Exerc. 36(11), 1985–1996 (2004)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and chemotherapy-induced musculoskeletal degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mathis</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.J.</ce:initials>
<ce:surname>Rogers</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JBMR Plus</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sturgeon, K.M., Mathis, K.M., Rogers, C.J., Schmitz, K.H., Waning, D.L.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ref-fulltext>
<ce:source-text>Sturgeon, K.M., Mathis, K.M., Rogers, C.J., Schmitz, K.H., Waning, D.L.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_10</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Cancer</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Body composition</author-keyword>
<author-keyword>Protein metabolism</author-keyword>
<author-keyword>Mediators</author-keyword>
<author-keyword>Therapeutics</author-keyword>
<author-keyword>Multimodal therapy</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">New Developments in Targeting Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>Janice</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.I.</ce:initials>
<ce:surname>Ramage</ce:surname>
<ce:given-name>Michael I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>Richard J. E.</ce:given-name>
<ce:e-address>richard.skipworth@nhslothian.scot.nhs.uk</ce:e-address>
</author>
<affiliation>
<organization>Royal Infirmary of Edinburgh</organization>
<city>Edinburgh</city>
<country iso-code="GBR"/>
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>Richard J. E.</ce:given-name>
</person>
<affiliation>
<organization>Royal Infirmary of Edinburgh</organization>
<city>Edinburgh</city>
<country iso-code="GBR"/>
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
<ce:e-address>richard.skipworth@nhslothian.scot.nhs.uk</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Within the cancer population, 50–80% of patients will develop cachexia, impacting negatively on their ability to tolerate or gain benefit from either curative or palliative treatment. To date, although collaborative management guidelines have been developed, there are no internationally standardised management programmes used in the clinical forum for patients with cancer cachexia. Furthermore, current available treatment strategies have limited efficacy. This chapter considers recent developments in the ability to target cachexia. Such “targeting” comes in two key forms: firstly, the ability to target and recognise new patients with, or at risk of, developing cancer cachexia. Some of the new developments in this field of study relate not just to improvements in patient targeting, but also a better understanding of the inherent pitfalls in this process. The second aspect of targeting relates to the identification of novel therapeutic biological targets for further clinical investigation.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>171</first-page>
<last-page>192</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="125">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
<ce:given-name>W.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Begg</ce:surname>
</author>
<author seq="3">
<ce:initials>P.T.</ce:initials>
<ce:surname>Lavin</ce:surname>
<ce:given-name>P.T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.R.</ce:initials>
<ce:surname>Band</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bennett</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.R.</ce:initials>
<ce:surname>Bertino</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Diagnostic criteria of cancer cachexia: Relation to quality of life, exercise capacity and survival in unselected palliative care patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Wallengren</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1569</first-page>
<last-page>1577</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallengren, O., Lundholm, K., Bosaeus, I.: Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 21(6), 1569–1577 (2013)</ref-fulltext>
<ce:source-text>Wallengren, O., Lundholm, K., Bosaeus, I.: Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 21(6), 1569–1577 (2013)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: Prevalence and impact in medicine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>400</first-page>
<last-page>407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tan, B.H., Fearon, K.C.: Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care. 11(4), 400–407 (2008)</ref-fulltext>
<ce:source-text>Tan, B.H., Fearon, K.C.: Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care. 11(4), 400–407 (2008)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
</author>
<author seq="6">
<ce:initials>R.L.</ce:initials>
<ce:surname>Fainsinger</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Vagnildhaug</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Balstad</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Almberg</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bruneli</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Knudsen</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Kaasa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1871</first-page>
<last-page>1880</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vagnildhaug, O., Balstad, T., Almberg, S., Bruneli, C., Knudsen, A., Kaasa, S., et al.: A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 26(6), 1871–1880 (2017)</ref-fulltext>
<ce:source-text>Vagnildhaug, O., Balstad, T., Almberg, S., Bruneli, C., Knudsen, A., Kaasa, S., et al.: A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 26(6), 1871–1880 (2017)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Leblanc</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Nipp</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Rushing</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Samsa</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Locke</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kamal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>680</first-page>
<last-page>689</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>LeBlanc, T., Nipp, R., Rushing, C., Samsa, G., Locke, S., Kamal, A., et al.: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J. Pain Symptom Manag. 49(4), 680–689 (2014)</ref-fulltext>
<ce:source-text>LeBlanc, T., Nipp, R., Rushing, C., Samsa, G., Locke, S., Kamal, A., et al.: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J. Pain Symptom Manag. 49(4), 680–689 (2014)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Blum</ce:surname>
</author>
<author seq="2">
<ce:initials>G.B.</ce:initials>
<ce:surname>Stene</ce:surname>
<ce:given-name>G.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Fayers</ce:surname>
</author>
<author seq="5">
<ce:initials>M.J.</ce:initials>
<ce:surname>Hjermstad</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1635</first-page>
<last-page>1642</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Blum, D., Stene, G.B., Solheim, T.S., Fayers, P., Hjermstad, M.J., Baracos, V.E., et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25(8), 1635–1642 (2014)</ref-fulltext>
<ce:source-text>Blum, D., Stene, G.B., Solheim, T.S., Fayers, P., Hjermstad, M.J., Baracos, V.E., et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25(8), 1635–1642 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia in cancer: What is in the definition?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vanhoutte</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Van de Wiel</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Wouters</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sels</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Bartolomeeussen</ce:surname>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Keersmaecker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Open Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., Keersmaecker, S.D., et al.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3(1), e000097 (2016)</ref-fulltext>
<ce:source-text>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., Keersmaecker, S.D., et al.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3(1), e000097 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A new definition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Argilés</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bales</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>793</first-page>
<last-page>799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Morley, J.E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., et al.: Cachexia: A new definition. Clin. Nutr. 27(6), 793–799 (2008)</ref-fulltext>
<ce:source-text>Evans, W.J., Morley, J.E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., et al.: Cachexia: A new definition. Clin. Nutr. 27(6), 793–799 (2008)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mourtzakis</ce:surname>
</author>
<author seq="2">
<ce:initials>C.M.M.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>C.M.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Lieffers</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Reiman</ce:surname>
</author>
<author seq="5">
<ce:initials>L.J.</ce:initials>
<ce:surname>McCargar</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>997</first-page>
<last-page>1006</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008)</ref-fulltext>
<ce:source-text>Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Birdsell</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Reiman</ce:surname>
</author>
<author seq="5">
<ce:initials>M.T.</ce:initials>
<ce:surname>Clandinin</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>McCargar</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1539</first-page>
<last-page>1547</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013)</ref-fulltext>
<ce:source-text>Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.F.</ce:initials>
<ce:surname>von Meyenfeldt</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>van Geenen</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Roy</ce:surname>
</author>
<author seq="6">
<ce:initials>D.J.</ce:initials>
<ce:surname>Gouma</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1479</first-page>
<last-page>1486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C.H., Von Meyenfeldt, M.F., Moses, A.G.W., Van Geenen, R., Roy, A., Gouma, D.J., et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 52(10), 1479–1486 (2003)</ref-fulltext>
<ce:source-text>Fearon, K.C.H., Von Meyenfeldt, M.F., Moses, A.G.W., Van Geenen, R., Roy, A., Gouma, D.J., et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 52(10), 1479–1486 (2003)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Cruz-Jentoft</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Baeyens</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bauer</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Boirie</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Cederholm</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>Landi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Age Ageing</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>423</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al.: Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39(4), 412–423 (2010)</ref-fulltext>
<ce:source-text>Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al.: Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39(4), 412–423 (2010)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting and cachexia in heart failure: Mechanisms and therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Ebner</ce:surname>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Dos Santos</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Springer</ce:surname>
</author>
<author seq="5">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>323</first-page>
<last-page>341</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Ebner, N., dos Santos, M.R., Springer, J., Anker, S.D.: Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat. Rev. Cardiol. 14(6), 323–341 (2017)</ref-fulltext>
<ce:source-text>von Haehling, S., Ebner, N., dos Santos, M.R., Springer, J., Anker, S.D.: Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat. Rev. Cardiol. 14(6), 323–341 (2017)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Myopenia—a new universal term for muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>3</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Evans, W.J., Anker, S.D.: Myopenia—a new universal term for muscle wasting. J. Cachexia. Sarcopenia Muscle. 2(1), 1–3 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Evans, W.J., Anker, S.D.: Myopenia—a new universal term for muscle wasting. J. Cachexia. Sarcopenia Muscle. 2(1), 1–3 (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Wells</ce:surname>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:surname>Nwulu</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Currow</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>108</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1196</first-page>
<last-page>1208</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Wells, L., Nwulu, U., Currow, D., Johnson, M., Skipworth, R.: Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. Am. J. Clin. Nutr. 108(6), 1196–1208 (2018)</ref-fulltext>
<ce:source-text>Miller, J., Wells, L., Nwulu, U., Currow, D., Johnson, M., Skipworth, R.: Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. Am. J. Clin. Nutr. 108(6), 1196–1208 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN expert group recommendations for action against cancer-related malnutrition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Bertz</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Bozzetti</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Calder</ce:surname>
</author>
<author seq="6">
<ce:initials>N.E.P.</ce:initials>
<ce:surname>Deutz</ce:surname>
<ce:given-name>N.E.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1187</first-page>
<last-page>1196</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N.E.P., et al.: ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36(5), 1187–1196 (2017)</ref-fulltext>
<ce:source-text>Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N.E.P., et al.: ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36(5), 1187–1196 (2017)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Epidemiology of sarcopenia among the elderly in New Mexico</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Koehler</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Gallagher</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Romero</ce:surname>
</author>
<author seq="5">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.R.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>R.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Epidemiol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>755</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al.: Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147(8), 755–763 (1998)</ref-fulltext>
<ce:source-text>Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al.: Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147(8), 755–763 (1998)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>The advantages and limitations of cross-sectional body composition analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>342</first-page>
<last-page>349</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Greig, C.A., Baracos, V.: The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support. Palliat. Care. 5(4), 342–349 (2011)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Greig, C.A., Baracos, V.: The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support. Palliat. Care. 5(4), 342–349 (2011)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Aulet</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Bensen</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Lichtman</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="1990"/>
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heymsfield, S.B., Smith, R., Aulet, M., Bensen, B., Lichtman, S., Wang, J., et al.: Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am. J. Clin. Nutr. 52(2), 214–218 (1990)</ref-fulltext>
<ce:source-text>Heymsfield, S.B., Smith, R., Aulet, M., Bensen, B., Lichtman, S., Wang, J., et al.: Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am. J. Clin. Nutr. 52(2), 214–218 (1990)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>The epidemiology of obesity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.M.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.B.</ce:initials>
<ce:surname>El-Serag</ce:surname>
<ce:given-name>H.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gastroenterol Clin North Am</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>7</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.M., El-Serag, H.B.: The epidemiology of obesity. Gastroenterol Clin North Am. 39(1), 1–7 (2010)</ref-fulltext>
<ce:source-text>Nguyen, D.M., El-Serag, H.B.: The epidemiology of obesity. Gastroenterol Clin North Am. 39(1), 1–7 (2010)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Flegal</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Carroll</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.K.</ce:initials>
<ce:surname>Kit</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Ogden</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>307</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L.: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 307(5), 491–497 (2012)</ref-fulltext>
<ce:source-text>Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L.: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 307(5), 491–497 (2012)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Risk factor paradox in wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kalantar-Zadeh</ce:surname>
</author>
<author seq="2">
<ce:initials>T.B.</ce:initials>
<ce:surname>Horwich</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Oreopoulos</ce:surname>
</author>
<author seq="4">
<ce:initials>C.P.</ce:initials>
<ce:surname>Kovesdy</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Younessi</ce:surname>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
<author seq="7">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr Opin Clin Nutr Metab Care</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., Kovesdy, C.P., Younessi, H., Anker, S.D., Morley, J.E.: Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 10(4), 433–442 (2007)</ref-fulltext>
<ce:source-text>Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., Kovesdy, C.P., Younessi, H., Anker, S.D., Morley, J.E.: Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 10(4), 433–442 (2007)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Diagnostic criteria for the classification of cancer-associated weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Senesse</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Gioulbasanis</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:surname>Bozzetti</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="7">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
</author>
<author seq="9">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Chasen</ce:surname>
</author>
<author seq="11">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
</author>
<author seq="12">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
<author seq="13">
<ce:initials>K.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="14">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>99</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R.T., Chasen, M., Lundholm, K., Bosaeus, I., Fearon, K.H., Baracos, V.E.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 33(1), 90–99 (2015)</ref-fulltext>
<ce:source-text>Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R.T., Chasen, M., Lundholm, K., Bosaeus, I., Fearon, K.H., Baracos, V.E.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 33(1), 90–99 (2015)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Health, Aging, and Body: Longitudinal study of muscle strength, quality, and adipose tissue infiltration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Delmonico</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Harris</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Conroy</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Velasquez-Mieyer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1579</first-page>
<last-page>1585</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Delmonico, M., Harris, T., Visser, M., Park, S., Conroy, M., Velasquez-Mieyer, P., et al.: Health, Aging, and Body: longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am. J. Clin. Nutr. 90, 1579–1585 (2009)</ref-fulltext>
<ce:source-text>Delmonico, M., Harris, T., Visser, M., Park, S., Conroy, M., Velasquez-Mieyer, P., et al.: Health, Aging, and Body: longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am. J. Clin. Nutr. 90, 1579–1585 (2009)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal intramyocellular lipid metabolism and insulin resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Yi</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Cichello</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biophys. Rev</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>98</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y., Xu, S., Zhang, X., Yi, Z., Cichello, S.: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys. Rev. 1, 90–98 (2015)</ref-fulltext>
<ce:source-text>Li, Y., Xu, S., Zhang, X., Yi, Z., Cichello, S.: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys. Rev. 1, 90–98 (2015)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Macgillivray</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Eeley</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Beggs</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>106</first-page>
<last-page>111</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gray, C., MacGillivray, T., Eeley, C., Stephens, N., Beggs, I., Fearon, K., et al.: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin. Nutr. 30, 106–111 (2011)</ref-fulltext>
<ce:source-text>Gray, C., MacGillivray, T., Eeley, C., Stephens, N., Beggs, I., Fearon, K., et al.: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin. Nutr. 30, 106–111 (2011)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Intramyocellular lipid droplets increase with progression of cachexia in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Greig</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>111</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N., Skipworth, R., MacDonald, A., Greig, C., Ross, J., Fearon, K.: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle. 2, 111–117 (2011)</ref-fulltext>
<ce:source-text>Stephens, N., Skipworth, R., MacDonald, A., Greig, C., Ross, J., Fearon, K.: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle. 2, 111–117 (2011)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.I.</ce:initials>
<ce:surname>Ramage</ce:surname>
<ce:given-name>M.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="3">
<ce:initials>C.D.A.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>C.D.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Ramage, M.I., Johns, N., Deans, C.D.A., Ross, J.A., Preston, T., Skipworth, R.J.E., et al.: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin. Nutr. Edinb. Scotl. (2016 Dec 27)</ref-fulltext>
<ce:source-text>Ramage, M.I., Johns, N., Deans, C.D.A., Ross, J.A., Preston, T., Skipworth, R.J.E., et al.: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin. Nutr. Edinb. Scotl. (2016 Dec 27)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Subcutaneous adiposity is an independent predictor of mortality in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="4">
<ce:initials>C.J.</ce:initials>
<ce:surname>Field</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Lehner</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br J Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>155</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Martin, L., Ghosh, S., Field, C.J., Lehner, R., Baracos, V.E., Mazurak, V.C.: Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 117(1), 148–155 (2017)</ref-fulltext>
<ce:source-text>Ebadi, M., Martin, L., Ghosh, S., Field, C.J., Lehner, R., Baracos, V.E., Mazurak, V.C.: Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 117(1), 148–155 (2017)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging body composition in cancer patients: Visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Yip</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Dinkel</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Mahajan</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Siddique</ce:surname>
</author>
<author seq="5">
<ce:initials>G.J.R.</ce:initials>
<ce:surname>Cook</ce:surname>
<ce:given-name>G.J.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Goh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Insights Imaging</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G.J.R., Goh, V.: Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 6(4), 489–497 (2015)</ref-fulltext>
<ce:source-text>Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G.J.R., Goh, V.: Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 6(4), 489–497 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle shape consistency and muscle volume prediction of thigh muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Mersmann</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bohm</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schroll</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Boeth</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Duda</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Arampatzis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Scand. J. Med. Sci. Sports</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e208</first-page>
<last-page>e213</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mersmann, F., Bohm, S., Schroll, A., Boeth, H., Duda, G., Arampatzis, A.: Muscle shape consistency and muscle volume prediction of thigh muscles. Scand. J. Med. Sci. Sports. 25(2), e208–e213 (2015)</ref-fulltext>
<ce:source-text>Mersmann, F., Bohm, S., Schroll, A., Boeth, H., Duda, G., Arampatzis, A.: Muscle shape consistency and muscle volume prediction of thigh muscles. Scand. J. Med. Sci. Sports. 25(2), e208–e213 (2015)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Willis</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.G.</ce:initials>
<ce:surname>Hollingsworth</ce:surname>
<ce:given-name>K.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Coombs</ce:surname>
</author>
<author seq="4">
<ce:initials>M.L.</ce:initials>
<ce:surname>Sveen</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Stojkovic</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One [Internet]</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Willis, T.A., Hollingsworth, K.G., Coombs, A., Sveen, M.L., Andersen, S., Stojkovic, T., et al.: Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study. PLoS One [Internet]. (2013 Aug 14) [cited 2016 May 18];8(8). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ref-fulltext>
<ce:source-text>Willis, T.A., Hollingsworth, K.G., Coombs, A., Sveen, M.L., Andersen, S., Stojkovic, T., et al.: Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study. PLoS One [Internet]. (2013 Aug 14) [cited 2016 May 18];8(8). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Karlsson</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Rosander</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Romu</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Tallberg</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Grönqvist</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Borga</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Magn. Reson. Imaging</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>41</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1558</first-page>
<last-page>1569</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Karlsson, A., Rosander, J., Romu, T., Tallberg, J., Grönqvist, A., Borga, M., et al.: Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI. J. Magn. Reson. Imaging. 41(6), 1558–1569 (2015)</ref-fulltext>
<ce:source-text>Karlsson, A., Rosander, J., Romu, T., Tallberg, J., Grönqvist, A., Borga, M., et al.: Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI. J. Magn. Reson. Imaging. 41(6), 1558–1569 (2015)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.E.</ce:initials>
<ce:surname>Rollins</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Tewari</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Ackner</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Awwad</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Madhusudan</ce:surname>
</author>
<author seq="6">
<ce:initials>I.A.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>I.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1103</first-page>
<last-page>1109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin. Nutr. Edinb. Scotl. 35(5), 1103–1109 (2016)</ref-fulltext>
<ce:source-text>Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin. Nutr. Edinb. Scotl. 35(5), 1103–1109 (2016)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Weber</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Krakowski-Roosen</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Schroder</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Kinscherf</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Krix</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kopp-Schneider</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>116</first-page>
<last-page>124</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weber, M., Krakowski-Roosen, H., Schroder, L., Kinscherf, R., Krix, M., Kopp-Schneider, A., et al.: Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48(1), 116–124 (2009)</ref-fulltext>
<ce:source-text>Weber, M., Krakowski-Roosen, H., Schroder, L., Kinscherf, R., Krix, M., Kopp-Schneider, A., et al.: Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48(1), 116–124 (2009)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Krix</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Krakowski-Roosen</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Huttner</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Delorme</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Kauczor</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Hildebrandt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Ultrasound Med</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>441</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Krix, M., Krakowski-Roosen, H., Huttner, H., Delorme, S., Kauczor, H., Hildebrandt, W.: Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography. J. Ultrasound Med. 24(4), 431–441 (2005)</ref-fulltext>
<ce:source-text>Krix, M., Krakowski-Roosen, H., Huttner, H., Delorme, S., Kauczor, H., Hildebrandt, W.: Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography. J. Ultrasound Med. 24(4), 431–441 (2005)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sabatino</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Regolistil</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Bozzoli</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Fani</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Antoniotti</ce:surname>
</author>
<author seq="6">
<ce:initials>U.</ce:initials>
<ce:surname>Maggiore</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1710</first-page>
<last-page>1715</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sabatino, A., Regolistil, G., Bozzoli, L., Fani, F., Antoniotti, R., Maggiore, U., et al.: Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 36(6), 1710–1715 (2017)</ref-fulltext>
<ce:source-text>Sabatino, A., Regolistil, G., Bozzoli, L., Fani, F., Antoniotti, R., Maggiore, U., et al.: Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 36(6), 1710–1715 (2017)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Qualitative ultrasound in acute critical illness muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Puthucheary</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Phadke</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rawal</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>McPhail</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Sidhu</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Rowlerson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Crit. Care Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1603</first-page>
<last-page>1611</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puthucheary, Z., Phadke, R., Rawal, J., McPhail, M., Sidhu, P., Rowlerson, A., et al.: Qualitative ultrasound in acute critical illness muscle wasting. Crit. Care Med. 43(8), 1603–1611 (2015)</ref-fulltext>
<ce:source-text>Puthucheary, Z., Phadke, R., Rawal, J., McPhail, M., Sidhu, P., Rowlerson, A., et al.: Qualitative ultrasound in acute critical illness muscle wasting. Crit. Care Med. 43(8), 1603–1611 (2015)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.J.</ce:initials>
<ce:surname>Gallagher</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutr</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>499</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J.E., et al.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31(4), 499–505 (2012)</ref-fulltext>
<ce:source-text>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J.E., et al.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31(4), 499–505 (2012)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sangster</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Voss</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Fallon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>391</first-page>
<last-page>401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skipworth, R.J.E., Moses, A., Sangster, K., Sturgeon, C., Voss, A., Fallon, M., et al.: Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 19(3), 391–401 (2011)</ref-fulltext>
<ce:source-text>Skipworth, R.J.E., Moses, A., Sangster, K., Sturgeon, C., Voss, A., Fallon, M., et al.: Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 19(3), 391–401 (2011)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Rejtar</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Reinker</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Brachat</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Badur</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stretch, C., Wang, K., Rejtar, T., Reinker, S., Brachat, S., Badur, R., et al.: Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients. J. Cachexia. Sarcopenia Muscle. 9(1), 183–212 (2018)</ref-fulltext>
<ce:source-text>Stretch, C., Wang, K., Rejtar, T., Reinker, S., Brachat, S., Badur, R., et al.: Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients. J. Cachexia. Sarcopenia Muscle. 9(1), 183–212 (2018)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
</author>
<author seq="3">
<ce:initials>B.H.L.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Sørhaug</ce:surname>
</author>
<author seq="6">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Johns, N., Stretch, C., Tan, B.H.L., Solheim, T.S., Sørhaug, S., Stephens, N.A., et al.: New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. (2016 Jan 1);n/a–n/a</ref-fulltext>
<ce:source-text>Johns, N., Stretch, C., Tan, B.H.L., Solheim, T.S., Sørhaug, S., Stephens, N.A., et al.: New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. (2016 Jan 1);n/a–n/a</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Rose-Zerilli</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Howell</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Jackson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deans, C., Rose-Zerilli, M., Wigmore, S.,Ross, J., Howell, M., Jackson, A., et al.: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14(2), 329–339 (2007)</ref-fulltext>
<ce:source-text>Deans, C., Rose-Zerilli, M., Wigmore, S.,Ross, J., Howell, M., Jackson, A., et al.: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14(2), 329–339 (2007)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barber</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Powell</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lynch</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1443</first-page>
<last-page>1447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barber, M., Powell, J., Lynch, S., Fearon, K., Ross, J.: A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 83, 1443–1447 (2000)</ref-fulltext>
<ce:source-text>Barber, M., Powell, J., Lynch, S., Fearon, K., Ross, J.: A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 83, 1443–1447 (2000)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barber</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Powell</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lynch</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Gough</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Immunol</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>425</first-page>
<last-page>429</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barber, M., Powell, J., Lynch, S., Gough, N., Fearon, K., Ross, J.: Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin. Exp. Immunol. 117, 425–429 (1999)</ref-fulltext>
<ce:source-text>Barber, M., Powell, J., Lynch, S., Gough, N., Fearon, K., Ross, J.: Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin. Exp. Immunol. 117, 425–429 (1999)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia and pancreatic cancer: Are there treatment options? World</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mueller</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Burmeister</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Bachmann</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Martignoni</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9361</first-page>
<last-page>9373</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mueller, T., Burmeister, M., Bachmann, J., Martignoni, M.: Cachexia and pancreatic cancer: Are there treatment options? World J. Gastroenterol. 20(28), 9361–9373 (2014)</ref-fulltext>
<ce:source-text>Mueller, T., Burmeister, M., Bachmann, J., Martignoni, M.: Cachexia and pancreatic cancer: Are there treatment options? World J. Gastroenterol. 20(28), 9361–9373 (2014)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Vazeille</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Jouinot</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Durand</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Neveux</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Boudou-Rouquette</ce:surname>
</author>
<author seq="6">
<ce:initials>O.</ce:initials>
<ce:surname>Huillard</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1139</first-page>
<last-page>1147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vazeille, C., Jouinot, A., Durand, J., Neveux, N., Boudou-Rouquette, P., Huillard, O., et al.: Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy. Am. J. Clin. Nutr. 105(5), 1139–1147 (2017)</ref-fulltext>
<ce:source-text>Vazeille, C., Jouinot, A., Durand, J., Neveux, N., Boudou-Rouquette, P., Huillard, O., et al.: Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy. Am. J. Clin. Nutr. 105(5), 1139–1147 (2017)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>van Dijk</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Horstman</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Smeets</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Den Dulk</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Grabsch</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Dejong</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>van Dijk, D., Horstman, A., Smeets, J., den Dulk, M., Grabsch, H., Dejong, C., et al.: Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 10(3) (2019)</ref-fulltext>
<ce:source-text>van Dijk, D., Horstman, A., Smeets, J., den Dulk, M., Grabsch, H., Dejong, C., et al.: Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 10(3) (2019)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>van Dijk</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Van de Poll</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.G.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
</author>
<author seq="5">
<ce:initials>S.W.</ce:initials>
<ce:surname>Olde Damink</ce:surname>
<ce:given-name>S.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.S.</ce:initials>
<ce:surname>Rensen</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>212</first-page>
<last-page>221</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Dijk, D.P., van de Poll, M.C., Moses, A.G., Preston, T., Olde Damink, S.W., Rensen, S.S., et al.: Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 6(3), 212–221 (2015)</ref-fulltext>
<ce:source-text>van Dijk, D.P., van de Poll, M.C., Moses, A.G., Preston, T., Olde Damink, S.W., Rensen, S.S., et al.: Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 6(3), 212–221 (2015)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.E.P.</ce:initials>
<ce:surname>Deutz</ce:surname>
<ce:given-name>N.E.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Safar</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Schutzler</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Memelink</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Ferrando</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Spencer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>759</first-page>
<last-page>768</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deutz, N.E.P., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H., et al.: Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. Edinb. Scotl. 30(6), 759–768 (2011)</ref-fulltext>
<ce:source-text>Deutz, N.E.P., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H., et al.: Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. Edinb. Scotl. 30(6), 759–768 (2011)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Small</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Husi</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rapid. Commun. Mass Spectrom. RCM</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1769</first-page>
<last-page>1777</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Small, A.C., Greig, C.A., Husi, H., Ross, J.A., Stephens, N.A., et al.: A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis. Rapid. Commun. Mass Spectrom. RCM. 27(15), 1769–1777 (2013)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Small, A.C., Greig, C.A., Husi, H., Ross, J.A., Stephens, N.A., et al.: A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis. Rapid. Commun. Mass Spectrom. RCM. 27(15), 1769–1777 (2013)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Greig</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.C.</ce:initials>
<ce:surname>Small</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. Assoc. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1734</first-page>
<last-page>1740</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Johns, N., Stephens, N., Greig, C., Ross, J.A., Small, A.C., et al.: Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Am. Assoc. Cancer Res. 21(7), 1734–1740 (2015)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Johns, N., Stephens, N., Greig, C., Ross, J.A., Small, A.C., et al.: Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Am. Assoc. Cancer Res. 21(7), 1734–1740 (2015)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M.: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45(10) (2013)</ref-fulltext>
<ce:source-text>Sandri, M.: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45(10) (2013)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Coming back: Autophagy in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Baccino</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>241</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., Baccino, F., Costelli, P.: Coming back: Autophagy in cachexia. Curr. Opin. Clin. Nutr. Metab. Care. 17(3), 241–246 (2014)</ref-fulltext>
<ce:source-text>Penna, F., Baccino, F., Costelli, P.: Coming back: Autophagy in cachexia. Curr. Opin. Clin. Nutr. Metab. Care. 17(3), 241–246 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of autophagy on cell death modalities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Ryter</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Mizumura</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Choi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
</ref-info>
<ref-fulltext>Ryter, S., Mizumura, K., Choi, A.: The impact of autophagy on cell death modalities. Int. J. Cell Biol. (2014)</ref-fulltext>
<ce:source-text>Ryter, S., Mizumura, K., Choi, A.: The impact of autophagy on cell death modalities. Int. J. Cell Biol. (2014)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="4">
<ce:initials>V.</ce:initials>
<ce:surname>Tadini</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Grosjean</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2046</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling. Sci. Rep. 7, 2046 (2017)</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling. Sci. Rep. 7, 2046 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
<author seq="3">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Frieauff</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., et al.: Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle. PLoS One. 9(1), e83618 (2014)</ref-fulltext>
<ce:source-text>Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., et al.: Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle. PLoS One. 9(1), e83618 (2014)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Wishart</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Boehm, I., Miller, J., Wishart, T., Wigmore, S., Skipworth, R., Jones, R., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., Miller, J., Wishart, T., Wigmore, S., Skipworth, R., Jones, R., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence and mechanisms of fat depletion in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
</author>
<author seq="2">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrients</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5280</first-page>
<last-page>5297</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Mazurak, V.C.: Evidence and mechanisms of fat depletion in cancer. Nutrients. 6(11), 5280–5297 (2014)</ref-fulltext>
<ce:source-text>Ebadi, M., Mazurak, V.C.: Evidence and mechanisms of fat depletion in cancer. Nutrients. 6(11), 5280–5297 (2014)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ryden</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Agustsson</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Laurencikiene</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Britton</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Sjolin</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Isaksson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>113</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1695</first-page>
<last-page>1704</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B., et al.: Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia. Cancer. 113(7), 1695–1704 (2008)</ref-fulltext>
<ce:source-text>Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B., et al.: Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia. Cancer. 113(7), 1695–1704 (2008)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mracek</ce:surname>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Bao</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Rydén</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mracek, T., Stephens, N.A., Gao, D., Bao, Y., Ross, J.A., Rydén, M., et al.: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer. 104(3), 441–447 (2011)</ref-fulltext>
<ce:source-text>Mracek, T., Stephens, N.A., Gao, D., Bao, Y., Ross, J.A., Rydén, M., et al.: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer. 104(3), 441–447 (2011)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Bathe</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Robinson</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Mazurak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1347</first-page>
<last-page>1353</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Baracos, V., Bathe, O., Robinson, L., Mazurak, V.: Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content. Clin. Nutr. 35(6), 1347–1353 (2016)</ref-fulltext>
<ce:source-text>Ebadi, M., Baracos, V., Bathe, O., Robinson, L., Mazurak, V.: Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content. Clin. Nutr. 35(6), 1347–1353 (2016)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Not all fat is equal: Differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Modesitt</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>J.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Chowbina</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.T.</ce:initials>
<ce:surname>Lawrence</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.L.</ce:initials>
<ce:surname>Hoehn</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>732</first-page>
<last-page>741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Modesitt, S.C., Hsu, J.Y., Chowbina, S.R., Lawrence, R.T., Hoehn, K.L.: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 22(5), 732–741 (2012)</ref-fulltext>
<ce:source-text>Modesitt, S.C., Hsu, J.Y., Chowbina, S.R., Lawrence, R.T., Hoehn, K.L.: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 22(5), 732–741 (2012)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Adipose triglyceride lipase contributes to cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Das</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Eder</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Schauer</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Diwoky</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Temmel</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Guertl</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>333</vol-first>
<iss-first>6039</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ref-fulltext>
<ce:source-text>Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kleiner</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>513</vol-first>
<iss-first>7516</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ref-fulltext>
<ce:source-text>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Paterson-Brown</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Black</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
</author>
<author seq="6">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1810</first-page>
<last-page>1818</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deans, C., Wigmore, S., Paterson-Brown, S., Black, J., Ross, J., Fearon, K.C.H.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 103(9), 1810–1818 (2005)</ref-fulltext>
<ce:source-text>Deans, C., Wigmore, S., Paterson-Brown, S., Black, J., Ross, J., Fearon, K.C.H.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 103(9), 1810–1818 (2005)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Komaba</ce:surname>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.P.</ce:initials>
<ce:surname>Economopoulos</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>W.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Lanske</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., Komaba, H., Garcia, A.P., Economopoulos, K.P., Liu, W., Lanske, B., et al.: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23(2), 315–323 (2016)</ref-fulltext>
<ce:source-text>Kir, S., Komaba, H., Garcia, A.P., Economopoulos, K.P., Liu, W., Lanske, B., et al.: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23(2), 315–323 (2016)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Chicheportiche</ce:surname>
</author>
<author seq="2">
<ce:initials>P.R.</ce:initials>
<ce:surname>Bourdon</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.M.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>Y.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Scott</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Hession</ce:surname>
</author>
 
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32401</first-page>
<last-page>32410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272(51), 32401–32410 (1997)</ref-fulltext>
<ce:source-text>Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272(51), 32401–32410 (1997)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dogra</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Changotra</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Wedhas</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Qin</ce:surname>
</author>
<author seq="5">
<ce:initials>J.E.</ce:initials>
<ce:surname>Wergedal</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1857</first-page>
<last-page>1869</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E., Kumar, A.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21(8), 1857–1869 (2007)</ref-fulltext>
<ce:source-text>Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E., Kumar, A.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21(8), 1857–1869 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.</ce:initials>
<ce:surname>Wiley</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Cassiano</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Lofton</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Davis-Smith</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Winkles</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Lindner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>837</first-page>
<last-page>846</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15(5), 837–846 (2001)</ref-fulltext>
<ce:source-text>Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15(5), 837–846 (2001)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.Y.</ce:initials>
<ce:surname>Feng</ce:surname>
<ce:given-name>S.L.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
<author seq="3">
<ce:initials>V.M.</ce:initials>
<ce:surname>Factor</ce:surname>
<ce:given-name>V.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.S.</ce:initials>
<ce:surname>Thorgeirsson</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Bell</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.R.</ce:initials>
<ce:surname>Testa</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>156</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1261</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feng, S.L.Y., Guo, Y., Factor, V.M., Thorgeirsson, S.S., Bell, D.W., Testa, J.R., et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 156(4), 1253–1261 (2000)</ref-fulltext>
<ce:source-text>Feng, S.L.Y., Guo, Y., Factor, V.M., Thorgeirsson, S.S., Bell, D.W., Testa, J.R., et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 156(4), 1253–1261 (2000)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>The TWEAK–Fn14 cytokine–receptor axis: Discovery, biology and therapeutic targeting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Winkles</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Winkles, J.A.: The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7(5), 411–425 (2008)</ref-fulltext>
<ce:source-text>Winkles, J.A.: The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7(5), 411–425 (2008)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: Insights from two exercise modes and a time course investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Raue</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Jemiolo</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Trappe</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>569</first-page>
<last-page>578</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raue, U., Jemiolo, B., Yang, Y., Trappe, S.: TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation. J. Appl. Physiol. 118(5), 569–578 (2015)</ref-fulltext>
<ce:source-text>Raue, U., Jemiolo, B., Yang, Y., Trappe, S.: TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation. J. Appl. Physiol. 118(5), 569–578 (2015)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Bhatnagar</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Mittal</ce:surname>
</author>
<author seq="3">
<ce:initials>S.K.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>227</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1042</first-page>
<last-page>1051</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhatnagar, S., Mittal, A., Gupta, S.K., Kumar, A.: TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell. Physiol. 227(3), 1042–1051 (2012)</ref-fulltext>
<ce:source-text>Bhatnagar, S., Mittal, A., Gupta, S.K., Kumar, A.: TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell. Physiol. 227(3), 1042–1051 (2012)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Johnston</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.T.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>K.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Jenkinson</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Laine</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Emmrich</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Faou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>162</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1365</first-page>
<last-page>1378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnston, A.J., Murphy, K.T., Jenkinson, L., Laine, D., Emmrich, K., Faou, P., et al.: Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 162(6), 1365–1378 (2015)</ref-fulltext>
<ce:source-text>Johnston, A.J., Murphy, K.T., Jenkinson, L., Laine, D., Emmrich, K., Faou, P., et al.: Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 162(6), 1365–1378 (2015)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Biswas</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Kandpal</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Cocker</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Grandgenett</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., Biswas, A., Ma, W., Kandpal, M., Cocker, C., Grandgenett, P., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., Biswas, A., Ma, W., Kandpal, M., Cocker, C., Grandgenett, P., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shakri</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Zhong</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Coker</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Calluori</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shakri, A., Zhong, T., Ma, W., Coker, C., Kim, S., Calluori, S., et al.: Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. 18(12), 3 (2019)</ref-fulltext>
<ce:source-text>Shakri, A., Zhong, T., Ma, W., Coker, C., Kim, S., Calluori, S., et al.: Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. 18(12), 3 (2019)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Tsai</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Husaini</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Sainsbury</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Breit</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V., Husaini, Y., Sainsbury, A., Brown, D., Breit, S.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018)</ref-fulltext>
<ce:source-text>Tsai, V., Husaini, Y., Sainsbury, A., Brown, D., Breit, S.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sadasivan</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Taneja</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Maresh</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>421</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sadasivan, S., Chen, Y., Gupta, N., Taneja, K., Maresh, S., Gonzalez, A., et al.: The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis. Cancer Res. 78, 421 (2018)</ref-fulltext>
<ce:source-text>Sadasivan, S., Chen, Y., Gupta, N., Taneja, K., Maresh, S., Gonzalez, A., et al.: The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis. Cancer Res. 78, 421 (2018)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 induces anorexia through nausea and emesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Shaulson</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ghidewon</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Barnett</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Horn</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Doyle</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>351</first-page>
<last-page>362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., Shaulson, E., Ghidewon, M., Barnett, A., Horn, C., Doyle, R., et al.: GDF15 induces anorexia through nausea and emesis. Cell Metab. 31(2), 351–362 (2020)</ref-fulltext>
<ce:source-text>Borner, T., Shaulson, E., Ghidewon, M., Barnett, A., Horn, C., Doyle, R., et al.: GDF15 induces anorexia through nausea and emesis. Cell Metab. 31(2), 351–362 (2020)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Blocking extracellular activation of myostatin as a strategy for treating muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Pirruccello-Straub</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jackson</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Wawersik</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Webster</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Salta</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Long</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2292</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, T., Salta, L., Long, K., et al.: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018)</ref-fulltext>
<ce:source-text>Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, T., Salta, L., Long, K., et al.: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Walton</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Hagg</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Colgan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>PNAS</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5266</first-page>
<last-page>5275</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J., Walton, K., Hagg, A., Colgan, T.: Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. PNAS. 114(26), 5266–5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J., Walton, K., Hagg, A., Colgan, T.: Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. PNAS. 114(26), 5266–5275 (2017)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sin</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>202</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, H., Zhang, G., Sin, K., Liu, Z.: Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase. J. Cachexia. Sarcopenia Muscle. 8(2), 202–212 (2017)</ref-fulltext>
<ce:source-text>Ding, H., Zhang, G., Sin, K., Liu, Z.: Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase. J. Cachexia. Sarcopenia Muscle. 8(2), 202–212 (2017)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Morvan</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Rondeau</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Zou</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Minetti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>47</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>12448</first-page>
<last-page>12453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morvan, F., Rondeau, J., Zou, C., Minetti, G.: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl. Acad. Sci. USA. 114(47), 12448–12453 (2017)</ref-fulltext>
<ce:source-text>Morvan, F., Rondeau, J., Zou, C., Minetti, G.: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl. Acad. Sci. USA. 114(47), 12448–12453 (2017)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Golan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Geva</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Richards</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Madhusudan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>871</first-page>
<last-page>879</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Golan, T., Geva, R., Richards, D., Madhusudan, S.: LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia. Sarcopenia Muscle. 9(5), 871–879 (2018)</ref-fulltext>
<ce:source-text>Golan, T., Geva, R., Richards, D., Madhusudan, S.: LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia. Sarcopenia Muscle. 9(5), 871–879 (2018)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Becker</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Lord</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Studenski</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Warden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Diabetes Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>948</first-page>
<last-page>957</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Becker, C., Lord, S., Studenski, S., Warden, S.: Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3(12), 948–957 (2015)</ref-fulltext>
<ce:source-text>Becker, C., Lord, S., Studenski, S., Warden, S.: Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3(12), 948–957 (2015)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brink</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wellen</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2509</first-page>
<last-page>2516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brink, M., Wellen, J., Delafontaine, P.: Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97(11), 2509–2516 (1996)</ref-fulltext>
<ce:source-text>Brink, M., Wellen, J., Delafontaine, P.: Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97(11), 2509–2516 (1996)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.Q.</ce:initials>
<ce:surname>Adigun</ce:surname>
<ce:given-name>A.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.A.</ce:initials>
<ce:surname>Ajayi</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>359</first-page>
<last-page>363</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adigun, A.Q., Ajayi, A.A.: The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia. Eur. J. Heart Fail. 3(3), 359–363 (2001)</ref-fulltext>
<ce:source-text>Adigun, A.Q., Ajayi, A.A.: The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia. Eur. J. Heart Fail. 3(3), 359–363 (2001)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II directly inhibits protein synthesis in murine myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Sanders</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>231</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>294</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Russell, S.T., Sanders, P.M., Tisdale, M.J.: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231(2), 290–294 (2006)</ref-fulltext>
<ce:source-text>Russell, S.T., Sanders, P.M., Tisdale, M.J.: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231(2), 290–294 (2006)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.M.</ce:initials>
<ce:surname>Sanders</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>425</first-page>
<last-page>434</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanders, P.M., Russell, S.T., Tisdale, M.J.: Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer. 93(4), 425–434 (2005)</ref-fulltext>
<ce:source-text>Sanders, P.M., Russell, S.T., Tisdale, M.J.: Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer. 93(4), 425–434 (2005)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Tabony</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Galvez</ce:surname>
</author>
<author seq="4">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Higashi</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Sukhanov</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2322</first-page>
<last-page>2332</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Tabony, A.M., Galvez, S., Mitch, W.E., Higashi, Y., Sukhanov, S., et al.: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45(10), 2322–2332 (2013)</ref-fulltext>
<ce:source-text>Yoshida, T., Tabony, A.M., Galvez, S., Mitch, W.E., Higashi, Y., Sukhanov, S., et al.: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45(10), 2322–2332 (2013)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Penafuerte</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Gagnon</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Sirois</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="6">
<ce:initials>M.L.</ce:initials>
<ce:surname>Tremblay</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>680</first-page>
<last-page>687</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penafuerte, C.A., Gagnon, B., Sirois, J., Murphy, J., MacDonald, N., Tremblay, M.L.: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer. 114(6), 680–687 (2016)</ref-fulltext>
<ce:source-text>Penafuerte, C.A., Gagnon, B., Sirois, J., Murphy, J., MacDonald, N., Tremblay, M.L.: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer. 114(6), 680–687 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Negassa</ce:surname>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Coats</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Afzal</ce:surname>
</author>
<author seq="5">
<ce:initials>P.A.</ce:initials>
<ce:surname>Poole-Wilson</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.N.</ce:initials>
<ce:surname>Cohn</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>361</vol-first>
<iss-first>9363</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1077</first-page>
<last-page>1083</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anker, S.D., Negassa, A., Coats, A.J., Afzal, R., Poole-Wilson, P.A., Cohn, J.N., et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet. 361(9363), 1077–1083 (2003)</ref-fulltext>
<ce:source-text>Anker, S.D., Negassa, A., Coats, A.J., Afzal, R., Poole-Wilson, P.A., Cohn, J.N., et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet. 361(9363), 1077–1083 (2003)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Marinho</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Alcantara</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Ottoch</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Seelaender</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marinho, R., Alcantara, P., Ottoch, J., Seelaender, M.: Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Front. Nutr. 4, 69 (2017)</ref-fulltext>
<ce:source-text>Marinho, R., Alcantara, P., Ottoch, J., Seelaender, M.: Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Front. Nutr. 4, 69 (2017)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Characterisation and Mechanisms of Altered Body Composition and Tissue Wasting in Cancer Cachexia</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<ref-text>University of Edinburgh</ref-text>
</ref-info>
<ref-fulltext>Miller, J.: Characterisation and mechanisms of altered body composition and tissue wasting in cancer cachexia. University of Edinburgh (2020)</ref-fulltext>
<ce:source-text>Miller, J.: Characterisation and mechanisms of altered body composition and tissue wasting in cancer cachexia. University of Edinburgh (2020)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Insights into the potential use of microRNAs as biomarker in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Anindo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Yaqinuddin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>443</first-page>
<last-page>449</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anindo, M., Yaqinuddin, A.: Insights into the potential use of microRNAs as biomarker in cancer. Int. J. Surg. 10(9), 443–449 (2012)</ref-fulltext>
<ce:source-text>Anindo, M., Yaqinuddin, A.: Insights into the potential use of microRNAs as biomarker in cancer. Int. J. Surg. 10(9), 443–449 (2012)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs as potential biomarkers in cancer: Opportunities and challenges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Lan</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Jin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int</ref-sourcetitle>
<ref-text>125094</ref-text>
</ref-info>
<ref-fulltext>Lan, H., Lu, H., Wang, X., Jin, H.: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed. Res. Int. 125094</ref-fulltext>
<ce:source-text>Lan, H., Lu, H., Wang, X., Jin, H.: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed. Res. Int. 125094</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Small RNAome profiling from human skeletal muscle: Novel miRNAs and their targets associated with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Narasimhan</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Greiner</ce:surname>
</author>
<author seq="5">
<ce:initials>O.</ce:initials>
<ce:surname>Bathe</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>405</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Narasimhan, A., Ghosh, S., Stretch, C., Greiner, R., Bathe, O., Baracos, V., et al.: Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia. Sarcopenia Muscle. 8(3), 405–416 (2017)</ref-fulltext>
<ce:source-text>Narasimhan, A., Ghosh, S., Stretch, C., Greiner, R., Bathe, O., Baracos, V., et al.: Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia. Sarcopenia Muscle. 8(3), 405–416 (2017)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Calore</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Londhe</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Canella</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Croce</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W., Calore, F., Londhe, P., Canella, A., Guttridge, D., Croce, C.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111(12), 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W., Calore, F., Londhe, P., Canella, A., Guttridge, D., Croce, C.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111(12), 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6, cancer and cachexia: Metabolic dysfunction creates the perfect storm</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>White</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Transl Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>280</first-page>
<last-page>285</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, J.: IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res. 6(2), 280–285 (2017)</ref-fulltext>
<ce:source-text>White, J.: IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res. 6(2), 280–285 (2017)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshikwa</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Takano</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Kouta</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Horikoshi</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Asakawa</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Kudoh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>15</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>e17544</first-page>
<last-page>e17544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshikwa, T., Takano, M., Kouta, H., Horikoshi, M., Asakawa, T., Kudoh, K.: Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol. Cancer. 36(15_suppl), e17544–e17544 (2018)</ref-fulltext>
<ce:source-text>Yoshikwa, T., Takano, M., Kouta, H., Horikoshi, M., Asakawa, T., Kudoh, K.: Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol. Cancer. 36(15_suppl), e17544–e17544 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>McLeod</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Alhayyani</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Szczepny</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Watkins</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3059</first-page>
<last-page>3066</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D., Chen, W., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–66 (2017)</ref-fulltext>
<ce:source-text>Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D., Chen, W., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–66 (2017)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ramsey</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Talbert</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Ahn</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Bekaii-Saab</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Badi</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Bloomston</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pancreatology</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>80</first-page>
<last-page>87</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ramsey, M., Talbert, E., Ahn, D., Bekaii-Saab, T., Badi, N., Bloomston, P., et al.: Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 19(1), 80–87 (2019)</ref-fulltext>
<ce:source-text>Ramsey, M., Talbert, E., Ahn, D., Bekaii-Saab, T., Badi, N., Bloomston, P., et al.: Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 19(1), 80–87 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Bayliss</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Dragnev</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Rigas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Expert. Opin. Biol. Ther</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1668</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayliss, T., Smith, J., Schuster, M., Dragnev, K., Rigas, J.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. 11(12), 1663–1668 (2011)</ref-fulltext>
<ce:source-text>Bayliss, T., Smith, J., Schuster, M., Dragnev, K., Rigas, J.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. 11(12), 1663–1668 (2011)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Tournadre</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Pereira</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Dutheil</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Giraud</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Courteix</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Sapin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>639</first-page>
<last-page>646</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al.: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia. Sarcopenia Muscle. 8, 639–646 (2017)</ref-fulltext>
<ce:source-text>Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al.: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia. Sarcopenia Muscle. 8, 639–646 (2017)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Callaway</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Delitto</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>D’Lugos</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Patel</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Nosacka</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Delitto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1863</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Callaway, C., Delitto, A., D’Lugos, A., Patel, R., Nosacka, R., Delitto, D., et al.: IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy. Cancers. 11(12), 1863 (2019)</ref-fulltext>
<ce:source-text>Callaway, C., Delitto, A., D’Lugos, A., Patel, R., Nosacka, R., Delitto, D., et al.: IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy. Cancers. 11(12), 1863 (2019)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Antunes</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Ferreira</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Moreira-Goncalves</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>709</first-page>
<last-page>727</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antunes, J., Ferreira, R., Moreira-Goncalves, D.: Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol. Med. 24(8), 709–727 (2018)</ref-fulltext>
<ce:source-text>Antunes, J., Ferreira, R., Moreira-Goncalves, D.: Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol. Med. 24(8), 709–727 (2018)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hall</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Griss</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Sanchez</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Sadek</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Tremblay</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages-text>e8307</pages-text>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hall, D., Griss, T., Ma, J., Sanchez, B., Sadek, J., Tremblay, A., et al.: The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol. Med. 10(7), e8307 (2018)</ref-fulltext>
<ce:source-text>Hall, D., Griss, T., Ma, J., Sanchez, B., Sadek, J., Tremblay, A., et al.: The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol. Med. 10(7), e8307 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">3292087</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Vanderveen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Fix</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Carson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2017"/>
</ref-info>
<ref-fulltext>VanderVeen, B., Fix, D., Carson, J.: Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation. Oxidative Med. Cell. Longev. 2017;Article ID 3292087</ref-fulltext>
<ce:source-text>VanderVeen, B., Fix, D., Carson, J.: Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation. Oxidative Med. Cell. Longev. 2017;Article ID 3292087</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Novel molecular targets of muscle wasting in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>204</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Skipworth, R.: Novel molecular targets of muscle wasting in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care. 22(3), 196–204 (2019)</ref-fulltext>
<ce:source-text>Miller, J., Skipworth, R.: Novel molecular targets of muscle wasting in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care. 22(3), 196–204 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Brzeszczynska</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schlib</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Langen</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Schols</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Aging</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1690</first-page>
<last-page>1702</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brzeszczynska, J., Johns, N., Schlib, A., Degen, S., Langen, R., Schols, A., et al.: Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging. 8(8), 1690–1702 (2016)</ref-fulltext>
<ce:source-text>Brzeszczynska, J., Johns, N., Schlib, A., Degen, S., Langen, R., Schols, A., et al.: Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging. 8(8), 1690–1702 (2016)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Temel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Abernethy</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Currow</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Friend</ce:surname>
</author>
<author seq="5">
<ce:initials>E.M.</ce:initials>
<ce:surname>Duus</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>531</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17(4), 519–531 (2016)</ref-fulltext>
<ce:source-text>Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17(4), 519–531 (2016)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Currow</ce:surname>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Temel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Abernethy</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Milanowski</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Friend</ce:surname>
</author>
<author seq="6">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1949</first-page>
<last-page>1956</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(8), 1949–1956 (2017)</ref-fulltext>
<ce:source-text>Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(8), 1949–1956 (2017)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Enobosarm and lean body mass in patients with non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Crawford</ce:surname>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Johnston</ce:surname>
</author>
<author seq="3">
<ce:initials>R.P.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>R.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.T.</ce:initials>
<ce:surname>Dalton</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.S.</ce:initials>
<ce:surname>Steiner</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol. [Internet]</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<page-information>
<pages>
<first-page>32</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">http://meetinglibrary.asco.org/content/128938-144</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Crawford, J., Johnston, M.A., Taylor, R.P., Dalton, J.T., Steiner, M.S.: Enobosarm and lean body mass in patients with non-small cell lung cancer. J. Clin. Oncol. [Internet]. (2014) [cited 2017 May 15];32, 5s(suppl; abstr 9618). Available from: http://meetinglibrary.asco.org/content/128938-144</ref-fulltext>
<ce:source-text>Crawford, J., Johnston, M.A., Taylor, R.P., Dalton, J.T., Steiner, M.S.: Enobosarm and lean body mass in patients with non-small cell lung cancer. J. Clin. Oncol. [Internet]. (2014) [cited 2017 May 15];32, 5s(suppl; abstr 9618). Available from: http://meetinglibrary.asco.org/content/128938-144</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-authors>
<collaboration seq="1">
<ce:text>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US)</ce:text>
</collaboration>
</ref-authors>
<ref-sourcetitle>2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://clinicaltrials.gov/ct2/show/NCT02330926</ce:e-address>
</ref-website>
<ref-text>Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov</ref-text>
</ref-info>
<ref-fulltext>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015, Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov. 2015 [cited 2016 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926</ref-fulltext>
<ce:source-text>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015, Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov. 2015 [cited 2016 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
<ce:given-name>B.J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.B.</ce:initials>
<ce:surname>Stene</ce:surname>
<ce:given-name>G.B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Bye</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
</ref-info>
<ref-fulltext>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Stene, G.B., Bye, A., Johns, N., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. (2017) Jun 14</ref-fulltext>
<ce:source-text>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Stene, G.B., Bye, A., Johns, N., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. (2017) Jun 14</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hellerstein</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Orwoll</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Cummings</ce:surname>
</author>
<author seq="5">
<ce:initials>P.M.</ce:initials>
<ce:surname>Cawthon</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
<last-page>21</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Hellerstein, M., Orwoll, E., Cummings, S., Cawthon, P.M.: D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia. Sarcopenia Muscle. 10(1), 14–21 (2019)</ref-fulltext>
<ce:source-text>Evans, W.J., Hellerstein, M., Orwoll, E., Cummings, S., Cawthon, P.M.: D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia. Sarcopenia Muscle. 10(1), 14–21 (2019)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Costa</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Caro</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>de Matos-Neto</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Lima</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Radloff</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Alves</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1116</first-page>
<last-page>1127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa, R., Caro, P., de Matos-Neto, E., Lima, J., Radloff, K., Alves, M., et al.: Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia. Sarcopenia Muscle. 10(5), 1116–1127 (2019)</ref-fulltext>
<ce:source-text>Costa, R., Caro, P., de Matos-Neto, E., Lima, J., Radloff, K., Alves, M., et al.: Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia. Sarcopenia Muscle. 10(5), 1116–1127 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Gut Microbes</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>189</first-page>
<last-page>200</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morrison, D., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016)</ref-fulltext>
<ce:source-text>Morrison, D., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>The immunological regulation of cancer cachexia and its therapeutic implications</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Laird</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Metastasis Treat</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>68</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Laird, B., Skipworth, R.: The immunological regulation of cancer cachexia and its therapeutic implications. J. Cancer Metastasis Treat. 5, 68 (2019)</ref-fulltext>
<ce:source-text>Miller, J., Laird, B., Skipworth, R.: The immunological regulation of cancer cachexia and its therapeutic implications. J. Cancer Metastasis Treat. 5, 68 (2019)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Roberts</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Deonarine</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Denton</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Feig</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Lyons</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>210</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1137</first-page>
<last-page>1157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roberts, E., Deonarine, A., Jones, J., Denton, A., Feig, C., Lyons, S., et al.: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 3(210), 1137–1157 (2013)</ref-fulltext>
<ce:source-text>Roberts, E., Deonarine, A., Jones, J., Denton, A., Feig, C., Lyons, S., et al.: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 3(210), 1137–1157 (2013)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Doan</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Sin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>589</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H., Sin, K., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(589) (2017)</ref-fulltext>
<ce:source-text>Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H., Sin, K., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(589) (2017)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Burfeind</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Levasseur</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Michaelis</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Norgard</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Marks</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Brain Behav. Immun</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>364</first-page>
<last-page>374</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Burfeind, K., Zhu, X., Levasseur, P., Michaelis, K., Norgard, M., Marks, D.: TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain Behav. Immun. 73, 364–374 (2018)</ref-fulltext>
<ce:source-text>Burfeind, K., Zhu, X., Levasseur, P., Michaelis, K., Norgard, M., Marks, D.: TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain Behav. Immun. 73, 364–374 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_11</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Muscle wasting</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Fatigue</author-keyword>
<author-keyword>Exercise</author-keyword>
<author-keyword>Physical activity</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Exercise: A Critical Component of Cachexia Prevention and Therapy in Cancer</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>Emidio E.</ce:given-name>
<ce:e-address>epistilli2@hsc.wvu.edu</ce:e-address>
</author>
<affiliation>
<organization>Division of Exercise Physiology</organization>
<organization>Department of Human Performance</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>Division of Exercise Physiology, Department of Human Performance, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
<organization>Cancer Institute</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>Cancer Institute, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
<organization>Department of Microbiology, Immunology, and Cell Biology</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
<organization>West Virginia Clinical and Translational Sciences Institute</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>West Virginia Clinical and Translational Sciences Institute, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
<organization>Division of Exercise Physiology</organization>
<organization>Department of Human Performance</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>Division of Exercise Physiology, Department of Human Performance, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
</affiliation>
<author seq="2">
<ce:initials>H.E.</ce:initials>
<ce:surname>Wilson</ce:surname>
<ce:given-name>Hannah E.</ce:given-name>
</author>
<affiliation>
<organization>Cancer Institute</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>Cancer Institute, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
</affiliation>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Stanton</ce:surname>
<ce:given-name>David A.</ce:given-name>
</author>
<affiliation>
<organization>Division of Exercise Physiology</organization>
<organization>Department of Human Performance</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA"/>
<ce:source-text>Division of Exercise Physiology, Department of Human Performance, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Cachexia is a condition characterized by loss of body weight as a result of chronic disease. In the setting of cancer, cachexia is more commonly observed in late stage and metastatic disease and the loss of body weight is attributed to varying combinations of muscle wasting and loss of adipose tissue. Cancer cachexia is a clinically relevant medical issue and is estimated to account for up to 20% of cancer mortality. Additionally, cachexia in cancer patients is associated with reduced tolerance to tumor-directed therapies. Cross-sectional studies support the observation that people with greater levels of physical activity and exercise habits have lower risk of a cancer diagnosis, as well as a lower risk for cancer recurrence. Exercise recommendations for patients with cancer do not differ from those of healthy adults, and patients should strive to be as physically active as their condition allows. The purpose of this chapter is to define cachexia and identify clinical parameters used to diagnose this condition, discuss recommendations for exercise prescription in cancer patients, and provide an overview of the expected physiological responses to both aerobic and resistance training in cancer patients, in order to have a positive impact on the incidence and prevalence of cachexia. In general, aerobic exercise training is not associated with significant increases in body mass or in reversal of body weight loss in cancer patients. In contrast, studies do suggest that resistance exercise training has a role in maintenance or prevention of the onset of cachexia in cancer patients, although differing responses may occur between different cancer types. Therefore, we suggest that structured exercise programs in patients with cancer include resistance training to take advantage of these effects on lean body mass and muscle functional capacity.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="80">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Fundamentals of  cancer metabolism.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>DeBerardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.S.</ce:initials>
<ce:surname>Chandel</ce:surname>
<ce:given-name>N.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Adv</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>2016</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>DeBerardinis, R.J., Chandel, N.S.: Fundamentals of  cancer metabolism. Sci. Adv. 2, e1600200 (2016)</ref-fulltext>
<ce:source-text>DeBerardinis, R.J., Chandel, N.S.: Fundamentals of  cancer metabolism. Sci. Adv. 2, e1600200 (2016)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>The hallmarks of cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>100</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>57</first-page>
<last-page>70</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: The hallmarks of cancer. Cell. 100,57–70 (2000)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: The hallmarks of cancer. Cell. 100,57–70 (2000)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Chemical and elemental analysis of humans  in vivo using improved body composition models.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Waki</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Kehayias</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Lichtman</ce:surname>
</author>
<author seq="5">
<ce:initials>F.A.</ce:initials>
<ce:surname>Dilmanian</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Kamen</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="8">
<ce:initials>R.N.</ce:initials>
<ce:surname>Pierson Jr.</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>261</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Heymsfield, S.B., Waki, M., Kehayias, J., Lichtman,  S., Dilmanian, F.A., Kamen, Y., Wang, J., Pierson Jr.,  R.N.: Chemical and elemental analysis of humans  in vivo using improved body composition models.  Am. J. Phys. 261, E190–E198 (1991)</ref-fulltext>
<ce:source-text> Heymsfield, S.B., Waki, M., Kehayias, J., Lichtman,  S., Dilmanian, F.A., Kamen, Y., Wang, J., Pierson Jr.,  R.N.: Chemical and elemental analysis of humans  in vivo using improved body composition models.  Am. J. Phys. 261, E190–E198 (1991)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Multi-component body composition  models: recent advances and future directions.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Pietrobelli</ce:surname>
</author>
<author seq="2">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.M.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Z.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Gallagher</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>75</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Pietrobelli, A., Heymsfield, S.B., Wang, Z.M.,  Gallagher, D.: Multi-component body composition  models: recent advances and future directions.  Eur. J. Clin. Nutr. 55,69–75 (2001)</ref-fulltext>
<ce:source-text> Pietrobelli, A., Heymsfield, S.B., Wang, Z.M.,  Gallagher, D.: Multi-component body composition  models: recent advances and future directions.  Eur. J. Clin. Nutr. 55,69–75 (2001)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: The last illness.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Lok</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>528</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>182</first-page>
<last-page>183</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Lok, C.: Cachexia: The last illness. Nature. 528,  182–183 (2015)</ref-fulltext>
<ce:source-text> Lok, C.: Cachexia: The last illness. Nature. 528,  182–183 (2015)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia. Nat. Rev.  Dis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Korc</ce:surname>
</author>
<author seq="4">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev.  Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>17105</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C.,  Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev.  Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C.,  Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev.  Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Diseases of the heart in the  works of Hippocrates.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Katz</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.B.</ce:initials>
<ce:surname>Katz</ce:surname>
<ce:given-name>P.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. Heart J</ref-sourcetitle>
<ref-publicationyear first="1962"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>257</first-page>
<last-page>264</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Katz, A.M., Katz, P.B.: Diseases of the heart in the  works of Hippocrates. Br. Heart J. 24, 257–264 (1962)</ref-fulltext>
<ce:source-text>Katz, A.M., Katz, P.B.: Diseases of the heart in the  works of Hippocrates. Br. Heart J. 24, 257–264 (1962)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: understanding the  molecular basis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Stemmler</ce:surname>
</author>
<author seq="4">
<ce:initials>F.J.</ce:initials>
<ce:surname>Lopez Soriano</ce:surname>
<ce:given-name>F.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., Busquets, S., Stemmler, B., Lopez Soriano, F.J.: Cancer cachexia: understanding the  molecular basis. Nat. Rev. Cancer. 14, 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., Busquets, S., Stemmler, B., Lopez Soriano, F.J.: Cancer cachexia: understanding the  molecular basis. Nat. Rev. Cancer. 14, 754–762 (2014)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A new definition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Argiles</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bales</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Kalantar-Zadeh</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Lochs</ce:surname>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
</author>
<author seq="11">
<ce:initials>D.</ce:initials>
<ce:surname>Marks</ce:surname>
</author>
<author seq="12">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="13">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="14">
<ce:initials>A.</ce:initials>
<ce:surname>Najand</ce:surname>
</author>
<author seq="15">
<ce:initials>P.</ce:initials>
<ce:surname>Ponikowski</ce:surname>
</author>
<author seq="16">
<ce:initials>F.</ce:initials>
<ce:surname>Rossi Fanelli</ce:surname>
</author>
<author seq="17">
<ce:initials>M.</ce:initials>
<ce:surname>Schambelan</ce:surname>
</author>
<author seq="18">
<ce:initials>A.</ce:initials>
<ce:surname>Schols</ce:surname>
</author>
<author seq="19">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
</author>
<author seq="20">
<ce:initials>D.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
<author seq="21">
<ce:initials>R.</ce:initials>
<ce:surname>Wolfe</ce:surname>
</author>
<author seq="22">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>793</first-page>
<last-page>799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Morley, J.E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., Marks, D., Mitch, W.E., Muscaritoli, M., Najand, A., Ponikowski, P., Rossi Fanelli, F., Schambelan, M., Schols, A., Schuster, M., Thomas, D., Wolfe, R., Anker, S.D.: Cachexia: A new definition. Clin. Nutr. 27, 793–799 (2008)</ref-fulltext>
<ce:source-text>Evans, W.J., Morley, J.E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., Marks, D., Mitch, W.E., Muscaritoli, M., Najand, A., Ponikowski, P., Rossi Fanelli, F., Schambelan, M., Schols, A., Schuster, M., Thomas, D., Wolfe, R., Anker, S.D.: Cachexia: A new definition. Clin. Nutr. 27, 793–799 (2008)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
</author>
<author seq="6">
<ce:initials>R.L.</ce:initials>
<ce:surname>Fainsinger</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Loprinzi</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
</author>
<author seq="11">
<ce:initials>M.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<author seq="12">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="13">
<ce:initials>F.</ce:initials>
<ce:surname>Ottery</ce:surname>
</author>
<author seq="14">
<ce:initials>L.</ce:initials>
<ce:surname>Radbruch</ce:surname>
</author>
<author seq="15">
<ce:initials>P.</ce:initials>
<ce:surname>Ravasco</ce:surname>
</author>
<author seq="16">
<ce:initials>D.</ce:initials>
<ce:surname>Walsh</ce:surname>
</author>
<author seq="17">
<ce:initials>A.</ce:initials>
<ce:surname>Wilcock</ce:surname>
</author>
<author seq="18">
<ce:initials>S.</ce:initials>
<ce:surname>Kaasa</ce:surname>
</author>
<author seq="19">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., Baracos, V.E.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12, 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., Baracos, V.E.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12, 489–495 (2011)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.E.</ce:initials>
<ce:surname>Wilson</ce:surname>
<ce:given-name>H.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Stanton</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Montgomery</ce:surname>
</author>
<author seq="4">
<ce:initials>A.M.</ce:initials>
<ce:surname>Infante</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Taylor</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Hazard-Jenkins</ce:surname>
</author>
<author seq="7">
<ce:initials>E.N.</ce:initials>
<ce:surname>Pugacheva</ce:surname>
<ce:given-name>E.N.</ce:given-name>
</author>
<author seq="8">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>NPJ Breast Cancer</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wilson, H.E., Stanton, D.A., Montgomery, C., Infante, A.M., Taylor, M., Hazard-Jenkins, H., Pugacheva, E.N., Pistilli, E.E.: Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype. NPJ Breast Cancer. 6, 18 (2020)</ref-fulltext>
<ce:source-text>Wilson, H.E., Stanton, D.A., Montgomery, C., Infante, A.M., Taylor, M., Hazard-Jenkins, H., Pugacheva, E.N., Pistilli, E.E.: Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype. NPJ Breast Cancer. 6, 18 (2020)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Delitto</ce:surname>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.J.</ce:initials>
<ce:surname>George</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.A.</ce:initials>
<ce:surname>Sarosi</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.M.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.E.</ce:initials>
<ce:surname>Behrns</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.J.</ce:initials>
<ce:surname>Hughes</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.R.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.G.</ce:initials>
<ce:surname>Trevino</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>930</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Delitto, D., Judge, S.M., George Jr., T.J., Sarosi, G.A., Thomas, R.M., Behrns, K.E., Hughes, S.J., Judge, A.R., Trevino, J.G.: A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Surgery. 161, 930–938 (2017)</ref-fulltext>
<ce:source-text>Delitto, D., Judge, S.M., George Jr., T.J., Sarosi, G.A., Thomas, R.M., Behrns, K.E., Hughes, S.J., Judge, A.R., Trevino, J.G.: A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Surgery. 161, 930–938 (2017)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia in cancer: What is in the definition?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vanhoutte</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Van de Wiel</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Wouters</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sels</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Bartolomeeussen</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>de Keersmaecker</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verschueren</ce:surname>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>de Vroey</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>de Wilde</ce:surname>
</author>
<author seq="10">
<ce:initials>E.</ce:initials>
<ce:surname>Smits</ce:surname>
</author>
<author seq="11">
<ce:initials>K.J.</ce:initials>
<ce:surname>Cheung</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="12">
<ce:initials>L.</ce:initials>
<ce:surname>de Clerck</ce:surname>
</author>
<author seq="13">
<ce:initials>P.</ce:initials>
<ce:surname>Aerts</ce:surname>
</author>
<author seq="14">
<ce:initials>D.</ce:initials>
<ce:surname>Baert</ce:surname>
</author>
<author seq="15">
<ce:initials>C.</ce:initials>
<ce:surname>Vandoninck</ce:surname>
</author>
<author seq="16">
<ce:initials>S.</ce:initials>
<ce:surname>Kindt</ce:surname>
</author>
<author seq="17">
<ce:initials>S.</ce:initials>
<ce:surname>Schelfhaut</ce:surname>
</author>
<author seq="18">
<ce:initials>M.</ce:initials>
<ce:surname>Vankerkhoven</ce:surname>
</author>
<author seq="19">
<ce:initials>A.</ce:initials>
<ce:surname>Troch</ce:surname>
</author>
<author seq="20">
<ce:initials>L.</ce:initials>
<ce:surname>Ceulemans</ce:surname>
</author>
<author seq="21">
<ce:initials>H.</ce:initials>
<ce:surname>Vandenbergh</ce:surname>
</author>
<author seq="22">
<ce:initials>S.</ce:initials>
<ce:surname>Leys</ce:surname>
</author>
<author seq="23">
<ce:initials>T.</ce:initials>
<ce:surname>Rondou</ce:surname>
</author>
<author seq="24">
<ce:initials>E.</ce:initials>
<ce:surname>Dewitte</ce:surname>
</author>
<author seq="25">
<ce:initials>K.</ce:initials>
<ce:surname>Maes</ce:surname>
</author>
<author seq="26">
<ce:initials>P.</ce:initials>
<ce:surname>Pauwels</ce:surname>
</author>
<author seq="27">
<ce:initials>B.</ce:initials>
<ce:surname>de Winter</ce:surname>
</author>
<author seq="28">
<ce:initials>L.</ce:initials>
<ce:surname>van Gaal</ce:surname>
</author>
<author seq="29">
<ce:initials>D.</ce:initials>
<ce:surname>Ysebaert</ce:surname>
</author>
<author seq="30">
<ce:initials>M.</ce:initials>
<ce:surname>Peeters</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Open Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., De Keersmaecker, S., Verschueren, C., De Vroey, V., De Wilde, A., Smits, E., Cheung, K.J., De Clerck, L., Aerts, P., Baert, D., Vandoninck, C., Kindt, S., Schelfhaut, S., Vankerkhoven, M., Troch, A., Ceulemans, L., Vandenbergh, H., Leys, S., Rondou, T., Dewitte, E., Maes, K., Pauwels, P., De Winter, B., Van Gaal, L., Ysebaert, D., Peeters, M.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3, e000097 (2016)</ref-fulltext>
<ce:source-text>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., De Keersmaecker, S., Verschueren, C., De Vroey, V., De Wilde, A., Smits, E., Cheung, K.J., De Clerck, L., Aerts, P., Baert, D., Vandoninck, C., Kindt, S., Schelfhaut, S., Vankerkhoven, M., Troch, A., Ceulemans, L., Vandenbergh, H., Leys, S., Rondou, T., Dewitte, E., Maes, K., Pauwels, P., De Winter, B., Van Gaal, L., Ysebaert, D., Peeters, M.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3, e000097 (2016)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Physiological basis of fatigue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.P.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys. Med. Rehabil</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S29</first-page>
<last-page>S46</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Lambert, C.P.: Physiological basis of fatigue. Am. J. Phys. Med. Rehabil. 86, S29–S46 (2007)</ref-fulltext>
<ce:source-text>Evans, W.J., Lambert, C.P.: Physiological basis of fatigue. Am. J. Phys. Med. Rehabil. 86, S29–S46 (2007)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle mass as a target to reduce fatigue in patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.W.</ce:initials>
<ce:surname>Neefjes</ce:surname>
<ce:given-name>E.C.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.M.</ce:initials>
<ce:surname>Van den Hurk</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Blauwhoff-Buskermolen</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Van der Vorst</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Becker-Commissaris</ce:surname>
</author>
<author seq="6">
<ce:initials>M.A.E.</ce:initials>
<ce:surname>De van der Schueren</ce:surname>
<ce:given-name>M.A.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>L.M.</ce:initials>
<ce:surname>Buffart</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.M.W.</ce:initials>
<ce:surname>Verheul</ce:surname>
<ce:given-name>H.M.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>623</first-page>
<last-page>629</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Neefjes, E.C.W., van den Hurk, R.M., Blauwhoff-Buskermolen, S., van der Vorst, M., Becker-Commissaris, A., de van der Schueren, M.A.E., Buffart, L.M., Verheul, H.M.W.: Muscle mass as a target to reduce fatigue in patients with advanced cancer. J. Cachexia. Sarcopenia Muscle. 8, 623–629 (2017)</ref-fulltext>
<ce:source-text>Neefjes, E.C.W., van den Hurk, R.M., Blauwhoff-Buskermolen, S., van der Vorst, M., Becker-Commissaris, A., de van der Schueren, M.A.E., Buffart, L.M., Verheul, H.M.W.: Muscle mass as a target to reduce fatigue in patients with advanced cancer. J. Cachexia. Sarcopenia Muscle. 8, 623–629 (2017)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Bower</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.A.</ce:initials>
<ce:surname>Ganz</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.A.</ce:initials>
<ce:surname>Desmond</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.E.</ce:initials>
<ce:surname>Meyerowitz</ce:surname>
<ce:given-name>B.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.R.</ce:initials>
<ce:surname>Belin</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>743</first-page>
<last-page>753</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., Belin, T.R.: Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 18, 743–753 (2000)</ref-fulltext>
<ce:source-text>Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., Belin, T.R.: Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 18, 743–753 (2000)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue in cancer patients compared with fatigue  in the general United States population.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cella</ce:surname>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.H.</ce:initials>
<ce:surname>Chang</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Peterman</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Slavin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>528</first-page>
<last-page>538</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cella, D., Lai, J.S., Chang, C.H., Peterman, A., Slavin,  M.: Fatigue in cancer patients compared with fatigue  in the general United States population. Cancer. 94,  528–538 (2002)</ref-fulltext>
<ce:source-text>Cella, D., Lai, J.S., Chang, C.H., Peterman, A., Slavin,  M.: Fatigue in cancer patients compared with fatigue  in the general United States population. Cancer. 94,  528–538 (2002)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of fatigue on patients with  cancer: overview of FATIGUE 1 and 2.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.A.</ce:initials>
<ce:surname>Curt</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Curt, G.A.: The impact of fatigue on patients with  cancer: overview of FATIGUE 1 and 2. Oncologist.  5(Suppl 2), 9–12 (2000)</ref-fulltext>
<ce:source-text>Curt, G.A.: The impact of fatigue on patients with  cancer: overview of FATIGUE 1 and 2. Oncologist.  5(Suppl 2), 9–12 (2000)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: Preclinical evaluation of interleukin-15 targeting fatigue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Bohlen</ce:surname>
</author>
<author seq="2">
<ce:initials>S.L.</ce:initials>
<ce:surname>McLaughlin</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Hazard-Jenkins</ce:surname>
</author>
<author seq="4">
<ce:initials>A.M.</ce:initials>
<ce:surname>Infante</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Montgomery</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<author seq="7">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bohlen, J., McLaughlin, S.L., Hazard-Jenkins, H., Infante, A.M., Montgomery, C., Davis, M., Pistilli, E.E.: Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: Preclinical evaluation of interleukin-15 targeting fatigue. J. Cachexia. Sarcopenia Muscle. 9, 701–714 (2018)</ref-fulltext>
<ce:source-text>Bohlen, J., McLaughlin, S.L., Hazard-Jenkins, H., Infante, A.M., Montgomery, C., Davis, M., Pistilli, E.E.: Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: Preclinical evaluation of interleukin-15 targeting fatigue. J. Cachexia. Sarcopenia Muscle. 9, 701–714 (2018)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Human breast cancer xenograft model  implicates peroxisome proliferator-activated receptor  signaling as driver of cancer-induced muscle fatigue.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.E.</ce:initials>
<ce:surname>Wilson</ce:surname>
<ce:given-name>H.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.K.</ce:initials>
<ce:surname>Rhodes</ce:surname>
<ce:given-name>K.K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Rodriguez</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Chahal</ce:surname>
</author>
<author seq="5">
<ce:initials>D.A.</ce:initials>
<ce:surname>Stanton</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Bohlen</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<author seq="8">
<ce:initials>A.M.</ce:initials>
<ce:surname>Infante</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Hazard-Jenkins</ce:surname>
</author>
<author seq="10">
<ce:initials>D.J.</ce:initials>
<ce:surname>Klinke</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="11">
<ce:initials>E.N.</ce:initials>
<ce:surname>Pugacheva</ce:surname>
<ce:given-name>E.N.</ce:given-name>
</author>
<author seq="12">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2336</first-page>
<last-page>2347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wilson, H.E., Rhodes, K.K., Rodriguez, D., Chahal, I.,  Stanton, D.A., Bohlen, J., Davis, M., Infante, A.M.,  Hazard-Jenkins, H., Klinke, D.J., Pugacheva, E.N.,  Pistilli, E.E.: Human breast cancer xenograft model  implicates peroxisome proliferator-activated receptor  signaling as driver of cancer-induced muscle fatigue.  Clin. Cancer Res. 25, 2336–2347 (2019)</ref-fulltext>
<ce:source-text>Wilson, H.E., Rhodes, K.K., Rodriguez, D., Chahal, I.,  Stanton, D.A., Bohlen, J., Davis, M., Infante, A.M.,  Hazard-Jenkins, H., Klinke, D.J., Pugacheva, E.N.,  Pistilli, E.E.: Human breast cancer xenograft model  implicates peroxisome proliferator-activated receptor  signaling as driver of cancer-induced muscle fatigue.  Clin. Cancer Res. 25, 2336–2347 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding sex differences in the regulation of cancer-induced muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Montalvo</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.R.</ce:initials>
<ce:surname>Counts</ce:surname>
<ce:given-name>B.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>394</first-page>
<last-page>403</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Montalvo, R.N., Counts, B.R., Carson, J.A.: Understanding sex differences in the regulation of cancer-induced muscle wasting. Curr. Opin. Support. Palliat. Care. 12, 394–403 (2018)</ref-fulltext>
<ce:source-text>Montalvo, R.N., Counts, B.R., Carson, J.A.: Understanding sex differences in the regulation of cancer-induced muscle wasting. Curr. Opin. Support. Palliat. Care. 12, 394–403 (2018)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The landscape of sex-differential transcriptome and its consequent selection in human adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gershoni</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Pietrokovski</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Biol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gershoni, M., Pietrokovski, S.: The landscape of sex-differential transcriptome and its consequent selection in human adults. BMC Biol. 15, 7 (2017)</ref-fulltext>
<ce:source-text>Gershoni, M., Pietrokovski, S.: The landscape of sex-differential transcriptome and its consequent selection in human adults. BMC Biol. 15, 7 (2017)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Sex differences in muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Anderson</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Exp. Med. Biol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>1043</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>197</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anderson, L.J., Liu, H., Garcia, J.M.: Sex differences in muscle wasting. Adv. Exp. Med. Biol. 1043, 153–197 (2017)</ref-fulltext>
<ce:source-text>Anderson, L.J., Liu, H., Garcia, J.M.: Sex differences in muscle wasting. Adv. Exp. Med. Biol. 1043, 153–197 (2017)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of muscle mass in the end of life in patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Wallengren</ce:surname>
</author>
<author seq="2">
<ce:initials>B.M.</ce:initials>
<ce:surname>Iresjo</ce:surname>
<ce:given-name>B.M,</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>79</first-page>
<last-page>86</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallengren, O., Iresjo, B.M., Lundholm, K., Bosaeus, I.: Loss of muscle mass in the end of life in patients with advanced cancer. Support Care Cancer. 23, 79–86 (2015)</ref-fulltext>
<ce:source-text>Wallengren, O., Iresjo, B.M., Lundholm, K., Bosaeus, I.: Loss of muscle mass in the end of life in patients with advanced cancer. Support Care Cancer. 23, 79–86 (2015)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.J.</ce:initials>
<ce:surname>Gallagher</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>499</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J., Ross, J.A., Fearon, K.C., Greig, C.A.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31, 499–505 (2012)</ref-fulltext>
<ce:source-text>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J., Ross, J.A., Fearon, K.C., Greig, C.A.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31, 499–505 (2012)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence against a sexual dimorphism in glucose and fatty acid metabolism in skeletal muscle cultures from age-matched men and post-menopausal women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Rune</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Salehzadeh</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Szekeres</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Kuhn</ce:surname>
</author>
<author seq="5">
<ce:initials>M.E.</ce:initials>
<ce:surname>Osler</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Al-Khalili</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Acta Physiol (Oxf.).</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>197</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>207</first-page>
<last-page>215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rune, A., Salehzadeh, F., Szekeres, F., Kuhn, I., Osler, M.E., Al-Khalili, L.: Evidence against a sexual dimorphism in glucose and fatty acid metabolism in skeletal muscle cultures from age-matched men and post-menopausal women. Acta Physiol (Oxf.). 197, 207–215 (2009)</ref-fulltext>
<ce:source-text>Rune, A., Salehzadeh, F., Szekeres, F., Kuhn, I., Osler, M.E., Al-Khalili, L.: Evidence against a sexual dimorphism in glucose and fatty acid metabolism in skeletal muscle cultures from age-matched men and post-menopausal women. Acta Physiol (Oxf.). 197, 207–215 (2009)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Gender dimorphism in the exercise-naive murine skeletal muscle proteome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Metskas</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Kulp</ce:surname>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Scordilis</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell. Mol. Biol. Lett</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>507</first-page>
<last-page>516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Metskas, L.A., Kulp, M., Scordilis, S.P.: Gender dimorphism in the exercise-naive murine skeletal muscle proteome. Cell. Mol. Biol. Lett. 15, 507–516 (2010)</ref-fulltext>
<ce:source-text>Metskas, L.A., Kulp, M., Scordilis, S.P.: Gender dimorphism in the exercise-naive murine skeletal muscle proteome. Cell. Mol. Biol. Lett. 15, 507–516 (2010)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>State of the epidemiological evidence on physical activity and cancer prevention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.K.</ce:initials>
<ce:surname>Neilson</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.M.</ce:initials>
<ce:surname>Lynch</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2593</first-page>
<last-page>2604</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedenreich, C.M., Neilson, H.K., Lynch, B.M.: State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer. 46, 2593–2604 (2010)</ref-fulltext>
<ce:source-text>Friedenreich, C.M., Neilson, H.K., Lynch, B.M.: State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer. 46, 2593–2604 (2010)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Lifestyle factors associated with cancer incidence, recurrence and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Neilson</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ACSM’s Guide to Exercise and Cancer Survivorship</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<page-information>
<pages>
<first-page>29</first-page>
<last-page>47</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Irwin, M.L. (ed.), Human Kinetics, Illinois</ref-text>
</ref-info>
<ref-fulltext>Neilson, H.K., Friedenreich, C.M.: Lifestyle factors associated with cancer incidence, recurrence and survival. In: Irwin, M.L. (ed.) ACSM’s guide to exercise and cancer survivorship, pp. 29–47. Human Kinetics, Illinois (2012)</ref-fulltext>
<ce:source-text>Neilson, H.K., Friedenreich, C.M.: Lifestyle factors associated with cancer incidence, recurrence and survival. In: Irwin, M.L. (ed.) ACSM’s guide to exercise and cancer survivorship, pp. 29–47. Human Kinetics, Illinois (2012)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and cancer risk: Dose-response and cancer, all sites and site-specific</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Thune</ce:surname>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Furberg</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S530</first-page>
<last-page>S550</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thune, I., Furberg, A.S.: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med. Sci. Sports Exerc. 33, S530–50 (2001); discussion S609–10</ref-fulltext>
<ce:source-text>Thune, I., Furberg, A.S.: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med. Sci. Sports Exerc. 33, S530–50 (2001); discussion S609–10</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Moore</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.M.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>I.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Weiderpass</ce:surname>
</author>
<author seq="4">
<ce:initials>P.T.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>P.T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.N.</ce:initials>
<ce:surname>Sampson</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kitahara</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Keadle</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Arem</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Berrington de Gonzalez</ce:surname>
</author>
<author seq="10">
<ce:initials>P.</ce:initials>
<ce:surname>Hartge</ce:surname>
</author>
<author seq="11">
<ce:initials>H.O.</ce:initials>
<ce:surname>Adami</ce:surname>
<ce:given-name>H.O.</ce:given-name>
</author>
<author seq="12">
<ce:initials>C.K.</ce:initials>
<ce:surname>Blair</ce:surname>
<ce:given-name>C.K.</ce:given-name>
</author>
<author seq="13">
<ce:initials>K.B.</ce:initials>
<ce:surname>Borch</ce:surname>
<ce:given-name>K.B.</ce:given-name>
</author>
<author seq="14">
<ce:initials>E.</ce:initials>
<ce:surname>Boyd</ce:surname>
</author>
<author seq="15">
<ce:initials>D.P.</ce:initials>
<ce:surname>Check</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
<author seq="16">
<ce:initials>A.</ce:initials>
<ce:surname>Fournier</ce:surname>
</author>
<author seq="17">
<ce:initials>N.D.</ce:initials>
<ce:surname>Freedman</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
<author seq="18">
<ce:initials>M.</ce:initials>
<ce:surname>Gunter</ce:surname>
</author>
<author seq="19">
<ce:initials>M.</ce:initials>
<ce:surname>Johannson</ce:surname>
</author>
<author seq="20">
<ce:initials>K.T.</ce:initials>
<ce:surname>Khaw</ce:surname>
<ce:given-name>K.T.</ce:given-name>
</author>
<author seq="21">
<ce:initials>M.S.</ce:initials>
<ce:surname>Linet</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="22">
<ce:initials>N.</ce:initials>
<ce:surname>Orsini</ce:surname>
</author>
<author seq="23">
<ce:initials>Y.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="24">
<ce:initials>E.</ce:initials>
<ce:surname>Riboli</ce:surname>
</author>
<author seq="25">
<ce:initials>K.</ce:initials>
<ce:surname>Robien</ce:surname>
</author>
<author seq="26">
<ce:initials>C.</ce:initials>
<ce:surname>Schairer</ce:surname>
</author>
<author seq="27">
<ce:initials>H.</ce:initials>
<ce:surname>Sesso</ce:surname>
</author>
<author seq="28">
<ce:initials>M.</ce:initials>
<ce:surname>Spriggs</ce:surname>
</author>
<author seq="29">
<ce:initials>R.</ce:initials>
<ce:surname>van Dusen</ce:surname>
</author>
<author seq="30">
<ce:initials>A.</ce:initials>
<ce:surname>Wolk</ce:surname>
</author>
<author seq="31">
<ce:initials>C.E.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="32">
<ce:initials>A.V.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA Intern. Med</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>816</first-page>
<last-page>825</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moore, S.C., Lee, I.M., Weiderpass, E., Campbell, P.T., Sampson, J.N., Kitahara, C.M., Keadle, S.K., Arem, H., Berrington de Gonzalez, A., Hartge, P., Adami, H.O., Blair, C.K., Borch, K.B., Boyd, E., Check, D.P., Fournier, A., Freedman, N.D., Gunter, M., Johannson, M., Khaw, K.T., Linet, M.S., Orsini, N., Park, Y., Riboli, E., Robien, K., Schairer, C., Sesso, H., Spriggs, M., Van Dusen, R., Wolk, A., Matthews, C.E., Patel, A.V.: Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176, 816–825 (2016)</ref-fulltext>
<ce:source-text>Moore, S.C., Lee, I.M., Weiderpass, E., Campbell, P.T., Sampson, J.N., Kitahara, C.M., Keadle, S.K., Arem, H., Berrington de Gonzalez, A., Hartge, P., Adami, H.O., Blair, C.K., Borch, K.B., Boyd, E., Check, D.P., Fournier, A., Freedman, N.D., Gunter, M., Johannson, M., Khaw, K.T., Linet, M.S., Orsini, N., Park, Y., Riboli, E., Robien, K., Schairer, C., Sesso, H., Spriggs, M., Van Dusen, R., Wolk, A., Matthews, C.E., Patel, A.V.: Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176, 816–825 (2016)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of physical activity and body size on  survival after diagnosis with colorectal cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Haydon</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Macinnis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.R.</ce:initials>
<ce:surname>English</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.G.</ce:initials>
<ce:surname>Giles</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut.</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>62</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Haydon, A.M., Macinnis, R.J., English, D.R., Giles,  G.G.: Effect of physical activity and body size on  survival after diagnosis with colorectal cancer. Gut.  55,62–67 (2006)</ref-fulltext>
<ce:source-text>Haydon, A.M., Macinnis, R.J., English, D.R., Giles,  G.G.: Effect of physical activity and body size on  survival after diagnosis with colorectal cancer. Gut.  55,62–67 (2006)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activ ity and survival after diagnosis of invasive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.N.</ce:initials>
<ce:surname>Holick</ce:surname>
<ce:given-name>C.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.A.</ce:initials>
<ce:surname>Newcomb</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Trentham-Dietz</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Titus-Ernstoff</ce:surname>
</author>
<author seq="5">
<ce:initials>A.J.</ce:initials>
<ce:surname>Bersch</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.J.</ce:initials>
<ce:surname>Stampfer</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Baron</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.M.</ce:initials>
<ce:surname>Egan</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>W.C.</ce:initials>
<ce:surname>Willett</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Epidemiol. Biomark</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>379</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Holick, C.N., Newcomb, P.A., Trentham-Dietz, A.,  Titus-Ernstoff, L., Bersch, A.J., Stampfer, M.J.,  Baron, J.A., Egan, K.M., Willett, W.C.: Physical activ ity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol. Biomark. Prev. 17, 379–386  (2008)</ref-fulltext>
<ce:source-text>Holick, C.N., Newcomb, P.A., Trentham-Dietz, A.,  Titus-Ernstoff, L., Bersch, A.J., Stampfer, M.J.,  Baron, J.A., Egan, K.M., Willett, W.C.: Physical activ ity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol. Biomark. Prev. 17, 379–386  (2008)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and gynecologic cancer  prevention.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E</ce:initials>
<ce:surname>Cust</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Recent Results Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>186</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
<last-page>185</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cust, A.E.: Physical activity and gynecologic cancer  prevention. Recent Results Cancer Res. 186, 159–185  (2011)</ref-fulltext>
<ce:source-text>Cust, A.E.: Physical activity and gynecologic cancer  prevention. Recent Results Cancer Res. 186, 159–185  (2011)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english></ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mazzilli</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.E.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.A.</ce:initials>
<ce:surname>Salerno</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Moore</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1845</first-page>
<last-page>1851</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mazzilli, K.M., Matthews, C.E., Salerno, E.A., Moore,  S.C.: Weight training and risk of 10 common types of  cancer. Med. Sci. Sports Exerc. 51, 1845–1851 (2019)</ref-fulltext>
<ce:source-text>Mazzilli, K.M., Matthews, C.E., Salerno, E.A., Moore,  S.C.: Weight training and risk of 10 common types of  cancer. Med. Sci. Sports Exerc. 51, 1845–1851 (2019)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Influence of  pre- and postdiagnosis physical activity on mortality in  breast cancer survivors: the health, eating, activity, and  lifestyle study.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.W.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>McTiernan</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Ballard Barbash</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Cronin</ce:surname>
</author>
<author seq="6">
<ce:initials>F.D.</ce:initials>
<ce:surname>Gilliland</ce:surname>
<ce:given-name>F.D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.N.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.B.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>K.B.</ce:given-name>
</author>
<author seq="9">
<ce:initials>L.</ce:initials>
<ce:surname>Bernstein</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3958</first-page>
<last-page>3964</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Irwin, M.L., Smith, A.W., McTiernan, A., Ballard Barbash, R., Cronin, K., Gilliland, F.D., Baumgartner,  R.N., Baumgartner, K.B., Bernstein, L.: Influence of  pre- and postdiagnosis physical activity on mortality in  breast cancer survivors: the health, eating, activity, and  lifestyle study. J. Clin. Oncol. 26, 3958–3964 (2008)</ref-fulltext>
<ce:source-text>Irwin, M.L., Smith, A.W., McTiernan, A., Ballard Barbash, R., Cronin, K., Gilliland, F.D., Baumgartner,  R.N., Baumgartner, K.B., Bernstein, L.: Influence of  pre- and postdiagnosis physical activity on mortality in  breast cancer survivors: the health, eating, activity, and  lifestyle study. J. Clin. Oncol. 26, 3958–3964 (2008)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Meyerhardt</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Heseltine</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Niedzwiecki</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Hollis</ce:surname>
</author>
<author seq="5">
<ce:initials>L.B.</ce:initials>
<ce:surname>Saltz</ce:surname>
<ce:given-name>L.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Mayer</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Nelson</ce:surname>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:surname>Whittom</ce:surname>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Hantel</ce:surname>
</author>
<author seq="11">
<ce:initials>R.L.</ce:initials>
<ce:surname>Schilsky</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="12">
<ce:initials>C.S.</ce:initials>
<ce:surname>Fuchs</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3535</first-page>
<last-page>3541</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., Thomas, J., Nelson, H., Whittom, R., Hantel, A., Schilsky, R.L., Fuchs, C.S.: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol. 24, 3535–3541 (2006)</ref-fulltext>
<ce:source-text>Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., Thomas, J., Nelson, H., Whittom, R., Hantel, A., Schilsky, R.L., Fuchs, C.S.: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol. 24, 3535–3541 (2006)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and survival after  breast cancer diagnosis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Holmes</ce:surname>
</author>
<author seq="2">
<ce:initials>W.Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>W.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Feskanich</ce:surname>
</author>
<author seq="4">
<ce:initials>C.H.</ce:initials>
<ce:surname>Kroenke</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.A.</ce:initials>
<ce:surname>Colditz</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA.</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>293</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2479</first-page>
<last-page>2486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Holmes, M.D., Chen, W.Y., Feskanich, D., Kroenke, C.H., Colditz, G.A.: Physical activity and survival after  breast cancer diagnosis. JAMA. 293, 2479–2486 (2005)</ref-fulltext>
<ce:source-text>Holmes, M.D., Chen, W.Y., Feskanich, D., Kroenke, C.H., Colditz, G.A.: Physical activity and survival after  breast cancer diagnosis. JAMA. 293, 2479–2486 (2005)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and survival after prostate can cer diagnosis in the health professionals follow-up  study.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Kenfield</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Stampfer</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E,</ce:initials>
<ce:surname>Giovannucci</ce:surname>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Chan</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>726</first-page>
<last-page>732</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kenfield, S.A., Stampfer, M.J., Giovannucci, E., Chan,  J.M.: Physical activity and survival after prostate can cer diagnosis in the health professionals follow-up  study. J. Clin. Oncol. 29, 726–732 (2011)</ref-fulltext>
<ce:source-text>Kenfield, S.A., Stampfer, M.J., Giovannucci, E., Chan,  J.M.: Physical activity and survival after prostate can cer diagnosis in the health professionals follow-up  study. J. Clin. Oncol. 29, 726–732 (2011)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity levels among breast  cancer survivors.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>McTiernan</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Bernstein</ce:surname>
</author>
<author seq="4">
<ce:initials>F.D.</ce:initials>
<ce:surname>Gilliland</ce:surname>
<ce:given-name>F.D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Ballard Barbash</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc.</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1484</first-page>
<last-page>1491</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Irwin, M.L., McTiernan, A., Bernstein, L., Gilliland,  F.D., Baumgartner, R., Baumgartner, K., Ballard Barbash, R.: Physical activity levels among breast  cancer survivors. Med. Sci. Sports Exerc. 36,  1484–1491 (2004)</ref-fulltext>
<ce:source-text>Irwin, M.L., McTiernan, A., Bernstein, L., Gilliland,  F.D., Baumgartner, R., Baumgartner, K., Ballard Barbash, R.: Physical activity levels among breast  cancer survivors. Med. Sci. Sports Exerc. 36,  1484–1491 (2004)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>State variation in  meeting the 2008 federal guidelines for both aerobic  and muscle-strengthening activities through leisure time physical activity among adults aged 18–64</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Blackwell</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.C.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>United States, 2010–2015.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first></vol-first>
<iss-first></iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page></first-page>
<last-page></last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Blackwell, D.L., Clarke, T.C.: State variation in  meeting the 2008 federal guidelines for both aerobic  and muscle-strengthening activities through leisure time physical activity among adults aged 18–64:  United States, 2010–2015. Natl Health Stat Report,  1–22 (2018)</ref-fulltext>
<ce:source-text>Blackwell, D.L., Clarke, T.C.: State variation in  meeting the 2008 federal guidelines for both aerobic  and muscle-strengthening activities through leisure time physical activity among adults aged 18–64:  United States, 2010–2015. Natl Health Stat Report,  1–22 (2018)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Life time recreational exercise activity and breast cancer  risk among black women and white women.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Bernstein</ce:surname>
</author>
<author seq="2">
<ce:initials>A.V.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Ursin</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Sullivan-Halley</ce:surname>
</author>
<author seq="5">
<ce:initials>M.F.</ce:initials>
<ce:surname>Press</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Deapen</ce:surname>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Berlin</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.R.</ce:initials>
<ce:surname>Daling</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.A.</ce:initials>
<ce:surname>McDonald</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.A.</ce:initials>
<ce:surname>Norman</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="11">
<ce:initials>K.E.</ce:initials>
<ce:surname>Malone</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
<author seq="12">
<ce:initials>B.L.</ce:initials>
<ce:surname>Strom</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="13">
<ce:initials>J.</ce:initials>
<ce:surname>Liff</ce:surname>
</author>
<author seq="14">
<ce:initials>S.G.</ce:initials>
<ce:surname>Folger</ce:surname>
<ce:given-name>S.G.</ce:given-name>
</author>
<author seq="15">
<ce:initials>M.S.</ce:initials>
<ce:surname>Simon</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="16">
<ce:initials>J.</ce:initials>
<ce:surname>Burkman</ce:surname>
</author>
<author seq="17">
<ce:initials>P.A.</ce:initials>
<ce:surname>Marchbanks</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="18">
<ce:initials>L.K.</ce:initials>
<ce:surname>Weiss</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="19">
<ce:initials>R.</ce:initials>
<ce:surname>Spirtas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl.  Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1671</first-page>
<last-page>1679</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bernstein, L., Patel, A.V., Ursin, G., Sullivan-Halley,  J., Press, M.F., Deapen, D., Berlin, J.A., Daling, J.R.,  McDonald, J.A., Norman, S.A., Malone, K.E., Strom,  B.L., Liff, J., Folger, S.G., Simon, M.S., Burkman, R.  T., Marchbanks, P.A., Weiss, L.K., Spirtas, R.: Life time recreational exercise activity and breast cancer  risk among black women and white women. J. Natl.  Cancer Inst. 97, 1671–1679 (2005)</ref-fulltext>
<ce:source-text>Bernstein, L., Patel, A.V., Ursin, G., Sullivan-Halley,  J., Press, M.F., Deapen, D., Berlin, J.A., Daling, J.R.,  McDonald, J.A., Norman, S.A., Malone, K.E., Strom,  B.L., Liff, J., Folger, S.G., Simon, M.S., Burkman, R.  T., Marchbanks, P.A., Weiss, L.K., Spirtas, R.: Life time recreational exercise activity and breast cancer  risk among black women and white women. J. Natl.  Cancer Inst. 97, 1671–1679 (2005)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Prospective cohort  study of lifetime physical activity and breast cancer  survival.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Gregory</ce:surname>
</author>
<author seq="3">
<ce:initials>K.A.</ce:initials>
<ce:surname>Kopciuk</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first=""/>
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
<iss-first></iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1954</first-page>
<last-page>1962</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedenreich, C.M., Gregory, J., Kopciuk, K.A.,  Mackey, J.R., Courneya, K.S.: Prospective cohort  study of lifetime physical activity and breast cancer  survival. Int. J. Cancer. 124, 1954–1962 (2009)</ref-fulltext>
<ce:source-text>Friedenreich, C.M., Gregory, J., Kopciuk, K.A.,  Mackey, J.R., Courneya, K.S.: Prospective cohort  study of lifetime physical activity and breast cancer  survival. Int. J. Cancer. 124, 1954–1962 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Recreational physical activity and the risk of breast  cancer in postmenopausal women: the Women’s  Health Initiative Cohort Study.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>McTiernan</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Kooperberg</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>White</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wilcox</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Coates</ce:surname>
</author>
<author seq="6">
<ce:initials>L.L.</ce:initials>
<ce:surname>Adams-Campbell</ce:surname>
<ce:given-name>L.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Woods</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Ockene</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Women’s Health Initiative Cohort</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>290</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1331</first-page>
<last-page>1336</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McTiernan, A., Kooperberg, C., White, E., Wilcox, S.,  Coates, R., Adams-Campbell, L.L., Woods, N.,  Ockene, J., Women’s Health Initiative Cohort, S.:  Recreational physical activity and the risk of breast  cancer in postmenopausal women: the Women’s  Health Initiative Cohort Study. JAMA. 290,  1331–1336 (2003)</ref-fulltext>
<ce:source-text>McTiernan, A., Kooperberg, C., White, E., Wilcox, S.,  Coates, R., Adams-Campbell, L.L., Woods, N.,  Ockene, J., Women’s Health Initiative Cohort, S.:  Recreational physical activity and the risk of breast  cancer in postmenopausal women: the Women’s  Health Initiative Cohort Study. JAMA. 290,  1331–1336 (2003)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Recreational physical activity and ovarian cancer risk and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.G.</ce:initials>
<ce:surname>Moorman</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Akushevich</ce:surname>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Schildkraut</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Epidemiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>178</first-page>
<last-page>187</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moorman, P.G., Jones, L.W., Akushevich, L., Schildkraut, J.M.: Recreational physical activity and ovarian cancer risk and survival. Ann. Epidemiol. 21, 178–187 (2011)</ref-fulltext>
<ce:source-text>Moorman, P.G., Jones, L.W., Akushevich, L., Schildkraut, J.M.: Recreational physical activity and ovarian cancer risk and survival. Ann. Epidemiol. 21, 178–187 (2011)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-authors>
<collaboration seq="1">
<ce:text>Committee, P. A. G. A</ce:text>
</collaboration>
</ref-authors>
<ref-sourcetitle>Physical Activity Guidelines Advisory Committee Report</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-text>US Department of Health and Human Services</ref-text>
</ref-info>
<ref-fulltext>Committee, P. A. G. A.: Physical activity guidelines advisory committee report: US Department of Health and Human Services (2008)</ref-fulltext>
<ce:source-text>Committee, P. A. G. A.: Physical activity guidelines advisory committee report: US Department of Health and Human Services (2008)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>American College of Sports, M: American College of Sports Medicine roundtable on exercise guidelines for cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Matthews</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Demark-Wahnefried</ce:surname>
</author>
<author seq="5">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.M.</ce:initials>
<ce:surname>Pinto</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.Y.</ce:initials>
<ce:surname>Wolin</ce:surname>
<ce:given-name>K.Y.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Lucia</ce:surname>
</author>
<author seq="11">
<ce:initials>C.M.</ce:initials>
<ce:surname>Schneider</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="12">
<ce:initials>V.E.</ce:initials>
<ce:surname>von Gruenigen</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="13">
<ce:initials>A.L.</ce:initials>
<ce:surname>Schwartz</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1409</first-page>
<last-page>1426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmitz, K.H., Courneya, K.S., Matthews, C., Demark-Wahnefried, W., Galvao, D.A., Pinto, B.M., Irwin, M.L., Wolin, K.Y., Segal, R.J., Lucia, A., Schneider, C.M., von Gruenigen, V.E., Schwartz, A.L., American College of Sports, M: American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med. Sci. Sports Exerc. 42, 1409–1426 (2010)</ref-fulltext>
<ce:source-text>Schmitz, K.H., Courneya, K.S., Matthews, C., Demark-Wahnefried, W., Galvao, D.A., Pinto, B.M., Irwin, M.L., Wolin, K.Y., Segal, R.J., Lucia, A., Schneider, C.M., von Gruenigen, V.E., Schwartz, A.L., American College of Sports, M: American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med. Sci. Sports Exerc. 42, 1409–1426 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptations to aerobic endurance training programs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Swank</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Sharp</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Essentials of Strength Training and Conditioning</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<page-information>
<pages>
<first-page>115</first-page>
<last-page>133</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Haff, G.G., Triplett, N.T. (eds.), Human Kinetics, Illinois</ref-text>
</ref-info>
<ref-fulltext>Swank, A., Sharp, C.: Adaptations to aerobic endurance training programs. In: Haff, G.G., Triplett, N.T. (eds.) Essentials of strength training and conditioning, pp. 115–133. Human Kinetics, Illinois (2016)</ref-fulltext>
<ce:source-text>Swank, A., Sharp, C.: Adaptations to aerobic endurance training programs. In: Haff, G.G., Triplett, N.T. (eds.) Essentials of strength training and conditioning, pp. 115–133. Human Kinetics, Illinois (2016)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle enzymes and fiber composition in male and female track athletes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Costill</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Daniels</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Evans</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Fink</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Krahenbuhl</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Saltin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="1976"/>
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>149</first-page>
<last-page>154</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costill, D.L., Daniels, J., Evans, W., Fink, W., Krahenbuhl, G., Saltin, B.: Skeletal muscle enzymes and fiber composition in male and female track athletes. J. Appl. Physiol. 40, 149–154 (1976)</ref-fulltext>
<ce:source-text>Costill, D.L., Daniels, J., Evans, W., Fink, W., Krahenbuhl, G., Saltin, B.: Skeletal muscle enzymes and fiber composition in male and female track athletes. J. Appl. Physiol. 40, 149–154 (1976)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Backman</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Wengstrom</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Johansson</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Skoldengen</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Borjesson</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Tarnbro</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Berglund</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>53</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>510</first-page>
<last-page>520</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Backman, M., Wengstrom, Y., Johansson, B., Skoldengen, I., Borjesson, S., Tarnbro, S., Berglund, A.: A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncol. 53, 510–520 (2014)</ref-fulltext>
<ce:source-text>Backman, M., Wengstrom, Y., Johansson, B., Skoldengen, I., Borjesson, S., Tarnbro, S., Berglund, A.: A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncol. 53, 510–520 (2014)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: A pilot study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Denysschen</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Burton</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Ademuyiwa</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Levine</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Tetewsky</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>O’Connor</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer Care (Engl)</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>493</first-page>
<last-page>501</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DeNysschen, C.A., Burton, H., Ademuyiwa, F., Levine, E., Tetewsky, S., O’Connor, T.: Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: A pilot study. Eur. J. Cancer Care (Engl). 23, 493–501 (2014)</ref-fulltext>
<ce:source-text>DeNysschen, C.A., Burton, H., Ademuyiwa, F., Levine, E., Tetewsky, S., O’Connor, T.: Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: A pilot study. Eur. J. Cancer Care (Engl). 23, 493–501 (2014)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Evaluation of a 12-week home-based walking intervention for breast cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Wilcox</ce:surname>
</author>
<author seq="3">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hanby</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>der Ananian</ce:surname>
</author>
<author seq="5">
<ce:initials>S.P.</ce:initials>
<ce:surname>Heiney</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Gebretsadik</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Shintani</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>203</first-page>
<last-page>211</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matthews, C.E., Wilcox, S., Hanby, C.L., Der Ananian, C., Heiney, S.P., Gebretsadik, T., Shintani, A.: Evaluation of a 12-week home-based walking intervention for breast cancer survivors. Support Care Cancer. 15, 203–211 (2007)</ref-fulltext>
<ce:source-text>Matthews, C.E., Wilcox, S., Hanby, C.L., Der Ananian, C., Heiney, S.P., Gebretsadik, T., Shintani, A.: Evaluation of a 12-week home-based walking intervention for breast cancer survivors. Support Care Cancer. 15, 203–211 (2007)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Nikander</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Sievanen</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Ojala</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Oivanen</ce:surname>
</author>
<author seq="5">
<ce:initials>P.L.</ce:initials>
<ce:surname>Kellokumpu-Lehtinen</ce:surname>
<ce:given-name>P.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Saarto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>181</first-page>
<last-page>186</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nikander, R., Sievanen, H., Ojala, K., Oivanen, T., Kellokumpu-Lehtinen, P.L., Saarto, T.: Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial. Acta Oncol. 46, 181–186 (2007)</ref-fulltext>
<ce:source-text>Nikander, R., Sievanen, H., Ojala, K., Oivanen, T., Kellokumpu-Lehtinen, P.L., Saarto, T.: Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial. Acta Oncol. 46, 181–186 (2007)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.C.</ce:initials>
<ce:surname>Janelsins</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.G.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Wideman</ce:surname>
</author>
<author seq="4">
<ce:initials>J.A.</ce:initials>
<ce:surname>Katula</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.K.</ce:initials>
<ce:surname>Sprod</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Peppone</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>O.G.</ce:initials>
<ce:surname>Palesh</ce:surname>
<ce:given-name>O.G.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.E.</ce:initials>
<ce:surname>Heckler</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.P.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="10">
<ce:initials>G.R.</ce:initials>
<ce:surname>Morrow</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="11">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mustian</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Janelsins, M.C., Davis, P.G., Wideman, L., Katula, J.A., Sprod, L.K., Peppone, L.J., Palesh, O.G., Heckler, C.E., Williams, J.P., Morrow, G.R., Mustian, K.M.: Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin. Breast Cancer. 11, 161–170 (2011)</ref-fulltext>
<ce:source-text>Janelsins, M.C., Davis, P.G., Wideman, L., Katula, J.A., Sprod, L.K., Peppone, L.J., Palesh, O.G., Heckler, C.E., Williams, J.P., Morrow, G.R., Mustian, K.M.: Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin. Breast Cancer. 11, 161–170 (2011)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise improves body fat, lean mass, and bone mass in breast cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Alvarez-Reeves</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Cadmus</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Mierzejewski</ce:surname>
</author>
<author seq="5">
<ce:initials>S.T.</ce:initials>
<ce:surname>Mayne</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="7">
<ce:initials>G.G.</ce:initials>
<ce:surname>Chung</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
<author seq="8">
<ce:initials>B.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
<author seq="9">
<ce:initials>M.T.</ce:initials>
<ce:surname>Knobf</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Dipietro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Obesity (Silver Spring)</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1534</first-page>
<last-page>1541</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Irwin, M.L., Alvarez-Reeves, M., Cadmus, L., Mierzejewski, E., Mayne, S.T., Yu, H., Chung, G.G., Jones, B., Knobf, M.T., DiPietro, L.: Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring). 17, 1534–1541 (2009)</ref-fulltext>
<ce:source-text>Irwin, M.L., Alvarez-Reeves, M., Cadmus, L., Mierzejewski, E., Mayne, S.T., Yu, H., Chung, G.G., Jones, B., Knobf, M.T., DiPietro, L.: Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring). 17, 1534–1541 (2009)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.F.</ce:initials>
<ce:surname>O'neill</ce:surname>
<ce:given-name>R.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Haseen</ce:surname>
</author>
<author seq="3">
<ce:initials>L.J.</ce:initials>
<ce:surname>Murray</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>O'sullivan</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.M.</ce:initials>
<ce:surname>Cantwell</ce:surname>
<ce:given-name>M.M</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Surviv</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>440</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>O'Neill, R.F., Haseen, F., Murray, L.J., O'Sullivan, J.M., Cantwell, M.M.: A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J. Cancer Surviv. 9, 431–440 (2015)</ref-fulltext>
<ce:source-text>O'Neill, R.F., Haseen, F., Murray, L.J., O'Sullivan, J.M., Cantwell, M.M.: A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J. Cancer Surviv. 9, 431–440 (2015)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr. Relat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Hvid</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Winding</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Rinnov</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Dejgaard</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Thomsen</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Iversen</ce:surname>
</author>
<author seq="7">
<ce:initials>K.</ce:initials>
<ce:surname>Brasso</ce:surname>
</author>
<author seq="8">
<ce:initials>K.J.</ce:initials>
<ce:surname>Mikines</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>van Hall</ce:surname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Lindegaard</ce:surname>
</author>
<author seq="11">
<ce:initials>T.P.</ce:initials>
<ce:surname>Solomon</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
<author seq="12">
<ce:initials>B.K.</ce:initials>
<ce:surname>Pedersen</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>621</first-page>
<last-page>632</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hvid, T., Winding, K., Rinnov, A., Dejgaard, T., Thomsen, C., Iversen, P., Brasso, K., Mikines, K.J., van Hall, G., Lindegaard, B., Solomon, T.P., Pedersen, B.K.: Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr. Relat. Cancer. 20, 621–632 (2013)</ref-fulltext>
<ce:source-text>Hvid, T., Winding, K., Rinnov, A., Dejgaard, T., Thomsen, C., Iversen, P., Brasso, K., Mikines, K.J., van Hall, G., Lindegaard, B., Solomon, T.P., Pedersen, B.K.: Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr. Relat. Cancer. 20, 621–632 (2013)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Piringer</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Fridrik</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Fridrik</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Leiherer</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Zabernigg</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Greil</ce:surname>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Eisterer</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Tschmelitsch</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Lang</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Frantal</ce:surname>
</author>
<author seq="11">
<ce:initials>S.</ce:initials>
<ce:surname>Burgstaller</ce:surname>
</author>
<author seq="12">
<ce:initials>M.</ce:initials>
<ce:surname>Gnant</ce:surname>
</author>
<author seq="13">
<ce:initials>J.</ce:initials>
<ce:surname>Thaler</ce:surname>
</author>
<author seq="14">
<ce:initials>B.</ce:initials>
<ce:surname>Austrian</ce:surname>
</author>
<author seq="15">
<ce:initials>G.</ce:initials>
<ce:surname>Colorectal Cancer Study</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1345</first-page>
<last-page>1352</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Piringer, G., Fridrik, M., Fridrik, A., Leiherer, A., Zabernigg, A., Greil, R., Eisterer, W., Tschmelitsch, J., Lang, A., Frantal, S., Burgstaller, S., Gnant, M., Thaler, J., Austrian, B., Colorectal Cancer Study, G: A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. Support Care Cancer. 26, 1345–1352 (2018)</ref-fulltext>
<ce:source-text>Piringer, G., Fridrik, M., Fridrik, A., Leiherer, A., Zabernigg, A., Greil, R., Eisterer, W., Tschmelitsch, J., Lang, A., Frantal, S., Burgstaller, S., Gnant, M., Thaler, J., Austrian, B., Colorectal Cancer Study, G: A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. Support Care Cancer. 26, 1345–1352 (2018)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>Y.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.C.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.M.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.H.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>G.H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1216</first-page>
<last-page>1222</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, Y.J., Cheng, J.C., Lee, J.M., Huang, P.M., Huang, G.H., Chen, C.C.: A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy. Oncologist. 20, 1216–1222 (2015)</ref-fulltext>
<ce:source-text>Xu, Y.J., Cheng, J.C., Lee, J.M., Huang, P.M., Huang, G.H., Chen, C.C.: A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy. Oncologist. 20, 1216–1222 (2015)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>exercise-dependent regulation of nk cells in cancer protection. trends mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Idorn</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Hojman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>565</first-page>
<last-page>577</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Idorn, M., Hojman, P.: Exercise-dependent regulation of NK cells in cancer protection. Trends Mol. Med. 22, 565–577 (2016)</ref-fulltext>
<ce:source-text>Idorn, M., Hojman, P.: Exercise-dependent regulation of NK cells in cancer protection. Trends Mol. Med. 22, 565–577 (2016)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>The muscular system: the control of muscle  mass. In: Farrell, P.A., Joyner, M.J., Caiozzo,  V.J. (eds.) ACSMs advanced exercise physiology,  pp.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tsika</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lippincot Williams and Wilkens</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<page-information>
<pages>
<first-page>152</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsika, R.: The muscular system: the control of muscle  mass. In: Farrell, P.A., Joyner, M.J., Caiozzo,  V.J. (eds.) ACSMs advanced exercise physiology,  pp. 152–170. Lippincot Williams and Wilkens (2012)</ref-fulltext>
<ce:source-text>Tsika, R.: The muscular system: the control of muscle  mass. In: Farrell, P.A., Joyner, M.J., Caiozzo,  V.J. (eds.) ACSMs advanced exercise physiology,  pp. 152–170. Lippincot Williams and Wilkens (2012)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptations to anaerobic training  programs. In: Haff, G.G., Triplett, N.T. (eds.)  Essentials of strength training and conditioning,  pp.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>French</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Human Kinetics, Illinois</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<page-information>
<pages>
<first-page>87</first-page>
<last-page>113</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>French, D.: Adaptations to anaerobic training  programs. In: Haff, G.G., Triplett, N.T. (eds.)  Essentials of strength training and conditioning,  pp. 87–113. Human Kinetics, Illinois (2016)</ref-fulltext>
<ce:source-text>French, D.: Adaptations to anaerobic training  programs. In: Haff, G.G., Triplett, N.T. (eds.)  Essentials of strength training and conditioning,  pp. 87–113. Human Kinetics, Illinois (2016)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Resistance exercise in men receiving androgen depri vation therapy for prostate cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Malone</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.B.</ce:initials>
<ce:surname>Parliament</ce:surname>
<ce:given-name>M.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.G.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>C.G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>P.M.</ce:initials>
<ce:surname>Venner</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.A.</ce:initials>
<ce:surname>Quinney</ce:surname>
<ce:given-name>H.A.</ce:given-name>
</author>
<author seq="9">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.E.</ce:initials>
<ce:surname>D'Angelo</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="11">
<ce:initials>G.A.</ce:initials>
<ce:surname>Wells</ce:surname>
<ce:given-name>G.A</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1653</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Segal, R.J., Reid, R.D., Courneya, K.S., Malone, S.C.,  Parliament, M.B., Scott, C.G., Venner, P.M., Quinney,  H.A., Jones, L.W., D'Angelo, M.E., Wells, G.A.:  Resistance exercise in men receiving androgen depri vation therapy for prostate cancer. J. Clin. Oncol. 21,  1653–1659 (2003)</ref-fulltext>
<ce:source-text>Segal, R.J., Reid, R.D., Courneya, K.S., Malone, S.C.,  Parliament, M.B., Scott, C.G., Venner, P.M., Quinney,  H.A., Jones, L.W., D'Angelo, M.E., Wells, G.A.:  Resistance exercise in men receiving androgen depri vation therapy for prostate cancer. J. Clin. Oncol. 21,  1653–1659 (2003)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Combined resistance and aerobic exer cise program reverses muscle loss in men undergoing  androgen suppression therapy for prostate cancer with out bone metastases: a randomized controlled  trial.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Taaffe</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Spry</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Joseph</ce:surname>
</author>
<author seq="5">
<ce:initials>R.U.</ce:initials>
<ce:surname>Newton</ce:surname>
<ce:given-name>R.U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>340</first-page>
<last-page>347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Galvao, D.A., Taaffe, D.R., Spry, N., Joseph, D.,  Newton, R.U.: Combined resistance and aerobic exer cise program reverses muscle loss in men undergoing  androgen suppression therapy for prostate cancer with out bone metastases: a randomized controlled  trial. J. Clin. Oncol. 28, 340–347 (2010)</ref-fulltext>
<ce:source-text>Galvao, D.A., Taaffe, D.R., Spry, N., Joseph, D.,  Newton, R.U.: Combined resistance and aerobic exer cise program reverses muscle loss in men undergoing  androgen suppression therapy for prostate cancer with out bone metastases: a randomized controlled  trial. J. Clin. Oncol. 28, 340–347 (2010)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Exer cise improves V O2max and body composition in  androgen deprivation therapy-treated prostate cancer  patients.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Wall</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvão</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Fatehee</ce:surname>
</author>
<author seq="4">
<ce:initials>D.R.</ce:initials>
<ce:surname>Taaffe</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Spry</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Joseph</ce:surname>
</author>
<author seq="7">
<ce:initials>J.J.</ce:initials>
<ce:surname>Hebert</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.U.</ce:initials>
<ce:surname>Newton</ce:surname>
<ce:given-name>R.U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1503</first-page>
<last-page>1510</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wall, B.A., Galvão, D.A., Fatehee, N., Taaffe, D.R.,  Spry, N., Joseph, D., Hebert, J.J., Newton, R.U.: Exer cise improves V O2max and body composition in  androgen deprivation therapy-treated prostate cancer  patients. Med. Sci. Sports Exerc. 49, 1503–1510(2017)</ref-fulltext>
<ce:source-text>Wall, B.A., Galvão, D.A., Fatehee, N., Taaffe, D.R.,  Spry, N., Joseph, D., Hebert, J.J., Newton, R.U.: Exer cise improves V O2max and body composition in  androgen deprivation therapy-treated prostate cancer  patients. Med. Sci. Sports Exerc. 49, 1503–1510(2017)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Combined aerobic and resistance training  in breast cancer survivors: a randomized, controlled  pilot trial. Int.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Herrero</ce:surname>
</author>
<author seq="2">
<ce:initials>A.F.</ce:initials>
<ce:surname>San Juan</ce:surname>
<ce:given-name>A.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Fleck</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Balmer</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Perez</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Canete</ce:surname>
</author>
<author seq="7">
<ce:initials>C.P.</ce:initials>
<ce:surname>Earnest</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Foster</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Lucia</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Sports Med</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>573</first-page>
<last-page>580</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Herrero, F., San Juan, A.F., Fleck, S.J., Balmer, J.,  Perez, M., Canete, S., Earnest, C.P., Foster, C.,  Lucia, A.: Combined aerobic and resistance training  in breast cancer survivors: a randomized, controlled  pilot trial. Int. J. Sports Med. 27, 573–580 (2006)</ref-fulltext>
<ce:source-text>Herrero, F., San Juan, A.F., Fleck, S.J., Balmer, J.,  Perez, M., Canete, S., Earnest, C.P., Foster, C.,  Lucia, A.: Combined aerobic and resistance training  in breast cancer survivors: a randomized, controlled  pilot trial. Int. J. Sports Med. 27, 573–580 (2006)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of  an individualized exercise intervention on body  composition in breast cancer patients undergoing treat ment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Battaglini</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Bottaro</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Dennehy</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Rae</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Shields</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Kirk</ce:surname>
</author>
<author seq="7">
<ce:initials>A.C.</ce:initials>
<ce:surname>Hackney</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sao Paulo Med. J</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>22</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Battaglini, C., Bottaro, M., Dennehy, C., Rae, L.,  Shields, E., Kirk, D., Hackney, A.C.: The effects of  an individualized exercise intervention on body  composition in breast cancer patients undergoing treat
ment. Sao Paulo Med. J. 125,22–28 (2007)</ref-fulltext>
<ce:source-text>Battaglini, C., Bottaro, M., Dennehy, C., Rae, L.,  Shields, E., Kirk, D., Hackney, A.C.: The effects of  an individualized exercise intervention on body  composition in breast cancer patients undergoing treat
ment. Sao Paulo Med. J. 125,22–28 (2007)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of exercise dose and type during breast cancer  chemotherapy: multicenter randomized trial.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McKenzie</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Gelmon</ce:surname>
</author>
<author seq="5">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Yasui</ce:surname>
</author>
<author seq="7">
<ce:initials>R.D.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="8">
<ce:initials>D.</ce:initials>
<ce:surname>Cook</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Jespersen</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Proulx</ce:surname>
</author>
<author seq="11">
<ce:initials>L.B.</ce:initials>
<ce:surname>Dolan</ce:surname>
<ce:given-name>L.B.</ce:given-name>
</author>
<author seq="12">
<ce:initials>C.C.</ce:initials>
<ce:surname>Forbes</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
<author seq="13">
<ce:initials>E.</ce:initials>
<ce:surname>Wooding</ce:surname>
</author>
<author seq="14">
<ce:initials>L.</ce:initials>
<ce:surname>Trinh</ce:surname>
</author>
<author seq="15">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl.  Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1821</first-page>
<last-page>1832</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Courneya, K.S., McKenzie, D.C., Mackey, J.R.,  Gelmon, K., Friedenreich, C.M., Yasui, Y., Reid, R.  D., Cook, D., Jespersen, D., Proulx, C., Dolan, L.B.,  Forbes, C.C., Wooding, E., Trinh, L., Segal, R.J.:  Effects of exercise dose and type during breast cancer  chemotherapy: multicenter randomized trial. J. Natl.  Cancer Inst. 105, 1821–1832 (2013)</ref-fulltext>
<ce:source-text>Courneya, K.S., McKenzie, D.C., Mackey, J.R.,  Gelmon, K., Friedenreich, C.M., Yasui, Y., Reid, R.  D., Cook, D., Jespersen, D., Proulx, C., Dolan, L.B.,  Forbes, C.C., Wooding, E., Trinh, L., Segal, R.J.:  Effects of exercise dose and type during breast cancer  chemotherapy: multicenter randomized trial. J. Natl.  Cancer Inst. 105, 1821–1832 (2013)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>A pilot study of group exercise training  (GET) for women with primary breast cancer: feasibil ity and health benefits. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.G.</ce:initials>
<ce:surname>Kolden</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.J.</ce:initials>
<ce:surname>Strauman</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Ward</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Kuta</ce:surname>
</author>
<author seq="5">
<ce:initials>T.E.</ce:initials>
<ce:surname>Woods</ce:surname>
<ce:given-name>T.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.L.</ce:initials>
<ce:surname>Schneider</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>E.</ce:initials>
<ce:surname>Heerey</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Sanborn</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Burt</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Millbrandt</ce:surname>
</author>
<author seq="11">
<ce:initials>N.H.</ce:initials>
<ce:surname>Kalin</ce:surname>
<ce:given-name>N.H.</ce:given-name>
</author>
<author seq="12">
<ce:initials>J.A.</ce:initials>
<ce:surname>Stewart</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="13">
<ce:initials>B.</ce:initials>
<ce:surname>Mullen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Psychooncology.</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>447</first-page>
<last-page>456</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolden, G.G., Strauman, T.J., Ward, A., Kuta, J.,  Woods, T.E., Schneider, K.L., Heerey, E., Sanborn, L., Burt, C., Millbrandt, L., Kalin, N.H., Stewart, J.A.,  Mullen, B.: A pilot study of group exercise training  (GET) for women with primary breast cancer: feasibil ity and health benefits. Psychooncology. 11, 447–456  (2002)</ref-fulltext>
<ce:source-text>Kolden, G.G., Strauman, T.J., Ward, A., Kuta, J.,  Woods, T.E., Schneider, K.L., Heerey, E., Sanborn,  L., Burt, C., Millbrandt, L., Kalin, N.H., Stewart, J.A.,  Mullen, B.: A pilot study of group exercise training  (GET) for women with primary breast cancer: feasibil ity and health benefits. Psychooncology. 11, 447–456  (2002)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of aerobic and resistance  exercise in breast cancer patients receiving adjuvant  chemotherapy: a multicenter randomized controlled  trial.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Gelmon</ce:surname>
</author>
<author seq="5">
<ce:initials>R.D.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.B.</ce:initials>
<ce:surname>Ladha</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Proulx</ce:surname>
</author>
<author seq="9">
<ce:initials>J.K.</ce:initials>
<ce:surname>Vallance</ce:surname>
<ce:given-name>J.K.</ce:given-name>
</author>
<author seq="10">
<ce:initials>K.</ce:initials>
<ce:surname>Lane</ce:surname>
</author>
<author seq="11">
<ce:initials>Y.</ce:initials>
<ce:surname>Yasui</ce:surname>
</author>
<author seq="12">
<ce:initials>D.C.</ce:initials>
<ce:surname>McKenzie</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4396</first-page>
<last-page>4404</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Courneya, K.S., Segal, R.J., Mackey, J.R., Gelmon,  K., Reid, R.D., Friedenreich, C.M., Ladha, A.B.,  Proulx, C., Vallance, J.K., Lane, K., Yasui, Y.,  McKenzie, D.C.: Effects of aerobic and resistance  exercise in breast cancer patients receiving adjuvant  chemotherapy: a multicenter randomized controlled  trial. J. Clin. Oncol. 25, 4396–4404 (2007)</ref-fulltext>
<ce:source-text>Courneya, K.S., Segal, R.J., Mackey, J.R., Gelmon,  K., Reid, R.D., Friedenreich, C.M., Ladha, A.B.,  Proulx, C., Vallance, J.K., Lane, K., Yasui, Y.,  McKenzie, D.C.: Effects of aerobic and resistance  exercise in breast cancer patients receiving adjuvant  chemotherapy: a multicenter randomized controlled  trial. J. Clin. Oncol. 25, 4396–4404 (2007)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Effects  of resistance exercise on fatigue and quality of life in  breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wiskemann</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Armbrust</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Schneeweiss</ce:surname>
</author>
<author seq="5">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ulrich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Steindorf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>137</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>480</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt, M.E., Wiskemann, J., Armbrust, P.,  Schneeweiss, A., Ulrich, C.M., Steindorf, K.: Effects  of resistance exercise on fatigue and quality of life in  breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int. J. Cancer. 137,  471–480 (2015)</ref-fulltext>
<ce:source-text>Schmidt, M.E., Wiskemann, J., Armbrust, P.,  Schneeweiss, A., Ulrich, C.M., Steindorf, K.: Effects  of resistance exercise on fatigue and quality of life in  breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int. J. Cancer. 137,  471–480 (2015)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Randomized, controlled trial of resistance training in  breast cancer patients receiving adjuvant radiotherapy:results on cancer-related fatigue and quality of life.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Steindorf</ce:surname>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Ulrich</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Oelmann</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Habermann</ce:surname>
</author>
<author seq="9">
<ce:initials>P.</ce:initials>
<ce:surname>Beckhove</ce:surname>
</author>
<author seq="10">
<ce:initials>R.</ce:initials>
<ce:surname>Owen</ce:surname>
</author>
<author seq="11">
<ce:initials>J.</ce:initials>
<ce:surname>Debus</ce:surname>
</author>
<author seq="12">
<ce:initials>J.</ce:initials>
<ce:surname>Wiskemann</ce:surname>
</author>
<author seq="">
<ce:initials>K.</ce:initials>
<ce:surname>Potthoff</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2237</first-page>
<last-page>2243</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steindorf, K., Schmidt, M.E., Klassen, O., Ulrich, C.  M., Oelmann, J., Habermann, N., Beckhove, P., Owen,  R., Debus, J., Wiskemann, J., Potthoff, K.:  Randomized, controlled trial of resistance training in  breast cancer patients receiving adjuvant radiotherapy:results on cancer-related fatigue and quality of life.  Ann. Oncol. 25, 2237–2243 (2014)</ref-fulltext>
<ce:source-text>Steindorf, K., Schmidt, M.E., Klassen, O., Ulrich, C.  M., Oelmann, J., Habermann, N., Beckhove, P., Owen,  R., Debus, J., Wiskemann, J., Potthoff, K.:  Randomized, controlled trial of resistance training in  breast cancer patients receiving adjuvant radiotherapy:results on cancer-related fatigue and quality of life.  Ann. Oncol. 25, 2237–2243 (2014)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a multimodal  high intensity exercise intervention in cancer patients  undergoing chemotherapy: randomised controlled  trial.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Adamsen</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Quist</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Moller</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Herrstedt</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Kronborg</ce:surname>
</author>
<author seq="7">
<ce:initials>M.T.</ce:initials>
<ce:surname>Baadsgaard</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Vistisen</ce:surname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Midtgaard</ce:surname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Christiansen</ce:surname>
</author>
<author seq="11">
<ce:initials>m.</ce:initials>
<ce:surname>Stage</ce:surname>
</author>
<author seq="12">
<ce:initials>M.T.</ce:initials>
<ce:surname>Kronborg</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="13">
<ce:initials>M.</ce:initials>
<ce:surname>Rorth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMJ</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>339</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Adamsen, L., Quist, M., Andersen, C., Moller, T.,  Herrstedt, J., Kronborg, D., Baadsgaard, M.T.,  Vistisen, K., Midtgaard, J., Christiansen, B., Stage,  M., Kronborg, M.T., Rorth, M.: Effect of a multimodal  high intensity exercise intervention in cancer patients  undergoing chemotherapy: randomised controlled  trial. BMJ. 339, b3410 (2009)</ref-fulltext> <ce:source-text>Adamsen, L., Quist, M., Andersen, C., Moller, T.,  Herrstedt, J., Kronborg, D., Baadsgaard, M.T.,  Vistisen, K., Midtgaard, J., Christiansen, B., Stage,  M., Kronborg, M.T., Rorth, M.: Effect of a multimodal  high intensity exercise intervention in cancer patients  undergoing chemotherapy: randomised controlled  trial. BMJ. 339, b3410 (2009)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english> The pathophysiology of lymphedema.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.S.</ce:initials>
<ce:surname>Mortimer</ce:surname>
<ce:given-name>P.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2798</first-page>
<last-page>2802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mortimer, P.S.: The pathophysiology of lymphedema.  Cancer. 83, 2798–2802 (1998)</ref-fulltext>
<ce:source-text>Mortimer, P.S.: The pathophysiology of lymphedema.  Cancer. 83, 2798–2802 (1998)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer-related lymphedema and  resistance exercise: a systematic review.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.L.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>N.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Strength  Cond. Res.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2656</first-page>
<last-page>2665</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nelson, N.L.: Breast cancer-related lymphedema and  resistance exercise: a systematic review. J. Strength  Cond. Res. 30, 2656–2665 (2016)</ref-fulltext> <ce:source-text>Nelson, N.L.: Breast cancer-related lymphedema and  resistance exercise: a systematic review. J. Strength  Cond. Res. 30, 2656–2665 (2016)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Physiologic aspects of lymphatic con tractile function: current perspectives.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.A.</ce:initials>
<ce:surname>Gashev</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Ann. N. Y.  Acad. Sci.</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>979</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>178</first-page>
<last-page>187</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>discussion 188–96</ref-text>
</ref-info>
<ref-fulltext>Gashev, A.A.: Physiologic aspects of lymphatic con tractile function: current perspectives. Ann. N. Y.  Acad. Sci. 979, 178–87 (2002); discussion 188–96</ref-fulltext>
 <ce:source-text>Gashev, A.A.: Physiologic aspects of lymphatic con tractile function: current perspectives. Ann. N. Y.  Acad. Sci. 979, 178–87 (2002); discussion 188–96</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Randomized controlled trial of weight training and  lymphedema in breast cancer survivors.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Ahmed</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Yee</ce:surname>
</author>
<author seq="4">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin.  Oncol.</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2765</first-page>
<last-page>2772</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ahmed, R.L., Thomas, W., Yee, D., Schmitz, K.H.:  Randomized controlled trial of weight training and  lymphedema in breast cancer survivors. J. Clin.  Oncol. 24, 2765–2772 (2006)</ref-fulltext> <ce:source-text>Ahmed, R.L., Thomas, W., Yee, D., Schmitz, K.H.:  Randomized controlled trial of weight training and  lymphedema in breast cancer survivors. J. Clin.  Oncol. 24, 2765–2772 (2006)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Weight lifting in women  with  breast-cancer-related  lymphedema.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.L.</ce:initials>
<ce:surname>Ahmed</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Troxel</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Cheville</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Lewis-Grant</ce:surname>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Bryan</ce:surname>
</author>
<author seq="8">
<ce:initials>C.T.</ce:initials>
<ce:surname>Williams Smith</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
<author seq="9">
<ce:initials>Q.P.</ce:initials>
<ce:surname>Greene</ce:surname>
<ce:given-name>Q.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>361</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>664</first-page>
<last-page>673</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmitz, K.H., Ahmed, R.L., Troxel, A., Cheville, A.,  Smith, R., Lewis-Grant, L., Bryan, C.J., Williams Smith, C.T., Greene, Q.P.: Weight lifting in women  with  breast-cancer-related  lymphedema. N. Engl. J. Med. 361, 664–673 (2009)</ref-fulltext> <ce:source-text>Schmitz, K.H., Ahmed, R.L., Troxel, A., Cheville, A.,  Smith, R., Lewis-Grant, L., Bryan, C.J., Williams Smith, C.T., Greene, Q.P.: Weight lifting in women  with  breast-cancer-related  lymphedema. N. Engl. J. Med. 361, 664–673 (2009)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Weight lifting for women at  risk for breast cancer-related lymphedema: a  randomized trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.L.</ce:initials>
<ce:surname>Ahmed</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.B.</ce:initials>
<ce:surname>Troxel</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Cheville</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Lewis-Grant</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Bryan</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.T.</ce:initials>
<ce:surname>Williams Smith</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Chittams</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>304</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2699</first-page>
<last-page>2705</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmitz, K.H., Ahmed, R.L., Troxel, A.B., Cheville,  A., Lewis-Grant, L., Smith, R., Bryan, C.J., Williams Smith, C.T., Chittams, J.: Weight lifting for women at  risk for breast cancer-related lymphedema: a  randomized trial. JAMA. 304, 2699–2705 (2010)</ref-fulltext> <ce:source-text>Schmitz, K.H., Ahmed, R.L., Troxel, A.B., Cheville,  A., Lewis-Grant, L., Smith, R., Bryan, C.J., Williams Smith, C.T., Chittams, J.: Weight lifting for women at  risk for breast cancer-related lymphedema: a  randomized trial. JAMA. 304, 2699–2705 (2010)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Obesity is a risk factor for developing  postoperative lymphedema in breast cancer patients.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.K.</ce:initials>
<ce:surname>Helyer</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Varnic</ce:surname>
</author>
<author seq="3">
<ce:initials>L.W</ce:initials>
<ce:surname>Le</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Leong</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>McCready</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast J.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>48</first-page>
<last-page>54</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Helyer, L.K., Varnic, M., Le, L.W., Leong, W.,  McCready, D.: Obesity is a risk factor for developing  postoperative lymphedema in breast cancer patients.  Breast J. 16,48–54 (2010)</ref-fulltext>
<ce:source-text>Helyer, L.K., Varnic, M., Le, L.W., Leong, W., McCready, D.: Obesity is a risk factor for developing  postoperative lymphedema in breast cancer patients.  Breast J. 16,48–54 (2010)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
</unit-content>
</unit>
</units>